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A B S T R A C T
Background
Public health strategies that target mosquito vectors, particularly pyrethroid long-lasting insecticidal nets (LLINs), have been largely
responsible for the substantial reduction in the number of people in Africa developing malaria. The spread of insecticide resistance in
Anopheles mosquitoes threatens these impacts. One way to control insecticide-resistant populations is by using insecticide synergists.
Piperonyl butoxide (PBO) is a synergist that inhibits specific metabolic enzymes within mosquitoes and has been incorporated into
pyrethroid-LLINs to form pyrethroid-PBO nets. Pyrethroid-PBO nets are currently produced by four LLIN manufacturers and,
following a recommendation from the World Health Organization (WHO) in 2017, are being included in distribution campaigns in
countries. This review examines epidemiological and entomological evidence on whether the addition of PBO to LLINs improves their
efficacy.
Objectives
1. Evaluate whether adding PBO to pyrethroid LLINs increases the epidemiological and entomological effectiveness of the nets.
2. Compare the effects of pyrethroid-PBO nets currently in commercial development or on the market with their non-PBO equivalent
in relation to:
a. malaria infection (prevalence or incidence);
b. entomological outcomes.
Search methods
We searched the Cochrane Infectious Diseases Group (CIDG) Specialized Register; CENTRAL, MEDLINE, Embase, Web of Science,
CAB Abstracts, and two clinical trial registers (ClinicalTrials.gov and WHO International Clinical Trials Registry Platform) up to 24
August 2018. We contacted organizations for unpublished data. We checked the reference lists of trials identified by the above methods.
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Selection criteria
We included laboratory trials, experimental hut trials, village trials, and randomized clinical trials with mosquitoes from the Anopheles
gambiae complex or Anopheles funestus group.
Data collection and analysis
Two review authors assessed each trial for eligibility, extracted data, and determined the risk of bias for included trials. We resolved
disagreements through discussion with a third review author. We analysed the data using Review Manager 5 and assessed the certainty
of the evidence using the GRADE approach.
Main results
Fifteen trials met the inclusion criteria: two laboratory trials, eight experimental hut trials, and five cluster-randomized controlled village
trials.
One village trial examined the effect of pyrethroid-PBO nets on malaria infection prevalence in an area with highly pyrethroid-resistant
mosquitoes. The latest endpoint at 21 months post-intervention showed that malaria prevalence probably decreased in the intervention
arm (OR 0.40, 95% CI 0.20 to 0.80; 1 trial, 1 comparison, moderate-certainty evidence).
In highly pyrethroid-resistant areas (< 30% mosquito mortality), in comparisons of unwashed pyrethroid-PBO nets to unwashed
standard-LLINs, PBO nets resulted in higher mosquito mortality (risk ratio (RR) 1.84, 95% CI 1.60 to 2.11; 14,620 mosquitoes, 5
trials, 9 comparisons, high-certainty evidence) and lower blood feeding success (RR 0.60, 95% CI 0.50 to 0.71; 14,000 mosquitoes,
4 trials, 8 comparisons, high-certainty evidence). However, in comparisons of washed pyrethroid-PBO nets to washed LLINs we do
not know if PBO nets have a greater effect on mosquito mortality (RR 1.20, 95% CI 0.88 to 1.63; 10,268 mosquitoes, 4 trials, 5
comparisons, very low-certainty evidence), although the washed pyrethroid-PBO nets do decrease blood feeding success compared to
standard-LLINs (RR 0.81, 95% CI 0.72 to 0.92; 9674 mosquitoes, 3 trials, 4 comparisons, high-certainty evidence).
In areas where pyrethroid resistance is considered moderate (31% to 60% mosquito mortality), there may be little or no difference in
effects of unwashed pyrethroid-PBO nets compared to unwashed standard-LLINs on mosquito mortality (RR 1.16, 95% CI 0.88 to
1.54; 242 mosquitoes, 1 trial, 1 comparison, low-certainty evidence), and there may be little or no difference in the effects on blood
feeding success (RR 0.87, 95% CI 0.67 to 1.13; 242 mosquitoes, 1 trial, 1 comparison, low-certainty evidence). The same pattern
is apparent for washed pyrethroid-PBO nets compared to washed standard-LLINs (mortality: RR 1.07, 95% CI 0.74 to 1.54; 329
mosquitoes, 1 trial, 1 comparison, low-certainty evidence; blood feeding success: RR 0.91, 95% CI 0.74 to 1.13; 329 mosquitoes, 1
trial, 1 comparison, low-certainty evidence).
In areas where pyrethroid resistance is low (61% to 90% mosquito mortality), there is probably little or no difference in the effect of
unwashed pyrethroid-PBO nets compared to unwashed standard-LLINs on mosquito mortality (RR 1.10, 95% CI 1.05 to 1.16; 708
mosquitoes, 1 trial, 2 comparisons, moderate-certainty evidence), but there is no evidence for an effect on blood feeding success (RR
0.67, 95% CI 0.06 to 7.37; 708 mosquitoes, 1 trial, 2 comparisons, very low-certainty evidence). For washed pyrethroid-PBO nets
compared to washed standard-LLINs we do not know if there is any difference in mosquito mortality (RR 1.16, 96% CI 0.83 to 1.63;
878 mosquitoes, 1 trial, 2 comparisons, very low-certainty evidence), but blood feeding may decrease (RR 1.50, 95% CI 0.89 to 2.54;
878 mosquitoes, 1 trial, 2 comparisons, low-certainty evidence).
In areas were mosquito populations are susceptible to insecticides (> 90% mosquito mortality), there may be little or no difference in
the effect of unwashed pyrethroid-PBO nets compared to unwashed standard-LLINs on mosquito mortality (RR 1.20, 95% CI 0.64 to
2.26; 2791 mosquitoes, 2 trials, 2 comparisons, low-certainty evidence). This is similar for washed nets (RR 1.07, 95% CI 0.92 to 1.25;
2644 mosquitoes, 2 trials, 2 comparisons, low-certainty evidence). We do not know if unwashed pyrethroid-PBO nets have any effect
on blood feeding success of susceptible mosquitoes (RR 0.50, 95% CI 0.11 to 2.32; 2791 mosquitoes, 2 trials, 2 comparisons, very
low-certainty evidence). The same applies to washed nets (RR 1.28, 95% CI 0.81 to 2.04; 2644 mosquitoes, 2 trials, 2 comparisons,
low-certainty evidence).
In village trials comparing pyrethroid-PBO nets to LLINs, there was no difference in sporozoite rate (4 trials, 5 comparison) and
mosquito parity (3 trials, 4 comparisons).
Authors’ conclusions
In areas of high insecticide resistance, pyrethroid-PBO nets reduce mosquito mortality and blood feeding rates, and results from a
single clinical trial demonstrate that this leads to lower malaria prevalence. Questions remain about the durability of PBO on nets, as
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the impact of pyrethroid-PBO LLINs on mosquito mortality was not sustained over 20 washes in experimental hut trials. There is little
evidence to support higher entomological efficacy of pyrethroid-PBO nets in areas where the mosquitoes show lower levels of resistance
to pyrethroids.
P L A I N L A N G U A G E S U M M A R Y
Pyrethroid-PBO nets to prevent malaria
Background
Bed nets treated with pyrethroid insecticides are an effective way to reduce malaria transmission and have been deployed across Africa.
However, mosquitoes that spread malaria are now developing resistance to this type of insecticide. One way to overcome this resistance
is to add another chemical, piperonyl butoxide (PBO), to the net. PBO is not an insecticide but blocks the substance (an enzyme)
inside the mosquito that stops pyrethroids working.
What is the aim of this review?
The aim of this Cochrane Review was to find out if pyrethroid-PBO nets add additional protection against malaria when compared to
standard pyrethroid-only nets.
Key messages
Pyrethroid-PBO nets are more effective than standard pyrethroid-only nets in killing mosquitoes and preventing them from blood
feeding in areas where the mosquito populations are very resistant to pyrethroid insecticides (high-certainty evidence). Pyrethroid-PBO
nets probably reduce the number of malaria infections (moderate-certainty evidence), although further high-quality studies measuring
clinical outcomes are needed.
What was studied in the review?
We included 15 trials conducted between 2010 to 2018 that compared standard pyrethroid nets to pyrethroid-PBOnets. These consisted
of two laboratory trials, eight experimental hut trials that measured the impact of the pyrethroid-PBO nets on a wild population of
mosquitoes, and five village trials. Only one village trial measured the impact of pyrethroid-PBO nets on malaria infection in humans;
all other studies recorded the impact on mosquito populations. We analysed all studies to determine whether the pyrethroid-PBO
nets were better at killing mosquitoes and preventing them from blood feeding. For the single clinical trial, we examined whether
pyrethroid-PBO nets reduced the number of malaria infections. As the benefit of adding PBO to nets is likely to depend on the level
of pyrethroid resistance in the mosquito population, we performed separate analyses for studies conducted in areas of high-, medium-,
and low-levels of pyrethroid resistance.
What are the main results of the review?
Where mosquitoes show high levels of resistance to pyrethroids, pyrethroid-PBO nets perform better than standard pyrethroid-only
nets at killing mosquitoes and preventing them from blood feeding. As expected, this effect is not seen in areas where the mosquitoes
show low or no resistance to the pyrethroid-only insecticides. Only one trial looked at the impact of using pyrethroid-PBO nets on the
number of people infected with the malaria parasite. This trial, involving 3966 participants and conducted in an area where mosquitoes
are very resistant to pyrethroids, found that fewer people were infected with malaria when the population used pyrethroid-PBO nets
compared to standard pyrethroid-only nets.
How up to date is this review?
We searched for studies that had been published up to 24 August 2018.
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S U M M A R Y O F F I N D I N G S F O R T H E M A I N C O M P A R I S O N [Explanation]
Pyrethroid-piperonyl butoxide (PBO) nets compared to long- lasting insecticidal nets (LLIN) for malaria control where insecticide resistance is high
Patient or population: Anopheles gambiae complex or Anopheles funestus group
Setting: areas of high insect icide resistance
Intervention: pyrethroid-PBO nets
Comparison: LLIN
Outcomes Anticipated absolute effects∗ (95% CI) Relative effect
(95% CI)
Number of participants
(trials)
Certainty of the evi-
dence
(GRADE)
Comments
Risk with LLIN Risk with pyrethroid-
PBO nets
Prevalence of malaria 527 per 1000a 211 per 1000 (105 to
422)a
OR 0.40 (0.20 to 0.80) 3966 people (1 trial, 1
comparison)
⊕⊕⊕©
MODERATEb,c
due to indirectness
Prevalence of malaria
is probably decreased
with pyrethroid-
PBO nets compared to
standard LLINs in areas
of high insect icide re-
sistance
Mosquito mortality
(unwashed nets)
238 per 1000a 438 per 1000
(381 to 503)a
RR 1.84
(1.60 to 2.11)
14,620 mosquitoes
(5 trials, 9 compar-
isons)
⊕⊕⊕⊕
HIGHb
Mosquito mortality is
increased with un-
washed pyrethroid-PBO
nets compared to stan-
dard unwashed LLINs
in areas of high insect i-
cide resistance
Mosquito mortality
(washed nets)
201 per 1000a 242 per 1000
(177 to 328)a
RR 1.20
(0.88 to 1.63)
10,268 mosquitoes
(4 trials, 5 compar-
isons)
⊕©©©
VERY LOWd,e
due to imprecision and in-
consistency
We do not know
if pyrethroid-PBO nets
have an ef fect on
mosquito mortality in
areas of high insect i-
cide resistance when
the nets have been
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washed
Blood- feeding success
(unwashed nets)
438 per 1000a 263 per 1000
(241 to 311)a
RR 0.60
(0.50 to 0.71)
14,000 mosquitoes
(4 trials, 8 compar-
isons)
⊕⊕⊕⊕
HIGHb
Mosquito blood-feed-
ing success is de-
creased with unwashed
pyrethroid-PBO nets
compared to standard
unwashed LLINs in ar-
eas of high insect icide
resistance
Blood- feeding success
(washed nets)
494 per 1000a 400 per 1000
(356 to 454)a
RR 0.81
(0.72 to 0.92)
9674 mosquitoes
(3 trials, 4 compar-
isons)
⊕⊕⊕⊕
HIGHb
Mosquito blood-feed-
ing success is de-
creased with washed
pyrethroid-PBO nets
compared to standard
washed LLINs in areas
of high insect icide re-
sistance
*The risk in the intervention group (and its 95%CI) is based on the assumed risk in the comparison group and the relative effect of the intervent ion (and its 95%CI).
Abbreviations: CI: conf idence interval; LLIN: long-last ing insect icidal nets; OR: odds rat io; PBO: pyrethroid-piperonyl butoxide; RR: risk rat io
GRADE Working Group grades of evidence
High certainty: we are very conf ident that the true ef fect lies close to that of the est imate of the ef fect.
Moderate certainty: we are moderately conf ident in the ef fect est imate: the true ef fect is likely to be close to the est imate of the ef fect, but there is a possibility that it is
substant ially dif f erent.
Low certainty: our conf idence in the ef fect est imate is lim ited: the true ef fect may be substant ially dif f erent f rom the est imate of the ef fect.
Very low certainty: we have very lit t le conf idence in the ef fect est imate: the true ef fect is likely to be substant ially dif f erent f rom the est imate of ef fect
aOriginal numbers used in this table, however in pooled analysis events and total numbers were generated f rom cluster-
adjusted results which uses the ef fect ive sample size. Note that cluster adjustments do not change the point est imate of
the ef fect size, just the standard error.
bNot downgraded for imprecision: both best and worst case scenarios in this situat ion are important ef fects.
cDowngraded by one for indirectness: the outcome is highly context specif ic and there is only one trial included here.
dDowngraded by two for inconsistency due to unexplained qualitat ive heterogeneity.
eDowngraded by one for imprecision due to wide CIs.
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B A C K G R O U N D
Description of the condition
Substantial progress has been made in reducing the burden of
malaria in the 21st century. It is estimated that the clinical in-
cidence of Plasmodium falciparum malaria in Africa dropped by
40% between 2000 and 2015, equating to the prevention of 663
million cases (Bhatt 2015; WHO-GMP 2015). However progress
has stalled in recent years (WHO 2017a). Targeting the mosquito
vector has proven to be the most effective method of malaria pre-
vention in Africa, with over two-thirds of the malaria cases averted
in the first 15 years of this century attributed to scale-up in the
use of long-lasting insecticidal nets (LLINs), (Bhatt 2015). This
method of malaria prevention is particularly effective in Africa
where the major malaria vectors, Anopheles gambiae and Anopheles
funestus, are largely endophagic (feed indoors) and endophilic (rest
indoors after blood feeding).
Currently only one insecticide class, the pyrethroids, is commonly
used to treat LLINs; pyrethroids have the required dual prop-
erties of low mammalian toxicity and rapid insecticidal activity
(Zaim 2000), and their repellent or contact irritant effects may
enhance the personal protection of LLINs. Unfortunately, resis-
tance to pyrethroids is now widespread in African malaria vectors
(Ranson 2016). This may be the result of mutations in target-
site proteins (target-site resistance), (Ranson 2011; Ridl 2008),
which results in reduced sensitivity to the insecticide or increased
activity of detoxification enzymes (metabolic resistance) (Mitchell
2012; Stevenson 2011), or other as yet poorly-described resistance
mechanisms, or a combination of all or some of these factors. The
evolution of insecticide resistance and its continuing spread threat-
ens the operational success of malaria vector control interventions.
The current impact of this resistance on malaria transmission is
largely unquantified and will vary depending on the level of resis-
tance, malaria endemicity, and proportion of the human popula-
tion using LLINs (Churcher 2016). A recent multi-country trial
found no evidence that pyrethroid resistance reduced the personal
protection provided by use of LLINs (Kleinschmidt 2018). How-
ever, it is generally accepted that resistance will eventually erode
the efficacy of pyrethroid-only LLINs and that innovation in the
LLIN market is essential to maintain the efficacy of this preventa-
tive measure (MPAC 2016).
Description of the intervention
One way of controlling insecticide-resistant mosquito popula-
tions is through the use of insecticide synergists. Synergists are
generally non-toxic and act by enhancing the potency of insecti-
cides. Piperonyl butoxide (PBO) is a synergist that inhibits spe-
cific metabolic enzymes withinmosquitoes, and has been incorpo-
rated into pyrethroid-treated LLINs to form PBO-combination
nets (hereafter referred to as pyrethroid-PBO nets). Insecticide-
synergist combination nets represent a new product class with the
capacity to affect insecticide-resistant populations. In 2017 the
World Health Organization (WHO), gave pyrethroid-PBO nets
an interim endorsement as a new vector control class and recom-
mended that countries consider deploying these nets in areaswhere
pyrethroid resistance has been confirmed in the main malaria vec-
tors (WHO-GMP 2017a).
Currently there are five pyrethroid-PBO nets in production: Ol-
yset® Plus; PermaNet® 3.0; Veeralin® LN; and DawaPlus 3.0
and 4.0. Olyset Plus, which is manufactured by Sumitomo Chem-
ical Company Ltd, is a polyethylene net treated with permethrin
(20 g/kg ± 25%) and PBO (10 g/kg ± 25%) across the whole
net (Sumitomo 2013). PermaNet 3.0, which is manufactured by
Vestergaard Frandsen, is a mixed polyester (sides) polyethylene
(roof ) net treated with deltamethrin and PBO; PBO is only found
on the roof of the net (25 g/kg ± 25%) and the concentration of
deltamethrin varies depending on location (roof: 4.0 g/kg ± 25%)
and yarn type (sides: 75 denier (thickness) yarn with 70 cm lower
border 2.8 g/kg ± 25%, 100 denier (thickness) yarnwithout border
2.1 g/kg ± 25%; Vestergaard 2015). Veeralin LN, manufactured
by Vector Control Innovations Private Ltd, is a polyethylene net
treated with alpha-cypermethrin (6.0 g/kg) and PBO (2.2 g/kg)
across the whole net (WHOPES 2016). DawaPlus 3.0 and 4.0 are
manufactured by Tana Netting, UAE, and contain PBO on the
roof only (3.0), or on all sides (4.0); deltamethrin suspension con-
centrate (SC) is coated on knitted multi-filament polyester fibres,
at the target dose of 1.33 g/kg in 75 denier (thickness) yarn and
1 g/kg in 100 denier (thickness) yarn, corresponding to 40 mg of
deltamethrin per m2, using a polymer as a binder. Ownership of
DawaPlus 4.0 is currently in the process of transferring ownership
to NRS Moon netting FZE (WHO 2018).
How the intervention might work
PBO inhibits metabolic enzyme families, in particular the cy-
tochrome P450 enzymes that detoxify or sequester pyrethroids.
Increased production of P450s is thought to be the most po-
tent mechanism of pyrethroid resistance in malaria vectors, and
pre-exposure to PBO has been shown to restore susceptibility to
pyrethroids in laboratory bioassays on multiple pyrethroid-resis-
tant vector populations (Churcher 2016).
Widespread use of conventional LLINs provides both personal
and community protection from malaria (Bhatt 2015; Lengeler
2004). In areas where the mosquito populations are resistant to
pyrethroids, experimental hut trials (as described in the ‘Types of
studies’ section), have shown that mosquito mortality rates and
protection from blood feeding are substantially reduced when us-
ing conventional LLINs (Abílio 2015; Awolola 2014; Bobanga
2013; N’Guessan 2007; Riveron 2015; Yewhalaw 2012). The ad-
dition of PBO to pyrethroids in LLINs can restore the killing
effects of LLINs in areas where this has been eroded by insec-
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ticide resistance. LLINs that contain PBO have been evaluated
in multiple experimental hut trials across Africa (Adeogun 2012;
Corbel 2010; Koudou 2011; N’Guessan 2010; Pennetier 2013;
Tungu 2010). In most settings, the pyrethroid-PBO nets resulted
in higher rates of mosquito mortality and greater blood-feeding
inhibition than conventional LLINs, although the magnitude of
this effect was variable. Village trials have measured the impact
on sporozoite infection rates in mosquitoes with mixed results
(Awolola 2014; Cisse 2017;Mzilahowa 2014; Stiles-Ocran 2013).
Recently, a cluster-randomized trial inTanzania demonstrated that
use of pyrethroid-PBO nets can reduce malaria prevalence in chil-
dren (Protopopoff 2018).
Why it is important to do this review
All LLINs approved by the WHO Prequalification Team (for-
merly theWHO Pesticide Evaluation Scheme (WHOPES)), con-
tain pyrethroids as the sole active ingredient. Five LLINs that con-
tain PBO have interim approval (WHOPES 2016), and have been
recognized as a new product class byWHO (WHO-GMP 2017a).
As pyrethroid-PBO nets are generally more expensive than con-
ventional LLINs, it is important to determine if they are superior
to conventional LLINs and, if so, under what circumstances, to
enable cost-effectiveness trials to be performed to inform procure-
ment decisions.
An Expert Review Group (ERG) commissioned by theWHO has
recommended pyrethroid-PBO nets be considered for use in ar-
eas where the major malaria vectors are resistant to pyrethroids
(WHO-GMP 2017a). This recommendation was largely based
on a single randomized controlled trial of one pyrethroid-PBO
net type conducted in Tanzania (Protopopoff 2018), but also
supported by a meta-analysis of performance of pyrethroid-PBO
nets in experimental hut trials, which was used to parameterize
a malaria transmission model to predict the public health benefit
of pyrethroid-PBO nets (Churcher 2016). However confusion re-
mains over the settings in which pyrethroid-PBO nets should be
deployed. The WHO recommendation is that countries should
consider deployment of this new product class in areas with in-
termediate levels of pyrethroid resistance but calls for further ev-
idence, including data from a second clinical trial. This guidance
has been adopted by some net providers; for example, the Presi-
dent’s Malaria Initiative (PMI) (PMI 2018).
In an attempt to assess the evidence of the effectiveness of
pyrethroid-PBO nets against African malaria vectors in areas with
differing levels of insecticide resistance, we have conducted a sys-
tematic review of all relevant trials and examined both epidemio-
logical and entomological endpoints. We appreciate that the eval-
uation of PBOwill depend on trials where the background insecti-
cide and dose is the same in both intervention and control groups
and are aware that most trials have evaluated pyrethroid-PBO nets
against pyrethroid-only LLINs with different background insecti-
cides and doses, which confounds the effects.
One of the problems with this research field is that pyrethroid-
PBO nets are commercial products. The pyrethroid-PBO nets
currently undergoing clinical trials have had additional alterations
made to them, such as changing the concentration or rate at which
the pyrethroid is released. However, these are the products for
which policy decisions are needed, based on evidence related to
their relative effectiveness. Thus, in this Cochrane Review, we
sought direct evidence for PBO alone on the effectiveness of nets,
and examined the evidence concerning the effectiveness of com-
mercial products. During these comparisons, we considered other
potential confounding factors.
O B J E C T I V E S
1. Evaluate whether adding PBO to pyrethroid LLINs
increases the epidemiological and entomological effectiveness of
the nets.
2. Compare the effects of pyrethroid-PBO nets currently in
commercial development or on the market with their non-PBO
equivalent in relation to:
i) malaria infection (prevalence or incidence);
ii) entomological outcomes.
M E T H O D S
Criteria for considering studies for this review
Types of studies
Objective 1
We included:
1. laboratory bioassay trials (for example, cone bioassays,
tunnel tests);
2. experimental hut trials; and
3. village trials.
Objective 2 (a and b)
We included:
1. experimental hut trials;
2. village trials; and
3. clinical trials.
See Table 1 for WHOPES definitions in detail.
7Piperonyl butoxide (PBO) combined with pyrethroids in insecticide-treated nets to prevent malaria in Africa (Review)
Copyright © 2018 The Authors. Cochrane Database of Systematic Reviews published by John Wiley & Sons, Ltd. on behalf of The
Cochrane Collaboration.
Types of participants
Mosquitoes
Anopheles gambiae complex or Anopheles funestus group. Included
trials had to test a minimum of 50 mosquitoes per trial arm. We
included all mosquito populations and examined the insecticide
resistance level (measured using phenotypic resistance) during data
analysis.
Humans
Adults and children living in malaria-endemic areas.
Types of interventions
Intervention
Combination LLIN treated with both PBO and a pyrethroid in-
secticide. The LLINs must have received a minimum of interim-
WHO approval (Table 2), and LLINs had to be treated with a
WHO-recommended dose of pyrethroid (Table 3).
Control
Conventional LLINs that contain pyrethroid only.
For objective 1 nets of the same fabric had to be treated with the
same insecticide, dose and release rate as the intervention net to
allow direct evaluation of the addition of PBO.
For objective 2 (a and b), nets could be treatedwith the same insec-
ticide at different doses from the intervention net to allow critical
appraisal of all pyrethroid-PBO nets currently in development or
on the market.
For both intervention and control arms, nets could be unholed,
holed, unwashed or washed, providing the trials adhered toWHO
guidelines (WHO 2013).
Types of outcome measures
Trials had to include at least one of the following outcomes to
be eligible for inclusion: mosquito knock-down, mosquito mor-
tality, blood feeding, sporozoite rate, parasite presence, clinical
malaria confirmation, not passed through net, deterrence, ex-
ophily, mosquito density, or parity rate.
Primary outcomes
Epidemiological
1. Parasite presence: presence of malaria parasites through
microscopy of blood or Rapid Diagnostic Tests (RDTs).
2. Clinical malaria confirmation: clinical diagnosis based on
the participant’s symptoms and on physical findings at
examination.
Entomological
1. Mosquito mortality: immediate death or delayed death (up
to 24 hours), or both, measured as a proportion of total
mosquito number. A mosquito is classified as dead if it is
immobile, cannot stand or fly, or shows no sign of life.
2. Mosquito knock-down: mosquito ‘mortality’ recorded one
hour post-insecticide exposure, termed ‘knock-down’ as some
mosquitoes may recover during the 24-hour recovery period
before mosquito mortality is recorded at 24 hours post-exposure.
3. Blood-feeding success: number of mosquitoes that have
blood-fed (alive or dead).
4. Sporozoite rate: percentage of mosquitoes with sporozoites
in salivary glands.
Secondary outcomes
Entomological
1. Not passed through net: the number of mosquitoes that do
not pass through a holed pyrethroid-PBO net to reach a human
bait relative to a standard LLIN, using a tunnel test.
2. Deterrence: the number of mosquitoes that enter a hut that
is using a pyrethroid-PBO net relative to the number of
mosquitoes found in a control hut that is using a standard LLIN
(experimental hut trials only).
3. Exophily: the proportion of mosquitoes found in exit/
veranda traps of a hut that is using a pyrethroid-PBO net,
relative to the control hut that is using a standard LLIN
(experimental hut trials only).
4. Mosquito density: measured using all standard methods,
such as window exit traps, indoor resting collections, floor sheet
collections, pyrethrum spray catch, and light traps (village trials).
5. Parity rate: percentage of parous mosquitoes which are
detected by mosquito ovary dissections (village trials).
Search methods for identification of studies
We identified all relevant trials regardless of language or publica-
tion status (published, unpublished, in press, and in progress). We
have presented the MEDLINE search strategy in Appendix 1.
Electronic searches
Vittoria Lutje, the Cochrane Infectious Diseases Group (CIDG)
Information Specialist, searched the following databases on 24
August 2018 using the search terms and strategy described in
Appendix 1: the CIDG Specialized Register; the Cochrane Cen-
tral Register of Controlled Trials (CENTRAL, included in the
Cochrane Library (Issue 8 2018); MEDLINE (PubMed); Embase
(OVID); Web of Science Core Collection, and CAB Abstracts.
She also searched the WHO International Clinical Trials Registry
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Platform (WHO ICTRP; www.who.int/ictrp/en/) and Clinical-
Trials.gov (clinicaltrials.gov/ct2/home) for trials in progress.
Searching other resources
We contacted the following organizations for unpublished data:
the PMI; the Innovative Vector Control Consortium (IVCC);
Vestergaard Frandsen; Sumitomo Chemical Company Ltd; Vector
Control Innovations Private Ltd; Endura SpA; and WHOPES.
We checked the reference lists of trials identified by the above
methods.
Data collection and analysis
All analyses were stratified by trial design. We also performed anal-
yses for the primary outcomes stratified by both trial design and
mosquito insecticide resistance level where possible. In addition,
for hut trials conducted in high-resistance areas, we also performed
analyses stratified by net type.
We determined whether mosquito populations are susceptible or
resistant to pyrethroid insecticides based on WHO definitions
(WHO 2016; Table 4). We used 24-hour mosquito mortality to
determine resistance status, however if this had been unavailable,
we intended to use knock-down 60 minutes after the end of the
assay. We stratified resistant populations into low-, moderate-,
or high-prevalence resistance (Table 5), by dividing the resistant
mosquitoes (that is, those with less than 90%mortality) into three
equal groups, with the lower third being the most resistant and
upper third the most susceptible.
Selection of studies
Two review authors (KG and NL) independently screened titles
and abstracts of all retrieved references based on the inclusion cri-
teria (Table 6).We resolved any inconsistencies between the review
authors’ selections by discussion. If we were unable to reach an
agreement, we consulted a third review author (HR).We retrieved
the full-text trial reports for all potentially relevant citations. Two
review authors independently screened the full-text articles and
identified trials for inclusion, and identified and recorded reasons
for exclusion of ineligible trials in a ‘Characteristics of excluded
studies’ table. We resolved any disagreements through discussion
or, if required, consulted a third review author ( HR). We identi-
fied and excluded duplicates and collated multiple reports of the
same trial so that each trial, rather than each report, was the unit
of interest in the review. We recorded the selection process in suffi-
cient detail to complete a PRISMA flow diagram ( Moher 2009).
Data extraction and management
After selection, we summarized all included trials according to the
tables in Appendix 2. Two review authors (KG and NL) inde-
pendently extracted data from the included trials using the pre-
designed data extraction form (Appendix 3). If data were missing
from an included trial, we contacted the trial authors for further
information. We entered data into Review Manager 5 (RevMan
5) (Review Manager 2014).
Assessment of risk of bias in included studies
Two review authors (KG and NL) independently assessed the risk
of bias of each included trial using a set of predetermined criteria
specific to each trial type adapted from Strode 2014 (Appendix
4). We assigned a classification of either low, high, or unclear risk
of bias for each component. For all included trials we assessed
whether any trial authors had submitted any conflicts of interest
that may have biased the trial methodology or results.
Laboratory bioassays
For laboratory bioassays we assessed five criteria: comparability of
mosquitoes between LLIN/pyrethroid-PBO net arms (for exam-
ple, all female, same age, and non-blood-fed), observers blinded,
incomplete outcome data, raw data reported for both net treat-
ments, and trial authors’ conflicting interests.
Experimental hut trials
For experimental hut trials we assessed 11 criteria: comparability
of mosquitoes between LLIN/pyrethroid-PBO net arms (for ex-
ample, species composition), collectors blinded, sleepers blinded,
sleeper bias accounted for, treatment allocation, treatment rota-
tion, standardized hut design, hut cleaning between treatments,
incomplete outcome data, raw data reported, and trial authors’
conflicting interests.
Village trials
We assessed 12 criteria for village trials: recruitment bias, compa-
rability of mosquitoes between LLIN/pyrethroid-PBO net house-
holds (for example, species composition), collectors blinded,
household blinded, treatment allocation, allocation concealment,
incomplete outcome data, raw data reported, clusters lost to fol-
low-up, selective reporting, adjusting for data clustering, and trial
authors’ conflicting interests.
Measures of treatment effect
For dichotomous data we presented the risk ratio (RR). There
were no continuous or count data; however if there had been, we
would have used the mean difference and rate ratios, respectively.
We have presented all results with 95% confidence intervals (CIs).
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Unit of analysis issues
For trials randomized by hut or village, we used the adjusted mea-
sure of effect reported in the paper if available. If not reported,
we adjusted the effect estimate using an intracluster correlation
coefficient (ICC), and average cluster size (Higgins 2011, Section
16.3.4). If the included trial did not report the ICC value, we es-
timated the ICC value and investigated the impact of estimating
the ICC in sensitivity analyses.
To adjust results of experimental hut trials for clustering,we treated
each ‘hut and sleeper’ combination as the unit of analysis, as each
‘hut and sleeper’ combination was tested with each type of net,
over a series of nights. We calculated effective sample sizes by
estimating an ICC and corresponding design effect. We divided
both the number of mosquitoes and the number experiencing the
event by this design effect.
To adjust results of village trials for clustering (for which the trial
authors had not adjusted the data themselves), we treated each
village as the unit of analysis. We calculated effective sample sizes
by estimating an ICC and corresponding design effect. Forest plots
for both hut and village trials show the effective number of events
after adjusting for clustering.
Dealing with missing data
In the case ofmissingdata, we contacted the trial authors to retrieve
this information. If we had identified trials where participants were
lost to follow-up, wewould have investigated the impact ofmissing
data via imputation using a best-worst case scenario analysis.
Where information on mosquito insecticide resistance was not
collected at the time of the trial, the review authors determined a
suitable proxy. The proxy resistance data had to be from the same
area, conducted within three years of the trial, and using the same
insecticide, dose, and mosquito species. More than 50 mosquitoes
per insecticide should have been tested using an appropriate con-
trol. Where no resistance data were available, we classed the resis-
tance status as unclassified.
Assessment of heterogeneity
Wepresented the results of the included trials in forest plots, which
we inspected visually to assess heterogeneity (that is, non-overlap-
ping CIs generally signify statistical heterogeneity). We also used
the Chi2 test with a P value of less than 0.1 to indicate statistical
heterogeneity. We quantified heterogeneity using the I2 statistic
(Higgins 2003), and we interpreted a value greater than 75% to
indicate considerable heterogeneity (Deeks 2017).
Assessment of reporting biases
To analyse the possibility of publication bias, we intended to use
funnel plots if 10 trials were included in any of the meta-analyses.
However, no analyses included 10 or more trials, so this was not
applicable.
Data synthesis
Where appropriate, we pooled the results of the included trials
using meta-analysis. We stratified results by type of trial, mosquito
resistance status and net type (i.e. product, for example Olyset
Plus).
Three review authors (KG, NL, and MR) analysed the data using
RevMan 5 (Review Manager 2014), and we used the random-
effects model (if we detected heterogeneity; the I2 statistic value
was more than 75%), or the fixed-effect model (for no heterogene-
ity; the I2 statistic value was less than 75%). We would have not
pooled trials in meta-analysis if it was not clinically meaningful to
do so, due to clinical or methodological heterogeneity.
Subgroup analysis and investigation of heterogeneity
We performed subgroup analyses according to whether nets were
washed or unwashed.
Sensitivity analysis
We intended to perform sensitivity analyses to determine the effect
of exclusion of trials that we considered to be at high risk of bias,
however this was not applicable. We would also have performed a
sensitivity analysis for missing data during imputation with best-
worst case scenarios, but again this was not applicable.
We performed sensitivity analyses to investigate the impact of esti-
mating an ICC to adjust trial results for clustering. We performed
analyses using ICCs of 0.01, 0.05, and 0.1. Since the results were
robust to these adjustments, we used the most conservative ICC
(0.1), and we adjusted all results from unadjusted cluster trials
using this ICC. We have not presented analyses using the smaller
ICCs (0.01 and 0.05).
Certainty of the evidence
We assessed the certainty of the evidence using the GRADE ap-
proach (Schünemann 2013). We constructed ‘Summary of find-
ings’ tables using the GRADEpro Guideline Development Tool
(GDT) software (GRADEpro GDT 2015).
R E S U L T S
Description of studies
Results of the search
We identified 168 records through the electronic searches, and
19 additional records from other sources. We removed duplicates,
leaving 175 records, and screened all articles for possible inclu-
sion. After abstract and title screening, we excluded 154 obviously
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ineligible trials. We assessed 22 full-text articles for eligibility and
excluded seven articles for the following reasons: five trials did not
share the full datasets and two studies are ongoing. Fifteen trials
met the inclusion criteria (Figure 1).
Figure 1. Study flow diagram
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Included studies
Fifteen trialsmet the inclusion criteria, andwe have described them
in the ‘Characteristics of included studies’ tables. Two trials were
laboratory bioassays (Darriet 2011;Darriet 2013), eight trials were
experimental hut trials (Bayili 2017 (Burkina Faso); Corbel 2010
(Burkina Faso, Benin, Cameroon); Koudou 2011 (Côte d’Ivoire);
Moore 2016 (Tanzania);N’Guessan 2010 (Benin); Pennetier 2013
(Benin); Toé 2018 (Burkina Faso); Tungu 2010 (Tanzania)), and
five trials were village trials (Awolola 2014 (Nigeria); Cisse 2017
(Mali); Mzilahowa 2014 (Malawi); Protopopoff 2018 (Tanzania);
Stiles-Ocran 2013 (Ghana)). All trials were conducted in Africa.
Interventions
Two trials compared anet treatedwith deltamethrin to a net treated
with deltamethrin and PBO (Darriet 2011; Darriet 2013). Six
trials compared Permanet 2.0 to Permanet 3.0 (Awolola 2014;
Corbel 2010; Koudou 2011;N’Guessan 2010; Stiles-Ocran 2013;
Tungu 2010). Two trials compared Olyset Net to Olyset Plus (
Pennetier 2013; Protopopoff 2018).One trial comparedMAGNet
LN to Veeralin LN (Moore 2016). Three trials compared both
OlysetNet toOlyset Plus and Permanet 2.0 to Permanet 3.0 (Cisse
2017;Mzilahowa 2014; Toé 2018).One trial comparedDawaPlus
2.0 to DawaPlus 3.0 and DawaPlus 4.0 (Bayili 2017).
Excluded studies
We assessed 22 full-text articles for eligibility and excluded seven
articles for the following reasons: five trials are awaiting classi-
fication because we were unable to obtain the full data sets af-
ter we contacted the trial authors (see ‘Characteristics of studies
awaiting classification’ table), and two trials are ongoing (see
‘Characteristics of ongoing studies’ section).
Risk of bias in included studies
We have provided a ‘Risk of bias’ assessment summary in Figure
2. The criteria we used to assess risk of bias are in Appendix 5
(laboratory bioassays), Appendix 6 (experimental hut trials), and
Appendix 7 (village trials).
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Figure 2. ‘Risk of bias’ summary: review authors’ judgements about each risk of bias item for each included
study.
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Allocation
Recruitment bias
We assessed all five village trials as at low risk of bias. Four village
trials were at low risk of recruitment bias as recruitment bias is
related to human participants and so not applicable to this review
(Awolola 2014; Cisse 2017;Mzilahowa 2014; Stiles-Ocran 2013).
We assessed one village trial as low risk as no participants were
recruited after clusters had been randomized (Protopopoff 2018).
Mosquito group comparability
We judged the two laboratory bioassays at low risk of bias (Darriet
2011;Darriet 2013), as they used the samemosquito strain, and all
eight experimental hut trials at low risk (Bayili 2017; Corbel 2010;
Koudou 2011; Moore 2016; N’Guessan 2010; Pennetier 2013;
Toé 2018; Tungu 2010), as the huts were situated in the same trial
area and therefore accessible to the samemosquito populations.We
judged four village trials at unclear risk (Awolola 2014; Cisse 2017;
Protopopoff 2018; Stiles-Ocran 2013), as the species composition
and resistance status varied slightly between treatment arms. We
deemed one village trial high risk (Mzilahowa 2014), as species
and resistance data were not separated by village, and it was not
possible to ascertain this from the information provided.
Blinding
We assessed the two laboratory trials (Darriet 2011;Darriet 2013),
and eight hut trials (Bayili 2017; Corbel 2010; Koudou 2011;
Moore 2016; N’Guessan 2010; Pennetier 2013; Toé 2018; Tungu
2010), as at unclear risk as they did not specify whether observers
(lab trials), or collectors and sleepers (hut trials) were blinded.
This is not standard protocol for these trial designs and is thought
unlikely to affect the results. We judged four village trials at high
risk of bias, as it was not stated if collectors were blinded, and
this may affect searching effort during collections (Awolola 2014;
Cisse 2017; Mzilahowa 2014; Stiles-Ocran 2013). We classed one
trial as low risk because collectors were masked to the treatment
(Protopopoff 2018). For household blinding we judged all five vil-
lage trials as low risk of bias. Four village trials did not state if house-
holds were blind to the intervention, however this was unlikely
to influence the results (Awolola 2014; Cisse 2017; Mzilahowa
2014; Stiles-Ocran 2013). We judged one village trial as low risk,
as inhabitants and field collectors were blinded to intervention
arms (Protopopoff 2018).
Sleeper bias
We assessed the eight hut trials at low risk for sleeper bias, as
sleeperswere rotated betweenhuts following aLatin square design (
Bayili 2017;Corbel 2010;Koudou 2011;Moore 2016;N’Guessan
2010; Pennetier 2013; Toé 2018; Tungu 2010).
Treatment allocation, rotation, and concealment
We assessed the eight hut trials at low risk for treatment allocation
and rotation (Bayili 2017; Corbel 2010; Koudou 2011; Moore
2016; N’Guessan 2010; Pennetier 2013; Toé 2018; Tungu 2010),
as treatments were rotated between huts following a Latin square
design. We assessed five village trials at low risk for treatment allo-
cation (Awolola 2014; Cisse 2017; Mzilahowa 2014; Protopopoff
2018; Stiles-Ocran 2013), as villages were randomly assigned to
treatment arms. We assessed all five village trials as low risk of bias
for allocation concealment (Awolola 2014; Cisse 2017;Mzilahowa
2014; Protopopoff 2018; Stiles-Ocran 2013).
Hut design
We assessed eight hut trials at low risk of bias, as huts were built to
standardWest- or East-African specifications (Bayili 2017; Corbel
2010; Koudou 2011;N’Guessan 2010; Pennetier 2013; Toé 2018;
Tungu 2010), or using modified but standardized designs (Moore
2016).
Cleaning
We assessed four hut trials at unclear risk as they did not state if
huts were cleaned between treatment arms (Bayili 2017; Corbel
2010; Moore 2016; Toé 2018; Tungu 2010). We assessed four at
low risk, as cleaning was conducted between treatment rotations
(Koudou 2011; N’Guessan 2010; Pennetier 2013; Tungu 2010).
Incomplete outcome data
We assessed all laboratory (Darriet 2011; Darriet 2013), hut (
Bayili 2017;Corbel 2010;Koudou 2011;Moore 2016;N’Guessan
2010; Pennetier 2013; Toé 2018; Tungu 2010), and village trials
(Awolola 2014; Cisse 2017; Mzilahowa 2014; Protopopoff 2018;
Stiles-Ocran 2013), as at low risk for both incomplete outcome
data and raw data reporting, as there were no incomplete outcome
data, or missing data were later provided by the trial authors. In
cases where raw data were not reported, we were able to calculate
them from the percentages and sample sizes given. When these
data were not available, we did not include the trials.
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Clustering bias
No clusters were lost to follow-up in any of the village trials, there-
fore we assessed all village trials as at low risk of bias (Awolola 2014;
Cisse 2017; Mzilahowa 2014; Protopopoff 2018; Stiles-Ocran
2013). We assessed four village trials as at high risk of bias for sta-
tistical methods used, as they did not adjust for clustering (Awolola
2014; Cisse 2017; Mzilahowa 2014; Stiles-Ocran 2013). We as-
sessed one trial as low risk of bias, as it took clustering into account
and adjusted for it in its statistical methods (Protopopoff 2018).
Selective reporting
We assessed all village trials as low risk of bias regarding selective
reporting, as they appear to have reported all measured outcomes
(Awolola 2014; Cisse 2017; Mzilahowa 2014; Protopopoff 2018;
Stiles-Ocran 2013).
Other potential sources of bias
Conflicting interests
We judged two lab trials (Darriet 2011; Darriet 2013), seven hut
trials (Bayili 2017; Corbel 2010; Koudou 2011; Moore 2016;
Pennetier 2013; Toé 2018; Tungu 2010), and three village trials
(Awolola 2014; Cisse 2017; Protopopoff 2018), as at low risk as
the trial authors reported no conflicting interests. We assessed one
hut trial at unclear risk (N’Guessan 2010), as the trial authors
stated that they had received funding from LLIN manufacturers
when conducting the trials, and the same funders also provided
comments on the manuscript. We assessed one village trial as un-
clear risk, as the trial authors did not state if there were conflicting
interests or not (Mzilahowa 2014), and another one as unclear
risk, as the trial was conducted to form part of the manufacturer’s
product dossier (Stiles-Ocran 2013).
Effects of interventions
See: Summary of findings for the main comparison ‘Summary
of findings’ table 1; Summary of findings 2 ‘Summary of findings’
table 2; Summary of findings 3 ‘Summary of findings’ table 3;
Summary of findings 4 ‘Summary of findings’ table 4
Objective 1
Objective 1 was to evaluate whether adding PBO to pyrethroid-
LLINs increases the epidemiological and entomological effective-
ness of bed nets.
Epidemiological results
None of the trials that met the inclusion criteria for Objective 1
measured parasite presence, or clinical malaria confirmation, in
adults or children.
Entomological results
Two laboratory trials evaluated the impact of an insecticide-
treated net (ITN), impregnated with deltamethrin (a pyrethroid
insecticide), only, compared to ITN plus PBO (PBO-ITN), on
mosquito mortality in an insecticide-resistant laboratory strain
(Darriet 2011; Darriet 2013). The pooled analysis showed sub-
stantially increased mosquito mortality when using pyrethroid-
PBO (RR 6.06, 95% CI 4.15 to 8.84; 558 mosquitoes, 2 trials;
Analysis 1.1).
Objective 2
Objective 2 compared the effects of pyrethroid-PBOnets currently
in commercial development or on the market with their non-
PBO equivalent in relation tomalaria infection and entomological
outcomes.
Epidemiological results
One trial examined the effect of pyrethroid-PBO nets on malaria
infection prevalence (Protopopoff 2018). Overall the latest end-
point at 21 months after the intervention showed that malaria
prevalence decreased in the intervention arm (OR 0.40, 95% CI
0.20 to 0.80; 1 trial, 1 comparison; Analysis 3.1).
Entomological results
Phase II experimental hut trials
Eight experimental hut trials (phase II trials), examined the effect
of pyrethroid-PBO nets on mosquito mortality, blood feeding, ex-
ophily, and deterrence (Bayili 2017; Corbel 2010; Koudou 2011;
Moore 2016; N’Guessan 2010; Pennetier 2013; Toé 2018; Tungu
2010). We subgrouped the data by net washing, into unwashed
and washed groups. Washed nets were all washed 20 times accord-
ing to WHO specifications (WHO 2013). We pooled the results
initially and then stratified them by insecticide resistance level and
net type. One trial did not wash their nets and so did not report
any data for the washed subgroup (Toé 2018). One trial did not
introduce holes into the nets and so did not report blood-feeding
success data (Koudou 2011).
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Pooled analysis
Pooled analysis of all experimental hut trials, using both un-
washed (Bayili 2017; Corbel 2010; Koudou 2011; Moore 2016;
N’Guessan 2010; Pennetier 2013; Toé 2018; Tungu 2010) and
washed nets (Bayili 2017; Corbel 2010; Koudou 2011; Moore
2016; N’Guessan 2010; Pennetier 2013; Tungu 2010), found that
pyrethroid-PBO nets significantly increased mosquito mortality,
by 36% (RR 1.36, 95%CI 1.20 to 1.54), and reduced blood-feed-
ing success by 24% (RR 0.76, 95% CI 0.67 to 0.88). The magni-
tude of effect was reduced by net washing. Unwashed pyrethroid-
PBO nets increased mosquito mortality by 54% compared to un-
washed LLINs, (RR 1.54, 95% CI 1.21 to 1.96; 8 trials, 15 com-
parisons; Analysis 2.1); when nets are washed this effect decreased
to 14%, (RR 1.14, 95% 1.00 to 1.31; 7 trials, 11 comparisons;
Analysis 2.1). Unwashed pyrethroid-PBO nets reduced mosquito
blood-feeding success by 34% (Bayili 2017; Corbel 2010; Moore
2016; N’Guessan 2010; Pennetier 2013; Toé 2018; Tungu 2010;
RR 0.66, 95% CI 0.54 to 0.79; 7 trials, 14 comparisons; Analysis
2.2); however this effect was lost when nets were washed (Bayili
2017; Corbel 2010; Moore 2016; N’Guessan 2010; Pennetier
2013; Tungu 2010; 6 trials, 10 comparisons; Analysis 2.2). There
was no effect on mosquito exophily in either unwashed (8 trials,
15 comparisons; Analysis 2.3) or washed (7 trials, 11 comparisons;
Analysis 2.3), groups. Mosquito deterrence data were presented
relative to an untreated control and hence are not included as a
forest plot. There was considerable variation in the deterrence rates
but no clear relationship with resistance level, net type, or washing
status (Table 7).
There was considerable heterogeneity in this pooled analysis, par-
ticularly for estimates of mortality. We therefore performed a pre-
specified, stratified analysis, dividing the results into trials con-
ducted in areas of low, moderate, or high resistance in the Anophe-
les population.
Stratified analysis: mosquito resistance status
We used the WHO and CDC definitions of mosquito mortality,
from WHO tube assays or CDC bottle tests (Table 4) to classify
mosquito resistance. Both tests definemosquitoes as resistantwhen
mortality is less than 90%. We further stratified resistance based
on the following mortality levels: < 30%, high resistance; 31%
to 60%, moderate resistance; 61% to 90%, low resistance (Table
5). When resistance data were not collected at the time of the
trial, we identified a suitable proxy based on previously described
criteria (see ‘Dealing with missing data’ section); when we could
not identify a suitable proxy, we classed the trial as ‘unclassified’
and did not include it in the resistance stratification.
Five trials were conducted in four areas where mosquito popula-
tions exhibited high resistance to pyrethroids (Bayili 2017; Corbel
2010;Koudou 2011; Pennetier 2013;Toé 2018).Under these con-
ditions unwashed pyrethroid-PBO nets increased mosquito mor-
tality by 84% in comparison to unwashed LLINs (RR 1.84, 95%
CI1.60 to 2.11; 5 trials, 9 comparisons; Analysis 2.4), however this
effect was lost when nets were washed (Bayili 2017; Corbel 2010;
Koudou 2011; Pennetier 2013; 4 trials, 5 comparisons; Analysis
2.4). Blood-feeding success was reduced by 40% in unwashed
pyrethroid-PBO-net groups compared to unwashed LLINs (Bayili
2017; Corbel 2010; Pennetier 2013; Toé 2018; RR 0.60, 95%
CI 0.50 to 0.71; 4 trials, 8 comparisons; Analysis 2.5), and by
19%when nets were washed (Bayili 2017; Corbel 2010; Pennetier
2013; RR 0.81, 95% CI 0.72 to 0.92; 3 trials, 4 comparisons;
Analysis 2.5).
One trial in one site was conducted in an area with moderate
insecticide resistance (N’Guessan 2010). No effect on mosquito
mortality (1 trial, 1 comparison; Analysis 2.6) or on blood-feeding
success (1 trial, 1 comparison; Analysis 2.7) was observed in either
washed or unwashed treatments.
One trial in two sites was conducted in an area with low insecticide
resistance (Corbel 2010). A small effect onmosquitomortality was
observed in unwashed nets (RR 1.10, 95%CI 1.05 to 1.16; 1 trial,
2 comparisons; Analysis 2.8), however this was lost by washing (1
trial, 2 observations; Analysis 2.8). No effect was seen in blood-
feeding success (1 trial, 2 comparisons; Analysis 2.9).
In susceptible sites (Moore 2016; Tungu 2010), no effect on
mosquito mortality (2 trials, 2 comparisons; Analysis 2.10), or
blood-feeding success (2 trials, 2 comparisons; Analysis 2.11), was
observed.
Stratified analysis: net type
After stratifying by resistance status, we performed a secondary
analysis stratified according to net type.Due to the limited number
of trials, we only performed this analysis for trials using PermaNet
3.0 or Olyset Plus. Although additional trials utilising Veeralin
LN, DawaPlus 3.0, and DawaPlus 4.0 have been conducted, not
all data weremade available to us for the purposes of this Cochrane
Review. Futhermore, the analysis was restricted to trials conducted
in areas of high resistance, as this analysis only indicated an impact
of pyrethroid-PBO nets in these settings. Three trials compared
PermaNet 2.0 (LLIN) to PermaNet 3.0 (pyrethroid-PBO nets),
and two comparedOlysetNets (LLIN) toOlyset Plus (pyrethroid-
PBO nets).
In the PermaNet group, in high-resistance settings, unwashed Per-
maNet 3.0 increased mosquito mortality by 81% compared to
PermaNet 2.0 (Corbel 2010; Koudou 2011; Toé 2018; RR 1.81,
95%CI 1.56 to 2.10; 3 trials, 4 comparisons; Analysis 2.12). After
washing there was no significant increase in mortality in the Per-
maNet 3.0 arm (Corbel 2010; Koudou 2011; 2 trials, 2 compar-
isons; Analysis 2.12). Blood-feeding success was reduced by 47%
when using unwashed PermaNet 3.0 (Corbel 2010; Toé 2018; RR
0.53, 95%CI 0.40 to 0.69; 2 trials, 3 comparisons; Analysis 2.13),
only one trial was available for washed nets (Corbel 2010), and
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here PermaNet 3.0 also reduced blood-feeding success (RR 0.76,
95% 0.61 to 0.93; 1 trial, 1 comparison; Analysis 2.13).
In high-resistance settings, Olyset Plus increased mosquito mor-
tality by 72% when nets were unwashed (Pennetier 2013; Toé
2018; RR 1.72, 95% CI 1.48 to 1.99; 2 trials, 3 comparisons;
Analysis 2.14). Only one trial compared washed Olyset Plus with
washedOlyset (Pennetier 2013); in this trial the enhancedmortal-
ity (81%) in the Olyset Plus arm was still observed after washing
(RR 1.81, 95% CI 1.25 to 2.61; 1 trial, 1 comparison; Analysis
2.14). There was no impact on blood-feeding success when com-
paring unwashed Olyset Plus with Olyset (2 trials, 3 comparisons;
Analysis 2.15); the single trial that looked at washed Olyset Plus
showed decreased blood feeding compared to Olyset (RR 0.50,
95% 0.27 to 0.93; 1 trial, 1 comparison; Analysis 2.15)
Phase III village trials
In the village trials there was no decrease in sporozoite rate in the
trial arms receiving pyrethroid-PBO nets (Awolola 2014; Cisse
2017; Protopopoff 2018; Stiles-Ocran 2013; RR 0.82, 95% CI
0.24 to 2.75; 4 trials, 5 comparisons; Analysis 3.2). Mosquito
parity was not reduced in pyrethroid-PBO villages (Cisse 2017;
Mzilahowa 2014; Stiles-Ocran 2013; 3 trials, 4 comparisons;
Analysis 3.3). It was not possible to stratify these data by resistance
status due to the variability in resistance levels between villages
within the same trial. Mosquito density was measured using a va-
riety of methods and summarized in different ways (for example,
mean number caught per house, mean number caught per village).
Where baseline data were collected, we calculated a percentage re-
duction. Higher reductions in mosquito densities were observed
in pyrethroid-PBO net villages compared to LLIN villages (Table
8).
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A D D I T I O N A L S U M M A R Y O F F I N D I N G S [Explanation]
Pyrethroid-piperonyl butoxide (PBO) nets compared to long- lasting insecticidal nets (LLIN) for malaria control where insecticide resistance is moderate
Patient or population: Anopheles gambiae complex or Anopheles funestus group
Setting: areas of moderate insect icide resistance
Intervention: pyrethroid-PBO nets
Comparison: LLIN
Outcomes Anticipated absolute effects∗ (95% CI) Relative effect
(95% CI)
Number of mosquitoes
(experimental hut tri-
als)
Certainty of the evi-
dence
(GRADE)
Comments
Risk with LLIN Risk with pyrethroid-
PBO nets
Mosquito mortality
(unwashed nets)
439 per 1000a 509 per 1000
(386 to 675)a
RR 1.16
(0.88 to 1.54)
242
(1 trial, 1 comparison)
⊕⊕©©
LOWb,c,d
due to imprecision and in-
directness
There may be lit -
t le or no dif ference
in the ef fect of un-
washed pyrethroid-PBO
nets on mosquito mor-
tality compared to stan-
dard unwashed LLINs in
areas of moderate in-
sect icide resistance
Mosquito mortality
(washed nets)
287 per 1000a 307 per 1000
(213 to 443)a
RR 1.07
(0.74 to 1.54)
329
(1 trial, 1 comparison)
⊕⊕©©
LOWb,c,d
due to imprecision and in-
directness
There may be lit t le or no
dif ference in the ef fect
of washed pyrethroid-
PBO nets on mosquito
mortality compared to
standard washed LLINs
(washed) in areas of
moderate insect icide
resistance
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Blood- feeding success
(unwashed nets)
553 per 1000a 481 per 1000
(370 to 624)a
RR 0.87
(0.67 to 1.13)
242
(1 trial, 1 comparison)
⊕⊕©©
LOWb,c,d
due to imprecision and in-
directness
There may be lit t le or
no dif ference in the ef -
fect of pyrethroid-PBO
nets (unwashed) on
mosquito blood-feed-
ing success compared
to standard LLINs in ar-
eas of moderate insec-
t icide resistance
Blood- feeding success
(washed nets)
586 per 1000a 533 per 1000
(434 to 662)a
RR 0.91
(0.74 to 1.13)
329
(1 trial, 1 comparison)
⊕⊕©©
LOWb,c,d
due to imprecision and in-
directness
There may be lit t le or no
dif ference in the ef fect
of washed pyrethroid-
PBO nets on mosquito
blood-feeding success
compared to standard
washed LLINs in areas
of moderate insect icide
resistance
*The risk in the intervention group (and its 95%CI) is based on the assumed risk in the comparison group and the relative effect of the intervent ion (and its 95%CI).
Abbreviations: CI: conf idence interval; LLIN: long-last ing insect icidal nets; PBO: pyrethroid-piperonyl butoxide; RR: risk rat io
GRADE Working Group grades of evidence
High certainty: we are very conf ident that the true ef fect lies close to that of the est imate of the ef fect.
Moderate certainty: we are moderately conf ident in the ef fect est imate: the true ef fect is likely to be close to the est imate of the ef fect, but there is a possibility that it is
substant ially dif f erent.
Low certainty: our conf idence in the ef fect est imate is lim ited: the true ef fect may be substant ially dif f erent f rom the est imate of the ef fect.
Very low certainty: we have very lit t le conf idence in the ef fect est imate: the true ef fect is likely to be substant ially dif f erent f rom the est imate of ef fect
aOriginal numbers used in this table, however in pooled analysis, we generated events and total numbers f rom cluster-adjusted
results, which used the ef fect ive sample size. Note that cluster adjustments do not change the point est imate of the ef fect
size, just the standard error.
bNot downgraded for inconsistency as only one trial measured this outcome in this sett ing.
cDowngraded by one for imprecision due to wide CIs.
dDowngraded by one for indirectness: the outcome is highly context-specif ic and there is only one trial included here.
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Pyrethroid-piperonyl butoxide (PBO) nets compared to long- lasting insecticidal nets (LLIN) for malaria control where insecticide resistance is low
Patient or population: Anopheles gambiae complex or Anopheles funestus group
Setting: areas of low insect icide resistance
Intervention: pyrethroid-PBO nets
Comparison: LLIN
Outcomes Anticipated absolute effects∗ (95% CI) Relative effect
(95% CI)
Number of mosquitoes
(experimental hut tri-
als)
Certainty of the evi-
dence
(GRADE)
Comments
Risk with LLIN Risk with pyrethroid-
PBO nets
Mosquito mortality
(unwashed nets)
871 per 1000a 958 per 1000
(914 to 1000)a
RR 1.10
(1.05 to 1.16)
708
(1 trial, 2 comparisons)
⊕⊕⊕©
MODERATEb
due to imprecision
There is probably lit -
t le or no dif ference
in the ef fect of un-
washed pyrethroid-PBO
nets on mosquito mor-
tality compared to stan-
dard unwashed LLINs in
areas of low insect icide
resistance
Mosquito mortality
(washed nets)
620 per 1000a 719 per 1000
(514 to 1000)a
RR 1.16
(0.83 to 1.63)
878
(1 trial, 2 comparisons)
⊕©©©
VERY LOWc,d
due to imprecision and in-
consistency
We do not know
if pyrethroid-PBO nets
have an ef fect on
mosquito mortality in
areas of low insect i-
cide resistance when
the nets have been
washed
Blood- feeding success
(unwashed nets)
72 per 1000a 48 per 1000
(4 to 529)a
RR 0.67
(0.06 to 7.37)
708
(1 trial, 2 comparisons)
⊕©©©
VERY LOWc,d
due to imprecision and in-
consistency
We do not know if
unwashed pyrethroid-
PBO nets have an ef -
fect on mosquito blood-
feeding success in ar-2
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eas of low insect icide
resistance
Blood- feeding success
(washed nets)
149 per 1000a 223 per 1000
(132 to 377)a
RR 1.50
(0.89 to 2.54)
878
(1 trial, 2 comparisons)
⊕⊕©©
LOWd
due to inconsistency
Mosquito blood-feed-
ing success may de-
crease with washed
pyrethroid-PBO nets
compared to standard
washed LLINs in areas
of low insect icide resis-
tance
*The risk in the intervention group (and its 95%CI) is based on the assumed risk in the comparison group and the relative effect of the intervent ion (and its 95%CI).
Abbreviations: CI: conf idence interval; LLIN: long-last ing insect icidal nets; PBO: pyrethroid-piperonyl butoxide; RR: risk rat io
GRADE Working Group grades of evidence
High certainty: we are very conf ident that the true ef fect lies close to that of the est imate of the ef fect.
Moderate certainty: we are moderately conf ident in the ef fect est imate: the true ef fect is likely to be close to the est imate of the ef fect, but there is a possibility that it is
substant ially dif f erent.
Low certainty: our conf idence in the ef fect est imate is lim ited: the true ef fect may be substant ially dif f erent f rom the est imate of the ef fect.
Very low certainty: we have very lit t le conf idence in the ef fect est imate: the true ef fect is likely to be substant ially dif f erent f rom the est imate of ef fect
aOriginal numbers used in this table, however in pooled analysis events and total numbers were generated f rom cluster
adjusted results which uses the ef fect ive sample size. Note that cluster adjustments do not change the point est imate of
the ef fect size, just the standard error.
bDowngraded by one for imprecision due to wide CIs.
cDowngraded by one for inconsistency due to unexplained heterogeneity.
dDowngraded by two for imprecision due to extremely wide CIs.
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Pyrethroid-piperonyl butoxide (PBO) nets compared to long- lasting insecticidal nets (LLIN) for malaria control where mosquitoes are susceptible
Patient or population: Anopheles gambiae complex or Anopheles funestus group
Setting: areas of insect icide-suscept ible mosquitoes
Intervention: pyrethroid-PBO nets
Comparison: LLIN
Outcomes Anticipated absolute effects∗ (95% CI) Relative effect
(95% CI)
Number of mosquitoes
(experimental hut tri-
als)
Certainty of the evi-
dence
(GRADE)
Comments
Risk with LLIN Risk with pyrethroid-
PBO nets
Mosquito mortality
(unwashed nets)
392 per 1000a 471 per 1000
(251 to 887)a
RR 1.20
(0.64 to 2.26)
2791
(2 trials, 2 compar-
isons)
⊕⊕©©
LOWb
due to imprecision
There may be lit -
t le or no dif ference
in the ef fect of un-
washed pyrethroid-PBO
nets on mosquito mor-
tality compared to stan-
dard unwashed LLINs in
areas of no insect icide
resistance
Mosquito mortality
(washed nets)
457 per 1000a 489 per 1000
(420 to 571)a
RR 1.07
(0.92 to 1.25)
2644
(2 trials, 2 compar-
isons)
⊕⊕©©
LOWb
due to imprecision
There may be lit t le or no
dif ference in the ef fect
of washed pyrethroid-
PBO nets on mosquito
mortality compared to
standard washed LLINs
in areas of no insect i-
cide resistance
Blood- feeding success
(unwashed nets)
57 per 1000a 29 per 1000
(6 to 132)a
RR 0.50
(0.11 to 2.32)
2791
(2 trials, 2 compar-
isons)
⊕©©©
VERY LOWb,c
due to imprecision and in-
consistency
We do not know if
unwashed pyrethroid-
PBO nets have an ef -
fect on mosquito blood-
feeding success in ar-2
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eas of no insect icide re-
sistance
Blood- feeding success
(washed nets)
64 per 1000a 82 per 1000
(52 to 131)a
RR 1.28
(0.81 to 2.04)
2644
(2 trials, 2 compar-
isons)
⊕⊕©©
LOWb
due to imprecision
There may be lit t le or no
dif ference in the ef fect
of washed pyrethroid-
PBO nets on mosquito
blood-feeding success
compared to standard
washed LLINs in areas
of no insect icide resis-
tance
*The risk in the intervention group (and its 95%CI) is based on the assumed risk in the comparison group and the relative effect of the intervent ion (and its 95%CI).
Abbreviations: CI: conf idence interval; LLIN: long-last ing insect icidal nets; PBO: pyrethroid-piperonyl butoxide; RR: risk rat io
GRADE Working Group grades of evidence
High certainty: we are very conf ident that the true ef fect lies close to that of the est imate of the ef fect.
Moderate certainty: we are moderately conf ident in the ef fect est imate: the true ef fect is likely to be close to the est imate of the ef fect, but there is a possibility that it is
substant ially dif f erent.
Low certainty: our conf idence in the ef fect est imate is lim ited: the true ef fect may be substant ially dif f erent f rom the est imate of the ef fect.
Very low certainty: we have very lit t le conf idence in the ef fect est imate: the true ef fect is likely to be substant ially dif f erent f rom the est imate of ef fect
aOriginal numbers used in this table, however in pooled analysis, events and total numbers were generated f rom cluster-
adjusted results, which use the ef fect ive sample size. Note that cluster adjustments do not change the point est imate of
the ef fect size, just the standard error.
bDowngraded by two for imprecision due to extremely wide CIs.
cDowngraded by one for inconsistency due to unexplained heterogeneity.
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D I S C U S S I O N
See Summary of findings for the main comparison, Summary of
findings 2, Summary of findings 3, and Summary of findings 4.
Summary of main results
There was a single cluster-RCT performed on pyrethroid-PBO
nets. This trial, which compared malaria prevalence in children
using Olyset Plus nets with those using Olyset nets, in a re-
gion of Tanzania where the mosquito vectors are highly resis-
tant to pyrethroids, found that pyrethroid-PBO nets reduced
malaria prevalence by 60% (Protopopoff 2018). All other trials
included in this review measured entomological endpoints. Four
villages measured sporozoite rates in mosquitoes collected from
houses using pyrethroid-PBOnets and standard pyrethroid LLINs
but the results were highly heterogeneous and there was no ev-
idence that pyrethroid-PBO nets reduced the mosquito infec-
tion rate from this pooled analysis (Awolola 2014; Cisse 2017;
Protopopoff 2018; Stiles-Ocran 2013). Similarly, the proportion
of parous mosquitoes (that is, mosquitoes that have survived past
one gonotrophic cycle, used as an indirect measure of longevity),
was not significantly affected by the presence of pyrethroid-PBO
nets (Cisse 2017; Mzilahowa 2014; Stiles-Ocran 2013).
When we pooled the results from the eight experimental hut
trials (Bayili 2017; Corbel 2010; Koudou 2011; Moore 2016;
N’Guessan 2010; Pennetier 2013; Toé 2018; Tungu 2010), the re-
sults showed an improved performance of pyrethroid-PBO LLINs
over standard LLINs in both increasing mosquito mortality and
reducing blood feeding but the results were highly heterogeneous.
Stratifying the experimental hut data by resistance levels in the
population reduced the heterogeneity. In areas where mosquitoes
are highly resistant to pyrethroids, pyrethroid-PBO nets will re-
duce mosquito blood-feeding rates (that is, users of the nets will
be better protected against mosquito bites by using pyrethroid-
PBO nets). This impact on blood feeding is reduced when nets
have been through the standard 20 washes recommended by the
WHO to assess chemical durability, but remains significant (high-
certainty evidence). When resistance is high and new unwashed
nets are used, mosquito mortality is substantially increased when
the nets contain PBO compared to pyrethroid-only LLINs (high-
certainty evidence). However this effect on mosquito mortality,
which is important for the community-level protection affordedby
LLIN usage (Hawley 2003; Maxwell 2002), is not sustained when
nets have beenwashedmultiple times. In this Cochrane Review we
classified mosquitoes as being highly resistant if fewer than 30%
were killed in a standard bioassay. When mortality rates exceeded
30%, there was little evidence that pyrethroid-PBO nets provided
greater personal protection or resulted in greater mosquito mor-
tality than standard pyrethroid-only nets. This result is not un-
expected given that, in areas where resistance is uncommon or
absent, exposure to pyrethroids alone would be expected to nega-
tively affect the mosquito; it is only in areas where the efficacy of
pyrethroids has been eroded by the development of high levels of
resistance where the addition of a synergist might be needed.
There was no evidence for any difference in the performance of
pyrethroid-PBO nets from different manufacturers against highly
pyrethroid-resistant mosquitoes. We only stratified results by net
type for trials that were conducted in areas of high resistance.
We have not reported comparisons for DawaPlus-PBO and Veer-
alin-PBO nets in this subanalysis as there was only a single data
point for these net types. Unwashed PermaNet 3.0 andOlyset Plus
resulted in similar increases in mosquito mortality compared to
pyrethroid-only LLINs from the same manufacturer although this
effect on mortality was not always sustained after washing (Corbel
2010; Koudou 2011; Pennetier 2013; Toé 2018). A significant
improvement in personal protection for unwashed pyrethroid-
PBO nets was only observed for PermaNet 3.0 (Corbel 2010; Toé
2018), but, after washing, pyrethroid-PBO nets from both man-
ufacturers provided greater personal protection than the equiva-
lent pyrethroid-only nets (Corbel 2010; Pennetier 2013). Results
from comparisons between pyrethroid-PBO nets from different
manufacturers should be taken with great caution given the very
limited number of data points available, particularly for washed
nets. Further trials, where nets from different manufacturers are
directly compared in the same trial are needed to address the issue
of equivalence between different pyrethroid-PBO nets.
Certainty of the evidence
We appraised the certainty of the evidence using the GRADE ap-
proach (Summary of findings for the main comparison, Summary
of findings 2, Summary of findings 3, and Summary of findings
4). The single RCT provides moderate-certainty evidence that
pyrethroid-PBO nets reduce the prevalence of malaria. However,
this result was obtained from a single setting (Protopopoff 2018).
The WHO recommends at least two RCTs in areas with differing
levels of malaria transmission to demonstrate public health value
(WHO-GMP 2017b). Hence this Cochrane Review will need to
be updated once data from the large-scale RCT of pyrethroid-
PBO nets in Uganda are available (ISRCTN17516395).
The certainty of evidence from trials using entomological end-
points varied. Data from village trials were difficult to assess as
there was considerable heterogeneity in the level of pyrethroid re-
sistance, and presumably also in the resistance mechanisms, both
within and between trials. Analysis of data from experimental hut
trials found high-certainty evidence for the superior performance
of pyrethroid-PBO nets in areas of high resistance but the evi-
dence for trials conducted in other settings was of low or very low
certainty.
Overall completeness and applicability of
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evidence
Only two published laboratory trials directly measured the impact
of adding PBO to LLINs (Darriet 2011; Darriet 2013). All other
trials included in this review compared pyrethroid-PBO nets with
the nearest equivalent pyrethroid-only LLIN. Further changes to
the net specification were often included when the manufactur-
ers incorporated the synergist. For example, the pyrethroid-PBO
net manufactured by Vestergaard (PermaNet 3.0), contains higher
levels of deltamethrin and a different denier (thickness) of yarn
compared to the pyrethroid-only equivalent, PermaNet 2.0; the
pyrethroid in Olyset Plus (Sumitomo Chemical Co Ltd), is re-
leased from the yarn at a different rate than in the Olyset nets.
These additional variations in the chemical or physical composi-
tion, or both, of the nets makes it difficult to directly assess the
added value of the addition of PBO. Furthermore the concen-
tration of PBO and its site of application differs markedly be-
tween nets from the different manufacturers. Two of the currently
available pyrethroid-PBOnets (PermaNet 3.0 and DawaPlus 3.0),
only contain PBO on the roof of the netting, exploiting the be-
havioural patterns of host-seeking mosquitoes to attempt to reach
the net user by approaching from above (Parker 2015), whilst the
remaining pyrethroid-PBO nets contain the synergist on all sides
of the net. The amount of PBO contained within the net differs
by a factor of 25-fold. It is not known how the net manufacturers
selected the doses of PBO to apply to the netting.
With the currently available data it is not possible to draw any
conclusions on which strategy for producing pyrethroid-PBO nets
will prove to be the most effective under field conditions. The
optimum PBO:pyrethroid ratio will likely differ depending on the
level of resistance in themosquito and the underpinning resistance
mechanisms. Data from experimental hut trials suggest that the
PBO component of the pyrethroid-PBO nets is lost after repeated
washing, as the enhanced mortality caused by the synergist nets is
not maintained after 20 washes. As yet, no trials on the durability
of pyrethroid-PBO nets under operational conditions have been
published. Encouragingly, the only clinical trial of pyrethroid-
PBOnets found that the superior protective efficacy of Olyset Plus
compared to standard Olyset nets was maintained over 20 months
of use (Protopopoff 2018); this trial is being extended further to
establish whether this effect lasts the full duration of an LLIN’s
intended 36-month lifespan.
Most of the available data evaluated the performance of
pyrethroid-PBO LLINs against An gambiae s.l., with very limited
data available for the second major species complex in Africa, An
funestus, and none for other minor vector species. As different
mosquito species may differ in their behaviour, and in the strength
and underpinning mechanisms of pyrethroid resistance, this rep-
resents an important data gap that may have implications for prac-
tice in areas where An gambiae complex is not the predominant
malaria vector.
Potential biases in the review process
As the addition of PBO to pyrethroid LLINs is only expected to
enhance their performance in areas where the mosquitoes are re-
sistant to pyrethroid insecticides, it was important to stratify the
results by resistance status. To do this we used the WHO defi-
nition of resistance as mosquito populations with less than 90%
mortality in a discriminating dose assay (WHO 2016), and then
split the resistant populations into three groups, depending on
the percentage of mortality observed. Discriminating dose assays
provide an estimate of the prevalence of resistance in a population
but do not indicate the strength of this resistance or give any indi-
cation of the mechanism(s) underpinning this resistance. As PBO
works primarily by inhibiting the metabolism of pyrethroids by
cytochrome P450s, this synergist is likely to have had most im-
pact in populations where resistance was primarily conferred by
elevated P450 activity and further stratification according to re-
sistance mechanism might have proved informative. However, in
reality, characterization of resistance in mosquitoes is still primar-
ily performed by bioassays alone and, the relevant contribution
of different resistance mechanisms to the phenotype remains un-
known. An exception to this is in An funestus, where pyrethroid re-
sistance is almost entirely due to elevated P450 activity (Churcher
2016). Unfortunately only one data set from experimental hut
trials conducted where An funestus was the primary vector were
made available to us at the time of this review.
Other examples of missing data that may have influenced the re-
sults include the absence of data on resistance status in some set-
tings. Three experimental hut trials did not measure resistance at
the time of the trial (Moore 2016; N’Guessan 2010; Pennetier
2013). For two of these trials we used proxies for resistance; how-
ever, no proxy data were available for An funestus in the Moore
2016 trial and hence we did not include this population in the
stratified analysis. Three trials did not share their data with the re-
view authors; this included trials on nets from two of the more re-
cent manufacturers to produce pyrethroid-PBO nets (N’Guessan
2016; Tungu 2017), which precluded stratified analysis for these
net types.
One of the key findings of this trial was the decline in perfor-
mance of pyrethroid-PBO nets after washing. However, as dis-
cussed above, it is not clear how the standardized washing protocol
employed in experimental hut trials of LLINs reflects the actual
chemical retention of active ingredients under operational use and
hence the policy implications of this remain to be determined.
Agreements and disagreements with other
studies or reviews
This is the first Cochrane Review of pyrethroid-PBO nets. An
earlier meta-analysis of experimental hut data indicated that
pyrethroid-PBO nets would have the greatest impact against
mosquito populations with intermediate levels of resistance (
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Churcher 2016). Using transmission models to convert entomo-
logical outputs into estimates of public health benefit, the trial
noted that the impact of pyrethroid-PBOnets would vary depend-
ing on mosquito species, resistance levels, malaria prevalence, and
LLIN usage. The importance of taking these key parameters into
account when predicting the public health impact of a switch to
pyrethroid-PBOnets has been somewhat lost in policy documents
and operational guidelines which, understandably, seek to provide
a simple decision rule to aid net selection. Hence, in the WHO
report from the 2017 Evidence Review Group on ‘Conditions for
deployment of mosquito nets treated with pyrethroid and piper-
onyl butoxide’, it is recommended that “National malaria con-
trol programmes and their partners should consider deployment
of pyrethroid-PBO nets in areas where pyrethroid resistance has
been confirmed in the main malaria vectors” (WHO 2017b). In
the technical guidelines from one of the major net distributors,
the PMI, the conditions for deployment of PBO nets are “moder-
ate levels of pyrethroid resistance (defined as 35-80% mortality),
evidence that PBO restores pyrethroid susceptibility, and moder-
ate to high malaria prevalence” (PMI 2018). The PMI definition
of moderate resistance overlaps with our definitions of moderate
and low resistance. However in our review, the best evidence for
superior efficacy of pyrethroid-PBO nets is from areas with high
resistance (< 30% mortality), and there was very little evidence
for improved performance in areas with moderate or low levels
of resistance. The differences between these trials may have arisen
from the incorporation of a large data set of laboratory bioassays,
comparing mosquito mortality with or without pre-exposure to
PBO, in the modelling trial. These laboratory bioassays rely on
use of a single discriminating dose and identified multiple trials
where highly resistant populations were not impacted by PBO. In
the current trial, the mosquito populations included were limited
to the sites in which experimental hut trials had been conducted
and this may not have fully captured the full diversity of resistance
mechanisms in Anopheles mosquitoes. This again highlights the
importance of further trials on the influence of resistance mecha-
nisms on the impact of pyrethroid-PBO LLINs.
A U T H O R S ’ C O N C L U S I O N S
Implications for practice
Thefindings of this review support the recentWHOpolicy recom-
mendation that pyrethroid-piperonyl butoxide (PBO) nets should
be considered for deployment in areas where pyrethroid resistance
has been confirmed in the main malaria vectors (WHO-GMP
2017a). Questions remain about the durability of the pyrethroid-
PBO nets. Encouragingly the single clinical trial of pyrethroid-
PBOnets did find that the protective efficacy of these nets lasted at
least 21 months and this trial is being extended to see if this effect
lasts the full 36 months of the intended lifespan of a long-lasting
insecticidal net (LLIN). TheWHOhas declaredOlyset Plus as the
first in class for pyrethroid-PBO nets and as a result, pyrethroid-
PBO nets from other manufacturers will not be required to gener-
ate epidemiological evidence on their efficacy. However, a second
clinical trial of pyrethroid-PBO nets is underway in Uganda; this
four-arm trial is comparing two pyrethroid-PBO nets (PermaNet
3.0 and Olyset Plus) with two standard LLINs (PermaNet 2.0 and
Olyset).
When evaluating these trials it is important to remember that the
PBO is an additive to the nets, intended to increase their efficacy
against pyrethroid-resistant mosquito populations. There is no
evidence to suggest that pyrethroid-PBO nets are less effective
than standard LLINs at inducing mosquito mortality under any
settings. For personal protection, blood-feeding rates are similarly
decreased under all resistance scenarios when unwashed PBO nets
are used, although this has not been shown for washed nets in
low-resistance or susceptible areas (low-certainty evidence). Hence
if pyrethroid-PBO nets perform as well, or better, than standard
LLINs, the decision on whether to switch to nets incorporating
the synergist is largely a question of economics.With fixed budgets
there is a risk that the target of universal coverage of LLINs may
be harder to reach if more expensive pyrethroid-PBO nets are
deployed. Indeed, the WHO clearly states that countries should
only consider deploying pyrethroid-PBO nets in situations where
coverage with standard vector-control interventions is not reduced
(WHO-GMP2017c). Trials of the cost effectiveness of pyrethroid-
PBO nets have not yet been possible due to the uncertainties over
the price differential between pyrethroid-PBO nets and LLINs.
Implications for research
Experimental hut trials, simultaneously comparing different
pyrethroid-PBO nets in areas wheremosquitoes have high levels of
pyrethroid resistance levels are needed to demonstrate equivalency
and inform procurement decisions, particularly given the very dif-
ferent approaches used to incorporate PBO into LLINs employed
by the different manufacturers. The issue of durability of bioactive
levels of the synergist on the nets also needs further study; current
WHO protocols for measuring LLIN durability will need adjust-
ing to utilize pyrethroid-resistant colonies of mosquitoes so that
the impact of PBO, and not just the insecticide, can be measured
over the net’s intended lifespan. The issue of the value of entomo-
logical endpoints to estimate the public health value of new types
of net remains contentious (Killeen 2018; WHO-GMP 2017c).
Performing experimental hut trials alongside future randomized
controlled trials of nets containing synergists, or other novel active
ingredients, would help resolve this issue.
In relation to reporting of trial results, study authors need to record
the level of resistance in the local mosquito population at the time
of the trial and include this when reporting the results. Data on
resistance mechanisms would also be of value to understand more
about how this influences the performance of pyrethroid-PBO
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C H A R A C T E R I S T I C S O F S T U D I E S
Characteristics of included studies [author-defined order]
Awolola 2014
Methods Village trial
Participants Ilara - An gambiae (100% S-form)
Irolu - 95% An gambiae (100% S-form), 4.5% An arabiensis
Ijesa - 98.1% An gambiae (80% S-form, 19% M-form), An arabiensis (1.6%)
Interventions Control: LLIN, PermaNet 2.0
Intervention: LLIN, PermaNet 3.0
Outcomes Mosquito mortality, blood feeding, sporozoite rate, mosquito density, parity rate
Mosquito resistance status Ilara - resistant - low (deltamethrin, 72.5% mortality, N = 120)
Irolu - resistant - low (deltamethrin, 62.5% mortality, N = 120)
Ijesa - resistant - low (deltamethrin, 66.7% mortality, N = 120)
Net treatment Nets unholed and unwashed
Location(s) Ilara, Nigeria - untreated net
Irolu, Nigeria - PermaNet 2.0
Ijesa, Nigera - PermaNet 3.0
Notes Trial conducted: March 2012-March 2013
Risk of bias
Bias Authors’ judgement Support for judgement
Recruitment bias Low risk Recruiment bias is related to human participants and so not
applicable to this study
Were the mosquitoes in LLIN and LLIN +
PBO groups comparable
Unclear risk Mosquito species composition varied slightly pre- and post-trial
between the treatment villages. However, resistance level was the
same
Collectors blinded High risk Not stated if collectors where blinded, therefore judged as high
risk as this is likely to impact searching effort
Household blinded Low risk Unclear if households were blinded - not stated in the publi-
cation. We judged this as low as this is unlikely to affect the
outcome
Treatment allocation (was the treatment
allocation sequence randomly/adequately
generated
Low risk Villages were randomly assigned to treatment arms
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Awolola 2014 (Continued)
Allocation concealment (selection bias) Low risk Allocation concealment procedures were not adhered to, how-
ever this is unlikely to affect the results
Were incomplete outcome data adequately
addressed
Low risk There were no incomplete data.
Were the raw data reported for LLIN and
LLIN + PBO groups
Low risk All necessary data were reported.
Clusters lost to follow-up Low risk No clusters lost to follow-up
Selective reporting (reporting bias) Low risk All measured outcomes appear to be reported
Correct statistical methods; adjusted for
clustering
High risk Study did not take clustering into account for statistical methods
Trial authors’ conflicting interest Low risk The trial authors declared no conflicting interests, however the
study was funded by Vestergaard (net manufacturers). Views
and findings in the publication are stated to be those of the trial
authors
Bayili 2017
Methods Experimental hut trial
Participants An coluzzii
Interventions Control: LLIN, DawaPlus 2.0
Intervention: LLIN: DawaPlus 3.0, DawaPlus 4.0
Outcomes Mosquito mortality, blood feeding, deterrence, exophily
Mosquito resistance status Resistant - high (6% mortality, N = 98)
Net treatment Nets holed, nets unwashed and washed (x 20)
Location(s) Vallée du Kou, Burkina Faso
Notes Trial conducted: August 2016-October 2016
Risk of bias
Bias Authors’ judgement Support for judgement
Were the mosquitoes in LLIN and LLIN +
PBO groups comparable
Low risk The hut trial was conducted in the same area, therefore char-
acteristics are similar
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Bayili 2017 (Continued)
Collectors blinded Unclear risk Paper does not state if collectors were blinded
Sleepers blinded Unclear risk Paper does not state if sleepers were blinded
Sleeper bias Low risk Sleepers were rotated between hut following a Latin square
design
Treatment allocation (was the treatment
allocation sequence randomly/adequately
generated
Low risk Treatments were not randomly allocated to huts however the
trial completed a full rotation through the huts
Treatment rotation Low risk Treatments were rotated between hut following a Latin square
design + 2 weeks
Standardized hut design Low risk Hut were built previously using standard West-African design
Hut cleaning between treatments Unclear risk Does not state if huts were cleaned between treatments
Were incomplete outcome data adequately
addressed
Low risk There were no incomplete data
Were the raw data reported for LLIN and
LLIN + PBO groups
Low risk All necessary data was reported
Trial authors’ conflicting interest Low risk The authors declare no conflicting interest in the WHOPES
report
Cisse 2017
Methods Village trial
Participants An gambiae s. s.
Interventions Control: LLIN, Olyset Net & PermaNet 2.0
Intervention: LLIN, Olyset Plus & PermaNet 3.0
Outcomes Sporozoite rate, mosquito density, parity rate
Mosquito resistance status Olyset Net villages - resistance - high (1% mortality, N = 305)
Olyset Plus villages - resistance - high (2% mortality, N = 411)
PermaNet 2.0 villages - resistance - high (29% mortality, N = 410)
PermaNet 3.0 villages - resistance - moderate (38% mortality, N = 408)
Net treatment Nets unholed and unwashed
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Cisse 2017 (Continued)
Location(s) Sikasso region, Mali
PermaNet 2.0 villages - Beko East, Dalabani, Berila, Dierila
PermaNet 3.0 villages - Beko West, Farabacoura East, Kola Djokada, Tieblembougou
Olyset Net villages - Karako, Geleba 2, Toula East, Toula West
Olyset Plus villages - Dialake, Farabacoura West, Deneklin, Faradjele
Notes Trial conducted: January 2014-January 2015
Risk of bias
Bias Authors’ judgement Support for judgement
Recruitment bias Low risk Recruiment bias is related to human participants and so not
applicable to this study
Were the mosquitoes in LLIN and LLIN +
PBO groups comparable
Unclear risk Mosquito species composition constant between villages, how-
ever resistance level varies slightly
Collectors blinded High risk Not stated if collectors where blinded therefore judged as high
risk as this is likely to affect searching effort
Household blinded Low risk Unclear if households were blinded - not stated in the publi-
cation. We judged this as low as this is unlikely to affect the
outcome
Treatment allocation (was the treatment
allocation sequence randomly/adequately
generated
Low risk Villages were randomly assigned to treatment arms.
Allocation concealment (selection bias) Low risk Allocation concealment procedures were not adhered to, how-
ever this is unlikely to affect the results
Were incomplete outcome data adequately
addressed
Low risk There were no incomplete data.
Were the raw data reported for LLIN and
LLIN + PBO groups
Low risk All necessary data were reported
Clusters lost to follow-up Low risk No clusters lost to follow-up
Selective reporting (reporting bias) Low risk All measured outcomes appear to be reported.
Correct statistical methods; adjusted for
clustering
High risk Study did not take clustering into account for statistical methods
Trial authors’ conflicting interest Low risk The trial authors have no competing interests
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Corbel 2010
Methods Experimental hut trial
Participants Vallée du Kou, Burkina Faso - 100% An gambiae: M-form (15%), S-form (85%)
Malanville, Benin - 95% An gambiae: M-form (100%), 5% An arabiensis
Pitoa, Cameroon - 5% An gambiae: S-form (100%), 95% An arabiensis
Interventions Control: LLIN, PermaNet 2.0
Intervention: LLIN, PermaNet 3.0
Outcomes Mosquito mortality, blood feeding, deterrence, exophily
Mosquito resistance status Vallée du Kou, Burkina Faso - resistant - high (deltamethrin, 23% mortality, N = 100)
Malanville, Benin - resistant - low (deltamethrin, 85% mortality, N = 100)
Pitoa, Cameroon - resistant - low (deltamethrin, 70% mortality, N = 100)
Net treatment Nets holed, nets unwashed and washed (x 20)
Location(s) Vallée du Kou, Burkina Faso
Malanville, Benin
Pitoa, Cameroon
Notes Trial conducted:
Vallée du Kou, Burkina Faso - September 2007 to November 2007
Malanville, Benin - July 2008 to September 2008
Pitoa, Cameroon - July 2008 to September 2008
Risk of bias
Bias Authors’ judgement Support for judgement
Were the mosquitoes in LLIN and LLIN +
PBO groups comparable
Low risk Huts situated in the same area - mosquito characteristics will
be the same
Collectors blinded Unclear risk Unclear if collectors blinded - not stated in publication
Sleepers blinded Unclear risk Unclear if sleeper blinded - not stated in publication
Sleeper bias Low risk Sleepers were rotated between huts using a Latin square design
Treatment allocation (was the treatment
allocation sequence randomly/adequately
generated
Low risk Treatments were randomly allocated to huts.
Treatment rotation Low risk Treatments were rotated between huts using a Latin square
design
Standardized hut design Low risk Huts were built in a standard West-African design.
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Corbel 2010 (Continued)
Hut cleaning between treatments Unclear risk Unclear if huts were cleaned between treatments - not stated
in publication
Were incomplete outcome data adequately
addressed
Low risk There were no incomplete outcome data
Were the raw data reported for LLIN and
LLIN + PBO groups
Low risk All necessary data were reported.
Trial authors’ conflicting interest Low risk The trial authors have no competing interests
Darriet 2011
Methods Cone assay
Participants 2-5-day-old female unfed An gambiae VKPR laboratory strain (originated from Kou
Valley, Burkina-Faso and maintained for > 15 years under laboratory conditions)
Interventions Control: ITN treated with deltamethrin (25 mg/m2)
Intervention: ITN treated with deltamethrin (25 mg/m2) & PBO (222.24 mg/m2)
Outcomes Mosquito mortality
Mosquito resistance status Resistant colony, unclassified
Net treatment Nets unwashed
Location(s) N/A
Notes
Risk of bias
Bias Authors’ judgement Support for judgement
Were the mosquitoes in LLIN and LLIN +
PBO groups comparable
Low risk Same mosquito strain used for all treatment groups
Were the study observers blinded to the al-
located intervention
Unclear risk Unclear if observers were blinded - not stated in the publication,
but also not common practice. We judged this as low as this is
unlikely to impact on the outcome
Were incomplete outcome data adequately
addressed
Low risk There were no incomplete data.
Were the raw data reported for LLIN and
LLIN + PBO groups
Low risk The resistance status of the Anopheles gambiae VKPR lab strain
is not stated in the publication.
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Darriet 2011 (Continued)
Trial authors’ conflicting interest Low risk The trial authors do not state any conflicting interests
Darriet 2013
Methods Cone assay
Participants 2-5-day-old female unfed An gambiae VKPR laboratory strain (originated from Kou
Valley, Burkina-Faso and maintained for > 15 years under laboratory conditions)
Interventions Control: ITN treated with deltamethrin (25 mg/m2)
Intervention: ITN treated with deltamethrin (25 mg/m2) & PBO (222.24 mg/m2)
Outcomes Mosquito mortality
Mosquito resistance status Resistant colony, unclassified
Net treatment N/A
Location(s) N/A
Notes
Risk of bias
Bias Authors’ judgement Support for judgement
Were the mosquitoes in LLIN and LLIN +
PBO groups comparable
Low risk Same mosquito strain used for all treatment groups
Were the study observers blinded to the al-
located intervention
Unclear risk Unclear if observers were blinded - not stated in the publication,
but also not common practice. We judged this as low as this is
unlikely to impact on the outcome
Were incomplete outcome data adequately
addressed
Low risk There were no incomplete data.
Were the raw data reported for LLIN and
LLIN + PBO groups
Low risk The resistance status of the Anopheles gambiae VKPR lab strain
is not stated in the publication.
Trial authors’ conflicting interest Low risk The trial authors do not state any conflicting interests.
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Koudou 2011
Methods Experimental hut trial
Participants An gambiae s.s.
Interventions Control: LLIN, PermaNet 2.0
Intervention: LLIN, PermaNet 3.0
Outcomes Mosquito mortality, deterrence, exophily
Mosquito resistance status Resistant - high (deltamethrin, 10.6% mortality, N = 80 min)
Net treatment Nets not holed, nets unwashed and washed (x 20)
Location(s) Yaokoffikro, Côte d’Ivoire
Notes Trial conducted: April 2009-July 2009
Risk of bias
Bias Authors’ judgement Support for judgement
Were the mosquitoes in LLIN and LLIN +
PBO groups comparable
Low risk Huts situated in the same area - mosquito characteristics will
be the same
Collectors blinded Unclear risk Unclear if collectors blinded - not stated in publication
Sleepers blinded Unclear risk Unclear if sleeper blinded - not stated in publication
Sleeper bias Low risk Sleepers were rotated between huts using a Latin square design
Treatment allocation (was the treatment
allocation sequence randomly/adequately
generated
Low risk Treatments were not randomly allocated to the huts.
However, results from trials performed before this trial showed
no significant difference in attractiveness of the different huts
Treatment rotation Low risk Treatments were rotated between huts using a Latin square
design
Standardized hut design Low risk Huts were built in a standard West-African design
Hut cleaning between treatments Low risk All huts were cleaned between treatments
Were incomplete outcome data adequately
addressed
Low risk There were no incomplete data
Were the raw data reported for LLIN and
LLIN + PBO groups
Low risk All necessary data were reported
Trial authors’ conflicting interest Low risk The trial authors declared there were no conflicting interests
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Moore 2016
Methods Experimental hut trial
Participants An arabiensis (100%), An funestus group (95% s.s.)
Interventions Control: LLIN, MAGNet LN
Intervention: LLIN, Veeralin LN
Outcomes Mosquito mortality, blood feeding, deterrence, exophily
Mosquito resistance status An arabiensis - susceptible (alphacypermethrin, 100% mortality, N = 97)
An funestus - unclassified
Net treatment Nets holed, nets unwashed and washed (x 20)
Location(s) Ifakara, Tanzania
Notes Although additional data provided showed resistance to deltamethrin and permethrin
in An gambaie s.l.
Risk of bias
Bias Authors’ judgement Support for judgement
Were the mosquitoes in LLIN and LLIN +
PBO groups comparable
Low risk The hut trial was conducted in the same area, therefore char-
acteristics are similar
Collectors blinded Unclear risk Paper does not state if collectors were blinded.
Sleepers blinded Unclear risk Paper does not state if sleepers were blinded.
Sleeper bias Low risk Sleepers were rotated between hut following a Latin square
design
Treatment allocation (was the treatment
allocation sequence randomly/adequately
generated
Low risk Treatments were not randomly allocated to huts however the
trial completed a full rotation through the huts
Treatment rotation Low risk Treatments were rotated between hut following a Latin square
design
Standardized hut design Low risk The study used the standard design of the Ifakara experimental
huts
Hut cleaning between treatments Unclear risk The paper does not state if hutswere cleared between treatments
Were incomplete outcome data adequately
addressed
Low risk No incomplete outcome data
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Moore 2016 (Continued)
Were the raw data reported for LLIN and
LLIN + PBO groups
Low risk No missing outcome data
Trial authors’ conflicting interest Low risk The trial authors declared they received prescribed standard
fees from Vestergaard Frandsen for evaluating their pesticide
products, however this is standard practice
Mzilahowa 2014
Methods Village trial
Participants An gambiae s. l., An funestus group
Interventions Control: LLIN, Olyset Net & PermaNet 2.0
Intervention: LLIN, Olyset Plus & PermaNet 3.0
Outcomes Mosquito density, parity rate
Mosquito resistance status An funestus (Balaka district)
Permethrin - resistant - moderate (55.5% mortality, N = unknown)
Deltamethrin - resistant - high (14.9% mortality, N = unknown)
An gambiae (Balaka district)
Permethrin - resistant - low (84.4% mortality, N = unknown)
(Machinga district)
Deltamethrin - resistant - moderate (54.5% mortality, N = unknown)
Net treatment Nets unholed and unwashed
Location(s) Balaka district, Malawi (12 villages)
Notes Trial conducted: December 2012-June 2014
Risk of bias
Bias Authors’ judgement Support for judgement
Recruitment bias Low risk Recruiment bias is related to human participants and so not
applicable to this study
Were the mosquitoes in LLIN and LLIN +
PBO groups comparable
High risk Mosquito species composition and resistance status are not
recorded per village. Village names are not provided in study,
instead villages are grouped by treatment type
Collectors blinded High risk Not stated if collectors were blinded, therefore judged as high
risk as this is likely to affect searching effort
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Mzilahowa 2014 (Continued)
Household blinded Low risk Unclear if households were blinded - not stated in the publi-
cation. We judged this as low as this is unlikely to affect the
outcome
Treatment allocation (was the treatment
allocation sequence randomly/adequately
generated
Low risk Villages were randomly assigned to treatment arms.
Allocation concealment (selection bias) Low risk Allocation concealment procedures were not adhered to, how-
ever this is unlikely to affect the results
Were incomplete outcome data adequately
addressed
Low risk There were no incomplete data.
Were the raw data reported for LLIN and
LLIN + PBO groups
Low risk All necessary data were reported
Clusters lost to follow-up Low risk No clusters lost to follow-up.
Selective reporting (reporting bias) Low risk All measured outcomes appear to be reported
Correct statistical methods; adjusted for
clustering
High risk Study did not take clustering into account when performing
statistical methods
Trial authors’ conflicting interest Unclear risk There is no information on trial authors’ possible conflicting
interests provided
N’Guessan 2010
Methods Experimental hut trial
Participants An gambiae
Interventions Control: LLIN, PermaNet 2.0
Intervention: LLIN, PermaNet 3.0
Outcomes Mosquito mortality, blood feeding, deterrence, exophily
Mosquito resistance status Proxy data. Adjara, Benin: resistant - moderate (deltamethrin, 50% mortality, N = 56)
(Aïzoun 2013)
Net treatment Nets holed, nets unwashed and washed (x 20)
Location(s) Akron, Benin
Notes Trial conducted: October 2008-January 2009
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N’Guessan 2010 (Continued)
Risk of bias
Bias Authors’ judgement Support for judgement
Were the mosquitoes in LLIN and LLIN +
PBO groups comparable
Low risk Huts situated in the same area - mosquito characteristics will
be the same
Collectors blinded Unclear risk Unclear if collectors blinded - not stated in publication
Sleepers blinded Unclear risk Unclear if sleeper blinded - not stated in publication
Sleeper bias Low risk Sleepers were rotated between huts using a Latin square design
Treatment allocation (was the treatment
allocation sequence randomly/adequately
generated
Low risk Treatments were randomly allocated to huts
Treatment rotation Low risk Treatments were rotated between huts using a Latin square
design
Standardized hut design Low risk Huts were built in a standard West-African design.
Hut cleaning between treatments Low risk All huts were cleaned between treatments.
Were incomplete outcome data adequately
addressed
Low risk There were no incomplete data.
Were the raw data reported for LLIN and
LLIN + PBO groups
Low risk All necessary data were reported
Trial authors’ conflicting interest Unclear risk The trial was sponsored by Vestergaard (net manufacturers),
who also commented on the manuscript
Pennetier 2013
Methods Experimental hut trial
Participants 95% An gambiae: M-form (100%), 5% An arabiensis (Corbel 2010)
Interventions Control: LLIN, Olyset Net
Intervention: LLIN, Olyset Plus
Outcomes Mosquito mortality, blood feeding, deterrence, exophily
Mosquito resistance status Proxy data. Resistant - high (permethrin, 22% mortality, N = 100) (Djègbè 2011)
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Pennetier 2013 (Continued)
Net treatment Nets holed, nets unwashed and washed (x 20)
Location(s) Malanville, Benin
Notes Trial conducted: September 2011-December 2011
Risk of bias
Bias Authors’ judgement Support for judgement
Were the mosquitoes in LLIN and LLIN +
PBO groups comparable
Low risk Huts situated in the same area - mosquito characteristics will
be the same
Collectors blinded Unclear risk Unclear if collectors blinded - not stated in publication
Sleepers blinded Unclear risk Unclear if sleeper blinded - not stated in publication
Sleeper bias Low risk Sleepers were rotated between huts using a Latin square design
Treatment allocation (was the treatment
allocation sequence randomly/adequately
generated
Low risk Treatments were not randomized to huts, but instead were ro-
tated fully between all of the huts using a Latin square design
Treatment rotation Low risk Treatments were rotated between huts using a Latin square
design
Standardized hut design Low risk Huts were built in a standard West-African design.
Hut cleaning between treatments Low risk All huts were cleaned between treatments.
Were incomplete outcome data adequately
addressed
Low risk There were no incomplete data.
Were the raw data reported for LLIN and
LLIN + PBO groups
Low risk All necessary data were reported.
Trial authors’ conflicting interest Low risk Funders of the trial stated that they had no part in data collec-
tion, data analysis or manuscript preparation
Protopopoff 2018
Methods Cluster-randomized controlled village trial
Participants 3966 children analysed (21months after intervention) aged 6months-14 years (excluding
the severely ill), Anopheles species (pooled). Total core cluster population area ranged
from 14,845 to 16,358
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Protopopoff 2018 (Continued)
Interventions Control: LLIN, Olyset Net
Intervention: LLIN, Olyset Plus
Outcomes Malaria infection prevalence, sporozoite rate, mosquito density
Mosquito resistance status Resistance - high (17.8% mortality, N = 107)
Net treatment Nets unholed and unwashed
Location(s) Muleba District, Tanzania
Notes Trial conducted: March 2014-December 2016
Risk of bias
Bias Authors’ judgement Support for judgement
Recruitment bias Low risk No participants recruited after clusters had
been randomized
Were the mosquitoes in LLIN and LLIN +
PBO groups comparable
Unclear risk Resistance level was only available for the
whole district, not at village level
Collectors blinded Low risk Field workers were masked to net treat-
ment.
Household blinded Low risk Inhabitants were masked to net treatment
Treatment allocation (was the treatment
allocation sequence randomly/adequately
generated
Low risk Restricted randomization was used to allo-
cate clusters to the study groups
Allocation concealment (selection bias) Low risk Restricted randomization was used to allo-
cate treatments to clusters
Were incomplete outcome data adequately
addressed
Low risk No incomplete outcome data
Were the raw data reported for LLIN and
LLIN + PBO groups
Low risk No missing outcome data
Clusters lost to follow-up Low risk No clusters lost to follow-up
Selective reporting (reporting bias) Low risk All measured outcomes appear to be re-
ported
Correct statistical methods; adjusted for
clustering
Low risk Clustering was taken into account and ad-
justed for during statistical analysis
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Protopopoff 2018 (Continued)
Trial authors’ conflicting interest Low risk The trial authors declared no conflicting
interests.
Stiles-Ocran 2013
Methods Village trial
Participants An gambiae
Interventions Control: LLIN, PermaNet 2.0
Intervention: LLIN, PermaNet 3.0
Outcomes Sporozoite rate, mosquito density, parity rate
Mosquito resistance status Futa - resistant - moderate (33.3% mortality, N = 96)
Abrabra- resistant - moderate (43.7% mortality, N = 126)
Kunkumso - resistant - high (28.4% mortality, N = 109)
Anyinabrim - resistant - moderate (53.2% mortality, N = 109)
Wenchi - resistant - low (61.9% mortality, N =126)
Net treatment Nets unholed and unwashed
Location(s) Futa, Ghana - no net control
Abrabra, Ghana - PermaNet 2.0
Kunkumso, Ghana - PermaNet 2.0
Anyinabrim, Ghana - PermaNet 3.0
Wench, Ghana - PermaNet 3.0
Notes Trial conducted: November 2010-August 2011
Risk of bias
Bias Authors’ judgement Support for judgement
Recruitment bias Low risk Recruiment bias is related to human participants and so not
applicable to this study
Were the mosquitoes in LLIN and LLIN +
PBO groups comparable
Unclear risk Mosquito species composition varied slightly. Resistance level
varies between villages. Data are, however, provided pre- and
post-trial
Collectors blinded High risk Not stated if collectors were blinded, therefore judged as high
risk as this is likely to affect searching effort
Household blinded Low risk Unclear if households were blinded - not stated in the publica-
tion. We judged this as low as this is unlikely to impact on the
outcome
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Stiles-Ocran 2013 (Continued)
Treatment allocation (was the treatment
allocation sequence randomly/adequately
generated
Low risk Villages were randomly assigned to treatment arms.
Allocation concealment (selection bias) Low risk Allocation concealment procedures were not adhered to, how-
ever this is unlikely to affect the results
Were incomplete outcome data adequately
addressed
Low risk There were no incomplete data.
Were the raw data reported for LLIN and
LLIN + PBO groups
Low risk All necessary data were reported.
Clusters lost to follow-up Low risk No clusters lost to follow-up
Selective reporting (reporting bias) Low risk All measured outcomes appear to be reported.
Correct statistical methods; adjusted for
clustering
High risk Study did not take clustering into account for statistical methods
Trial authors’ conflicting interest Unclear risk Study data were collected for use in Vestergaard PermaNet 3.0
product dossier
Toé 2018
Methods Experimental hut trial
Participants An coluzzii
Interventions Control: LLIN, PermaNet 2.0, Olyset Net
Intervention: LLIN, PermaNet 3.0, Olyset Plus
Outcomes Mosquito mortality, blood feeding, deterrence, exophily
Mosquito resistance status Vallée du Kou 5 - resistant - high (deltamethrin, 2.5% mortality, N = 163; permethrin,
5% mortality, N = 153)
Tengrela - resistant - high (deltamethrin, 34% mortality, N = 85; permethrin, 14%
mortality, N = 101)
Net treatment Nets holed, nets unwashed
Location(s) Vallée du Kou 5, Burkina Faso
Tengrela, Burkina Faso
Notes Trial conducted: September 2014-October 2014
Risk of bias
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Toé 2018 (Continued)
Bias Authors’ judgement Support for judgement
Were the mosquitoes in LLIN and LLIN +
PBO groups comparable
Low risk Huts situated in the same area - mosquito characteristics will
be the same
Collectors blinded Unclear risk Unclear if collectors blinded - not stated in publication
Sleepers blinded Unclear risk Unclear if sleeper blinded - not stated in publication
Sleeper bias Low risk Sleepers were rotated between huts using a Latin square design
Treatment allocation (was the treatment
allocation sequence randomly/adequately
generated
Low risk Treatments were not randomized to huts, but instead were ro-
tated fully between all of the huts using a Latin square design
Treatment rotation Low risk Treatments were rotated between huts using a Latin square
design
Standardized hut design Low risk Huts were built in a standard West-African design.
Hut cleaning between treatments Unclear risk Unclear if huts were cleaned between treatments - not stated
in the publication
Were incomplete outcome data adequately
addressed
Low risk There were no incomplete data.
Were the raw data reported for LLIN and
LLIN + PBO groups
Low risk All necessary data were reported.
Trial authors’ conflicting interest Low risk The trial authors have no competing interests.
Tungu 2010
Methods Experimental hut trial
Participants An gambiae
Interventions Control: LLIN, PermaNet 2.0
Intervention: LLIN, PermaNet 3.0
Outcomes Mosquito mortality, blood feeding, deterrence, exophily
Mosquito resistance status Susceptible (deltamethrin, 100% mortality, N = not stated)
Net treatment Nets holed, nets unwashed and washed (x 20)
Location(s) Zeneti, Muheza, Tanzania
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Tungu 2010 (Continued)
Notes Trial conducted: July 2008-October 2008
Risk of bias
Bias Authors’ judgement Support for judgement
Were the mosquitoes in LLIN and LLIN +
PBO groups comparable
Low risk Huts situated in the same area - mosquito characteristics will
be the same
Collectors blinded Unclear risk Unclear if collectors blinded - not stated in publication
Sleepers blinded Unclear risk Unclear if sleeper blinded - not stated in publication
Sleeper bias Low risk Sleepers were rotated between huts using a Latin square design
Treatment allocation (was the treatment
allocation sequence randomly/adequately
generated
Low risk Treatments were randomly allocated to huts.
Treatment rotation Low risk Treatments were rotated between huts using a Latin square
design
Standardized hut design Low risk Huts were built in a standard West-African design.
Hut cleaning between treatments Low risk All huts were cleaned between treatments
Were incomplete outcome data adequately
addressed
Low risk There were no incomplete data.
Were the raw data reported for LLIN and
LLIN + PBO groups
Low risk All necessary data were reported.
Trial authors’ conflicting interest Low risk The trial authors have no competing interests.
Abbreviations: An arabiensis:Anopheles arabiensis;An coluzzii:Anopheles coluzzii;An funestus: Anopheles funestus;An gambiae: Anopheles
gambiae; ITN: insecticide-treated net; LLIN: long-lasting insecticidal net(s); PBO: piperonyl butoxide
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Characteristics of studies awaiting assessment [ordered by study ID]
Koudou 2012
Methods Village trial
Participants Bouaké - 100% An gambiae: (70% S-form, 30% M-form)
Tiassalé - 100% An gambiae: (70% S-form, 30% M-form)
Interventions Control: LLIN, PermaNet 2.0 Extra,
Intervention: LLIN, PermaNet 3.0
Outcomes Blood feeding, mosquito density
Mosquito Resistance Status Bouaké - resistant - moderate (43.9% mortality, N = 114)
Tiassalé - resistant - moderate (7.5% mortality, N = 106)
Net Treatment Nets unholed and unwashed
Location(s) Bouaké, Côte d’Ivoire
Tiassalé, Côte d’Ivoire
Notes Trial conducted: November 2009-January 2012
Martine 2017
Methods Cluster-randomized controlled village trial
Participants Wild mosquitoes in Muleba, Tanzania (An gambiae and An funestus)
Interventions Control: LLIN, Olyset Net
Intervention: LLIN, Olyset Plus
Outcomes Physical integrity of the net
Number of mosquitoes resting inside net
Insecticidal activity
Mosquito Resistance Status At baseline using adopted WHO resistance assays, field mosquitoes were 7%, 13% and 60%, 63% (An
gambiae, An funestus) resistant to Olyset Plus and standard Olyset nets.
Net Treatment Nets unholed and unwashed
Location(s) Tanzania
Notes Entomological trial that was part of Protopopoff 2018
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N’Guessan 2016
Methods Experimental hut trial
Participants An gambiae
Interventions Control: LLIN, MAGNet LN
Intervention: LLIN, Veeralin LN
Outcomes Mosquito mortality, blood feeding, deterrence, exophily
Mosquito Resistance Status
Net Treatment Nets holed, nets unwashed and washed (x 20)
Location(s) M’be, Côte d’Ivoire
Notes
Shono 2017
Methods Not available
Participants Not available
Interventions Not available
Outcomes Not available
Mosquito Resistance Status Not available
Net Treatment Control: LLIN, Olyset Net
Intervention: LLIN, Olyset Plus
Location(s) Not available
Notes
Tungu 2017
Methods Experimental hut trial
Participants An funestus
Interventions Control: LLIN, DawaPlus 2.0
Intervention: LLIN, DawaPlus 3.0, DawaPlus 4.0
Outcomes Mosquito mortality, blood feeding, deterrence, exophily
Mosquito Resistance Status
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Tungu 2017 (Continued)
Net Treatment Nets holed, nets unwashed and washed (x 20)
Location(s) Muheza, Tanzania
Notes
Abbreviations: An funestus: Anopheles funestus;An gambiae: Anopheles gambiae; LLIN: long-lasting insecticidal net(s)
Characteristics of ongoing studies [ordered by study ID]
ISRCTN17516395
Trial name or title Impact of long-lasting insecticide treated bed nets with and without piperonly butoxide (PBO) on malaria
indictators in Uganda
Methods Cluster-randomized trial
Participants Households with at least one adult resident and one child aged 2-10 years
Interventions PermaNet 2.0
PermaNet 3.0
Olyset Net
Olyset Plus
Outcomes Primary outcomes; parasite prevalence (proportion of thick blood smears that are positive for asexual parasites)
in children ages 2-10 years, asssessed prior to net distribution, and up to 3 times after nets are distributed
Secondary outcomes; prevalence of anaemia and mean haemoglobin in children ages 2-10 years, frequency of
molecularmarkers associatedwith insecticide resistance in the primarymalaria vector, prevalence of phenotypic
insecticide resistance in mosquitoes
Starting date January 2017
Contact information Professor Martin Donnelly
Notes
NCT03289663
Trial name or title Effectiveness study of new generation bednets in the context of conventional insecticide resistance in the
Democratic Republic of the Congo (Net-PBO)
Methods Cluster-randomized trial
Participants 1680 participants, 0-10-year-old subjects in 30 villages
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NCT03289663 (Continued)
Interventions Control: bed net treated with pyrethroid only
Intervention: bed net treated with both pyrethroid and PBO
Outcomes Incidence rate of laboratory confirmed clinical cases of Malaria (time frame: participants will be actively
followed up for 12 months and any suspected case of clinical malaria will immediately lead to microscopy
and RDT for confirmation.) Microscopy to confirm the diagnosis of malaria sporozoite rate (time frame:
Anopheles mosquitoes will be captured every 3 months during 1 year), sporozoite detection by ELISA to
determine infectivity of Anopheles
Starting date 2 October 2017
Contact information
Notes
Abbreviations: ELISA: enzyme-linked immunosorbent assay; PBO: piperonyl butoxide
53Piperonyl butoxide (PBO) combined with pyrethroids in insecticide-treated nets to prevent malaria in Africa (Review)
Copyright © 2018 The Authors. Cochrane Database of Systematic Reviews published by John Wiley & Sons, Ltd. on behalf of The
Cochrane Collaboration.
D A T A A N D A N A L Y S E S
Comparison 1. Pyrethroid-PBO nets versus LLINs: laboratory bioassay (cone trials)
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Mosquito mortality 2 558 Risk Ratio (M-H, Fixed, 95% CI) 6.06 [4.15, 8.84]
Comparison 2. Commercial pyrethroid-PBO nets versus commercial LLINs: hut trials
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Mosquito mortality (pooled)
hut/night
8 14334 Risk Ratio (M-H, Random, 95% CI) 1.36 [1.20, 1.54]
1.1 Unwashed 8 7742 Risk Ratio (M-H, Random, 95% CI) 1.54 [1.21, 1.96]
1.2 Washed 7 6592 Risk Ratio (M-H, Random, 95% CI) 1.14 [1.00, 1.31]
2 Mosquito blood-feeding success
(pooled) hut/night
7 11070 Risk Ratio (M-H, Random, 95% CI) 0.76 [0.67, 0.88]
2.1 Unwashed 7 6355 Risk Ratio (M-H, Random, 95% CI) 0.66 [0.54, 0.79]
2.2 Washed 6 4715 Risk Ratio (M-H, Random, 95% CI) 0.91 [0.78, 1.06]
3 Mosquito exophily (pooled)
hut/night
8 11933 Risk Ratio (M-H, Random, 95% CI) 0.99 [0.94, 1.06]
3.1 Unwashed 8 6793 Risk Ratio (M-H, Random, 95% CI) 1.01 [0.91, 1.12]
3.2 Washed 7 5140 Risk Ratio (M-H, Random, 95% CI) 0.98 [0.92, 1.04]
4 Mosquito mortality (high
resistance) hut/night
5 7997 Risk Ratio (M-H, Random, 95% CI) 1.58 [1.34, 1.86]
4.1 Unwashed 5 4896 Risk Ratio (M-H, Random, 95% CI) 1.84 [1.60, 2.11]
4.2 Washed 4 3101 Risk Ratio (M-H, Random, 95% CI) 1.20 [0.88, 1.63]
5 Mosquito blood-feeding success
(high resistance) hut/night
4 7134 Risk Ratio (M-H, Random, 95% CI) 0.66 [0.57, 0.76]
5.1 Unwashed 4 4458 Risk Ratio (M-H, Random, 95% CI) 0.60 [0.50, 0.71]
5.2 Washed 3 2676 Risk Ratio (M-H, Random, 95% CI) 0.81 [0.72, 0.92]
6 Mosquito mortality (moderate
resistance) hut/night
1 493 Risk Ratio (M-H, Fixed, 95% CI) 1.12 [0.90, 1.40]
6.1 Unwashed 1 217 Risk Ratio (M-H, Fixed, 95% CI) 1.16 [0.88, 1.54]
6.2 Washed 1 276 Risk Ratio (M-H, Fixed, 95% CI) 1.07 [0.74, 1.54]
7 Mosquito blood-feeding success
(moderate resistance) hut/night
1 499 Risk Ratio (M-H, Random, 95% CI) 0.90 [0.76, 1.06]
7.1 Unwashed 1 217 Risk Ratio (M-H, Random, 95% CI) 0.87 [0.67, 1.13]
7.2 Washed 1 282 Risk Ratio (M-H, Random, 95% CI) 0.91 [0.74, 1.13]
8 Mosquito mortality (low
resistance) hut/night
1 1224 Risk Ratio (M-H, Random, 95% CI) 1.13 [1.02, 1.25]
8.1 Unwashed 1 577 Risk Ratio (M-H, Random, 95% CI) 1.10 [1.05, 1.16]
8.2 Washed 1 647 Risk Ratio (M-H, Random, 95% CI) 1.16 [0.83, 1.63]
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9 Mosquito blood-feeding success
(low resistance) hut/night
1 1224 Risk Ratio (M-H, Random, 95% CI) 1.43 [0.85, 2.41]
9.1 Unwashed 1 577 Risk Ratio (M-H, Random, 95% CI) 0.67 [0.06, 7.37]
9.2 Washed 1 647 Risk Ratio (M-H, Random, 95% CI) 1.50 [0.89, 2.54]
10 Mosquito mortality
(susceptible) hut/night
2 1916 Risk Ratio (M-H, Random, 95% CI) 1.05 [0.96, 1.15]
10.1 Unwashed 2 948 Risk Ratio (M-H, Random, 95% CI) 1.20 [0.64, 2.26]
10.2 Washed 2 968 Risk Ratio (M-H, Random, 95% CI) 1.07 [0.92, 1.25]
11 Mosquito blood-feeding
success (susceptible) hut/night
2 1916 Risk Ratio (M-H, Random, 95% CI) 0.87 [0.40, 1.89]
11.1 Unwashed 2 948 Risk Ratio (M-H, Random, 95% CI) 0.52 [0.12, 2.22]
11.2 Washed 2 968 Risk Ratio (M-H, Random, 95% CI) 1.25 [0.82, 1.91]
12 Mosquito mortality (high
resistance/Permanet) hut/night
3 2806 Risk Ratio (M-H, Random, 95% CI) 1.59 [1.26, 2.01]
12.1 Not Washed 3 1877 Risk Ratio (M-H, Random, 95% CI) 1.81 [1.56, 2.10]
12.2 Washed 2 929 Risk Ratio (M-H, Random, 95% CI) 1.18 [0.61, 2.28]
13Mosquito blood-feeding success
(high resistance/Permanet)
hut/night
2 1943 Risk Ratio (M-H, Random, 95% CI) 0.58 [0.45, 0.76]
13.1 Unwashed 2 1439 Risk Ratio (M-H, Random, 95% CI) 0.53 [0.40, 0.69]
13.2 Washed 1 504 Risk Ratio (M-H, Random, 95% CI) 0.76 [0.61, 0.93]
14 Mosquito mortality (high
resistance/Olyset) hut/night
2 1410 Risk Ratio (M-H, Random, 95% CI) 1.73 [1.51, 1.97]
14.1 Unwashed 2 1257 Risk Ratio (M-H, Random, 95% CI) 1.72 [1.48, 1.99]
14.2 Washed 1 153 Risk Ratio (M-H, Random, 95% CI) 1.81 [1.25, 2.61]
15 Mosquito blood-feeding
success (high resistance/Olyset)
hut/night
2 1470 Risk Ratio (M-H, Random, 95% CI) 0.63 [0.40, 0.98]
15.1 Unwashed 2 1257 Risk Ratio (M-H, Random, 95% CI) 0.67 [0.38, 1.18]
15.2 Washed 1 213 Risk Ratio (M-H, Random, 95% CI) 0.50 [0.27, 0.93]
Comparison 3. Commercial pyrethroid-PBO nets versus commercial LLINs: village trials
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Prevalence of malaria 1 Odds Ratio (Fixed, 95% CI) 0.40 [0.20, 0.80]
2 Mosquito sporozoite-positive
(adjusted ICC 0.1)
4 424 Risk Ratio (M-H, Random, 95% CI) 0.82 [0.24, 2.75]
3 Mosquito parous (adjusted ICC
0.1)
3 220 Risk Ratio (M-H, Random, 95% CI) 0.97 [0.82, 1.13]
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Analysis 1.1. Comparison 1 Pyrethroid-PBO nets versus LLINs: laboratory bioassay (cone trials), Outcome
1 Mosquito mortality.
Review: Piperonyl butoxide (PBO) combined with pyrethroids in insecticide-treated nets to prevent malaria in Africa
Comparison: 1 Pyrethroid-PBO nets versus LLINs: laboratory bioassay (cone trials)
Outcome: 1 Mosquito mortality
Study or subgroup pyrethroid-PBO nets LLINs Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Darriet 2011 93/160 12/160 45.1 % 7.75 [ 4.43, 13.57 ]
Darriet 2013 71/124 14/114 54.9 % 4.66 [ 2.79, 7.79 ]
Total (95% CI) 284 274 100.0 % 6.06 [ 4.15, 8.84 ]
Total events: 164 (pyrethroid-PBO nets), 26 (LLINs)
Heterogeneity: Chi2 = 1.74, df = 1 (P = 0.19); I2 =43%
Test for overall effect: Z = 9.34 (P < 0.00001)
Test for subgroup differences: Not applicable
0.01 0.1 1 10 100
Favours LLINs Favours pyrethroid-PBO nets
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Analysis 2.1. Comparison 2 Commercial pyrethroid-PBO nets versus commercial LLINs: hut trials,
Outcome 1 Mosquito mortality (pooled) hut/night.
Review: Piperonyl butoxide (PBO) combined with pyrethroids in insecticide-treated nets to prevent malaria in Africa
Comparison: 2 Commercial pyrethroid-PBO nets versus commercial LLINs: hut trials
Outcome: 1 Mosquito mortality (pooled) hut/night
Study or subgroup PBO-LLINs LLINs Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
1 Unwashed
Bayili 2017 (1) 197/457 125/837 4.3 % 2.89 [ 2.38, 3.50 ]
Bayili 2017 (2) 144/664 113/753 4.2 % 1.45 [ 1.16, 1.81 ]
Corbel 2010 (3) 170/176 177/200 4.7 % 1.09 [ 1.03, 1.16 ]
Corbel 2010 (4) 181/232 73/165 4.3 % 1.76 [ 1.47, 2.12 ]
Corbel 2010 (5) 110/117 70/84 4.6 % 1.13 [ 1.01, 1.25 ]
Koudou 2011 (6) 117/214 78/224 4.2 % 1.57 [ 1.26, 1.95 ]
Moore 2016 (7) 5/68 6/87 1.0 % 1.07 [ 0.34, 3.35 ]
Moore 2016 (8) 23/161 22/239 2.5 % 1.55 [ 0.90, 2.69 ]
N’Guessan 2010 (9) 59/115 45/102 3.9 % 1.16 [ 0.88, 1.54 ]
Pennetier 2013 (10) 53/66 39/95 3.9 % 1.96 [ 1.49, 2.56 ]
To 2018 (11) 125/199 116/325 4.4 % 1.76 [ 1.47, 2.11 ]
To 2018 (12) 62/221 57/293 3.7 % 1.44 [ 1.05, 1.97 ]
To 2018 (13) 116/249 52/269 3.9 % 2.41 [ 1.83, 3.18 ]
To 2018 (14) 146/272 97/310 4.3 % 1.72 [ 1.41, 2.09 ]
Tungu 2010 (15) 223/233 300/315 4.8 % 1.00 [ 0.97, 1.04 ]
Subtotal (95% CI) 3444 4298 58.7 % 1.54 [ 1.21, 1.96 ]
Total events: 1731 (PBO-LLINs), 1370 (LLINs)
Heterogeneity: Tau2 = 0.20; Chi2 = 677.87, df = 14 (P<0.00001); I2 =98%
Test for overall effect: Z = 3.53 (P = 0.00041)
2 Washed
Bayili 2017 (16) 105/683 149/895 4.1 % 0.92 [ 0.73, 1.16 ]
Bayili 2017 (17) 136/780 141/848 4.2 % 1.05 [ 0.85, 1.30 ]
Corbel 2010 (18) 101/144 94/133 4.5 % 0.99 [ 0.85, 1.16 ]
Corbel 2010 (19) 82/105 112/199 4.5 % 1.39 [ 1.18, 1.63 ]
Corbel 2010 (20) 183/371 122/404 4.4 % 1.63 [ 1.36, 1.96 ]
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(. . . Continued)
Study or subgroup PBO-LLINs LLINs Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
Koudou 2011 (21) 72/224 77/201 4.0 % 0.84 [ 0.65, 1.09 ]
Moore 2016 (22) 23/186 28/198 2.7 % 0.87 [ 0.52, 1.46 ]
Moore 2016 (23) 4/67 6/81 0.9 % 0.81 [ 0.24, 2.74 ]
N’Guessan 2010 (24) 40/130 42/146 3.4 % 1.07 [ 0.74, 1.54 ]
Pennetier 2013 (25) 64/96 43/117 3.9 % 1.81 [ 1.38, 2.39 ]
Tungu 2010 (26) 271/285 260/299 4.8 % 1.09 [ 1.04, 1.15 ]
Subtotal (95% CI) 3071 3521 41.3 % 1.14 [ 1.00, 1.31 ]
Total events: 1081 (PBO-LLINs), 1074 (LLINs)
Heterogeneity: Tau2 = 0.03; Chi2 = 48.33, df = 10 (P<0.00001); I2 =79%
Test for overall effect: Z = 2.00 (P = 0.045)
Total (95% CI) 6515 7819 100.0 % 1.36 [ 1.20, 1.54 ]
Total events: 2812 (PBO-LLINs), 2444 (LLINs)
Heterogeneity: Tau2 = 0.09; Chi2 = 525.72, df = 25 (P<0.00001); I2 =95%
Test for overall effect: Z = 4.74 (P < 0.00001)
Test for subgroup differences: Chi2 = 4.54, df = 1 (P = 0.03), I2 =78%
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(1) Valle du Kou, DawaPlus 4.0, High resistance
(2) Valle du Kou, DawaPlus 3.0, High resistance
(3) Malanville, Permanet 3.0, Low resistance
(4) Vall e du Kou, Permanet 3.0, High resistance
(5) Pitoa, Permanet 3.0, Low resistance
(6) Yaokoffikro, Permanet 3.0, High resistance
(7) Ifakara, Veeralin, Unclassified, An. funestus
(8) Ifakara, Veeralin, Susceptible, An. arabiensis
(9) Akron, Permanet 3.0, Moderate resistance
(10) Malanaville, Olyset Plus, High resistance
(11) Vallee du Kou 5, Permanet 3.0, High resistance
(12) Tengrela, Olyset Plus, High resistance
(13) Tengrela, Permanet 3.0, High resistance
(14) Vallee du Kou 5, Olyset Plus, High resistance
(15) Zeneti, Permanet 3.0, Susceptible
(16) Valle du Kou, DawaPlus 4.0, High resistance
(17) Valle du Kou, DawaPlus 3.0, High resistance
(18) Malanville, Permanet 3.0, Low resistance
(19) Pitoa, Permanet 3.0, Low resistance
(20) Vall e du Kou, Permanet 3.0, High resistance
(21) Yaokoffikro, Permanet 3.0, High resistance
(22) Ifakara, Veeralin, Susceptible, An. arabiensis
(23) Ifakara, Veeralin, Unclassified, An. funestus
(24) Akron, Permanet 3.0, Moderate resistance
(25) Malanaville, Olyset Plus, High resistance
(26) Zeneti, Permanet 3.0, Susceptible
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Analysis 2.2. Comparison 2 Commercial pyrethroid-PBO nets versus commercial LLINs: hut trials,
Outcome 2 Mosquito blood-feeding success (pooled) hut/night.
Review: Piperonyl butoxide (PBO) combined with pyrethroids in insecticide-treated nets to prevent malaria in Africa
Comparison: 2 Commercial pyrethroid-PBO nets versus commercial LLINs: hut trials
Outcome: 2 Mosquito blood-feeding success (pooled) hut/night
Study or subgroup PBO-LLINs LLINs Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
1 Unwashed
Bayili 2017 (1) 182/425 290/482 7.2 % 0.71 [ 0.62, 0.81 ]
Bayili 2017 (2) 102/302 333/553 6.9 % 0.56 [ 0.47, 0.67 ]
Corbel 2010 (3) 48/232 58/165 5.3 % 0.59 [ 0.42, 0.82 ]
Corbel 2010 (4) 1/176 7/200 0.4 % 0.16 [ 0.02, 1.31 ]
Corbel 2010 (5) 33/117 13/84 3.2 % 1.82 [ 1.02, 3.25 ]
Moore 2016 (6) 6/161 8/239 1.4 % 1.11 [ 0.39, 3.15 ]
Moore 2016 (7) 4/68 4/87 0.9 % 1.28 [ 0.33, 4.93 ]
N’Guessan 2010 (8) 55/115 56/102 6.0 % 0.87 [ 0.67, 1.13 ]
Pennetier 2013 (9) 7/66 11/95 1.8 % 0.92 [ 0.37, 2.24 ]
To 2018 (10) 31/272 83/310 4.8 % 0.43 [ 0.29, 0.62 ]
To 2018 (11) 63/249 113/269 6.1 % 0.60 [ 0.47, 0.78 ]
To 2018 (12) 62/221 94/293 5.9 % 0.87 [ 0.67, 1.14 ]
To 2018 (13) 28/199 119/325 4.9 % 0.38 [ 0.26, 0.56 ]
Tungu 2010 (14) 6/233 32/315 1.9 % 0.25 [ 0.11, 0.60 ]
Subtotal (95% CI) 2836 3519 56.8 % 0.66 [ 0.54, 0.79 ]
Total events: 628 (PBO-LLINs), 1221 (LLINs)
Heterogeneity: Tau2 = 0.07; Chi2 = 49.11, df = 13 (P<0.00001); I2 =74%
Test for overall effect: Z = 4.40 (P = 0.000011)
2 Washed
Bayili 2017 (15) 215/474 259/515 7.2 % 0.90 [ 0.79, 1.03 ]
Bayili 2017 (16) 170/420 277/550 7.1 % 0.80 [ 0.70, 0.93 ]
Corbel 2010 (17) 23/178 10/165 2.5 % 2.13 [ 1.05, 4.34 ]
Corbel 2010 (18) 26/105 40/199 4.3 % 1.23 [ 0.80, 1.90 ]
Corbel 2010 (19) 88/241 127/263 6.5 % 0.76 [ 0.61, 0.93 ]
Moore 2016 (20) 13/186 8/198 1.9 % 1.73 [ 0.73, 4.08 ]
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(. . . Continued)
Study or subgroup PBO-LLINs LLINs Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
Moore 2016 (21) 0/67 5/81 0.2 % 0.11 [ 0.01, 1.95 ]
N’Guessan 2010 (22) 70/130 85/146 6.5 % 0.92 [ 0.75, 1.14 ]
Pennetier 2013 (23) 12/96 29/117 3.0 % 0.50 [ 0.27, 0.93 ]
Tungu 2010 (24) 30/285 28/299 3.9 % 1.12 [ 0.69, 1.83 ]
Subtotal (95% CI) 2182 2533 43.2 % 0.91 [ 0.78, 1.06 ]
Total events: 647 (PBO-LLINs), 868 (LLINs)
Heterogeneity: Tau2 = 0.02; Chi2 = 20.67, df = 9 (P = 0.01); I2 =56%
Test for overall effect: Z = 1.25 (P = 0.21)
Total (95% CI) 5018 6052 100.0 % 0.76 [ 0.67, 0.88 ]
Total events: 1275 (PBO-LLINs), 2089 (LLINs)
Heterogeneity: Tau2 = 0.06; Chi2 = 94.59, df = 23 (P<0.00001); I2 =76%
Test for overall effect: Z = 3.87 (P = 0.00011)
Test for subgroup differences: Chi2 = 7.10, df = 1 (P = 0.01), I2 =86%
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(1) Vallee du Kou, DawaPlus 3.0, High resistance
(2) Vallee du Kou, DawaPlus 4.0, High resistanceVallee du Kou, DawaPlus 4.0, High resistance
(3) Vall e du Kou, Permanet 3.0, High resistance
(4) Malanville, Permanet 3.0, Low resistance
(5) Pitoa, Permanet 3.0, Low resistance
(6) Ifakara, Veeralin, Susceptible, An. arabiensis
(7) Ifakara, Veeralin, Unclassified, An. funestus
(8) Akron, Permanet 3.0, Moderate resistance
(9) Akron, Permanet 3.0, Moderate resistance
(10) Vallee du Kou 5, Olyset Plus, High resistance
(11) Tengrela, Permanet 3.0, High resistance
(12) Tengrela, Olyset Plus, High resistance
(13) Vallee du Kou 5, Permanet 3.0, High resistance
(14) Zeneti, Permanet 3.0, Susceptible
(15) Vallee du Kou, DawaPlus 3.0, High resistance
(16) Vallee du Kou, DawaPlus 4.0, High resistance
(17) Malanville, Permanet 3.0, Low resistance
(18) Pitoa, Permanet 3.0, Low resistance
(19) Vall e du Kou, Permanet 3.0, High resistance
(20) Ifakara, Veeralin, Susceptible, An. arabiensis
(21) Ifakara, Veeralin, Unclassified, An. funestus
(22) Akron, Permanet 3.0, Moderate resistance
(23) Malanville, Olyset Plus, High resistance
(24) Zeneti, Permanet 3.0, Susceptible
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Analysis 2.3. Comparison 2 Commercial pyrethroid-PBO nets versus commercial LLINs: hut trials,
Outcome 3 Mosquito exophily (pooled) hut/night.
Review: Piperonyl butoxide (PBO) combined with pyrethroids in insecticide-treated nets to prevent malaria in Africa
Comparison: 2 Commercial pyrethroid-PBO nets versus commercial LLINs: hut trials
Outcome: 3 Mosquito exophily (pooled) hut/night
Study or subgroup PBO-LLIN LLIN Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
1 Unwashed
Bayili 2017 (1) 216/425 194/482 4.1 % 1.26 [ 1.09, 1.46 ]
Bayili 2017 (2) 210/302 223/553 4.3 % 1.72 [ 1.52, 1.96 ]
Corbel 2010 (3) 93/176 122/200 3.7 % 0.87 [ 0.72, 1.04 ]
Corbel 2010 (4) 185/232 133/165 4.7 % 0.99 [ 0.90, 1.09 ]
Corbel 2010 (5) 68/117 52/84 3.1 % 0.94 [ 0.75, 1.18 ]
Koudou 2011 (6) 109/214 131/224 3.8 % 0.87 [ 0.73, 1.03 ]
Moore 2016 (7) 55/68 73/87 4.1 % 0.96 [ 0.83, 1.12 ]
Moore 2016 (8) 129/161 197/239 4.7 % 0.97 [ 0.88, 1.07 ]
N’Guessan 2010 (9) 67/115 64/102 3.2 % 0.93 [ 0.75, 1.15 ]
Pennetier 2013 (10) 36/66 67/95 2.8 % 0.77 [ 0.60, 1.00 ]
To 2018 (11) 146/272 174/310 4.1 % 0.96 [ 0.82, 1.11 ]
To 2018 (12) 102/199 170/325 3.8 % 0.98 [ 0.83, 1.16 ]
To 2018 (13) 80/249 80/269 2.7 % 1.08 [ 0.84, 1.40 ]
To 2018 (14) 85/221 105/293 3.1 % 1.07 [ 0.86, 1.35 ]
Tungu 2010 (15) 184/233 269/315 4.9 % 0.92 [ 0.85, 1.00 ]
Subtotal (95% CI) 3050 3743 56.9 % 1.01 [ 0.91, 1.12 ]
Total events: 1765 (PBO-LLIN), 2054 (LLIN)
Heterogeneity: Tau2 = 0.03; Chi2 = 99.15, df = 14 (P<0.00001); I2 =86%
Test for overall effect: Z = 0.15 (P = 0.88)
2 Washed
Bayili 2017 (16) 211/420 265/550 4.3 % 1.04 [ 0.92, 1.19 ]
Bayili 2017 (17) 227/474 248/515 4.3 % 0.99 [ 0.87, 1.13 ]
Corbel 2010 (18) 120/178 99/165 3.9 % 1.12 [ 0.96, 1.32 ]
Corbel 2010 (19) 54/105 103/199 3.0 % 0.99 [ 0.79, 1.25 ]
Corbel 2010 (20) 183/241 178/263 4.6 % 1.12 [ 1.01, 1.25 ]
0.01 0.1 1 10 100
Favours PBO-LLINs Favours LLINs
(Continued . . . )
63Piperonyl butoxide (PBO) combined with pyrethroids in insecticide-treated nets to prevent malaria in Africa (Review)
Copyright © 2018 The Authors. Cochrane Database of Systematic Reviews published by John Wiley & Sons, Ltd. on behalf of The
Cochrane Collaboration.
(. . . Continued)
Study or subgroup PBO-LLIN LLIN Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
Koudou 2011 (21) 113/224 119/201 3.7 % 0.85 [ 0.72, 1.01 ]
Moore 2016 (22) 140/186 162/198 4.6 % 0.92 [ 0.83, 1.02 ]
Moore 2016 (23) 49/67 62/81 3.5 % 0.96 [ 0.79, 1.15 ]
N’Guessan 2010 (24) 65/130 74/146 3.0 % 0.99 [ 0.78, 1.25 ]
Pennetier 2013 (25) 50/96 81/117 3.1 % 0.75 [ 0.60, 0.94 ]
Tungu 2010 (26) 242/285 264/299 5.0 % 0.96 [ 0.90, 1.03 ]
Subtotal (95% CI) 2406 2734 43.1 % 0.98 [ 0.92, 1.04 ]
Total events: 1454 (PBO-LLIN), 1655 (LLIN)
Heterogeneity: Tau2 = 0.00; Chi2 = 19.16, df = 10 (P = 0.04); I2 =48%
Test for overall effect: Z = 0.68 (P = 0.50)
Total (95% CI) 5456 6477 100.0 % 0.99 [ 0.94, 1.06 ]
Total events: 3219 (PBO-LLIN), 3709 (LLIN)
Heterogeneity: Tau2 = 0.02; Chi2 = 119.44, df = 25 (P<0.00001); I2 =79%
Test for overall effect: Z = 0.17 (P = 0.86)
Test for subgroup differences: Chi2 = 0.22, df = 1 (P = 0.64), I2 =0.0%
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(1) Vallee du Kou. DawaPlus 3.0, High resistance
(2) Vallee du Kou. DawaPlus 4.0, High resistance
(3) Malanville, Permanet 3.0, Low resistance
(4) Vall e du Kou, Permanet 3.0, HIgh resistance
(5) Pitoa, Permanet 3.0, Low resistance
(6) Yaokoffikro, Permanet 3.0, High resistance
(7) Ifakara, Veeralin, Unclassified, An. funestus
(8) Ifakara, Veeralin, Susceptible, An. arabiensis
(9) Akron, Permanet 3.0, Moderate resistance
(10) Malanville, Olyset Plus, High resistance
(11) Vallee du Kou 5 ,Olyset Plus, High resistance
(12) Vallee du Kou 5, Permanet 3.0, High resistance
(13) Tengrela, Permanet 3.0, High resistance
(14) Tengrela, Olyset Plus, High resistance
(15) Zeneti, Permanet 3.0, Susceptible
(16) Vallee du Kou. DawaPlus 4.0, High resistance
(17) Vallee du Kou. DawaPlus 3.0, High resistance
(18) Malanville, Permanet 3.0, Low resistance
(19) Pitoa, Permanet 3.0, Low resistance
(20) Vall e du Kou, Permanet 3.0, HIgh resistance
(21) Yaokoffikro, Permanet 3.0, High resistance
(22) Ifakara, Veeralin, Susceptible, An. arabiensis
(23) Ifakara, Veeralin, Unclassified, An. funestus
(24) Akron, Permanet 3.0, Moderate resistance
(25) Malanville, Olyset Plus, High resistance
(26) Zeneti, Permanet 3.0, Susceptible
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Analysis 2.4. Comparison 2 Commercial pyrethroid-PBO nets versus commercial LLINs: hut trials,
Outcome 4 Mosquito mortality (high resistance) hut/night.
Review: Piperonyl butoxide (PBO) combined with pyrethroids in insecticide-treated nets to prevent malaria in Africa
Comparison: 2 Commercial pyrethroid-PBO nets versus commercial LLINs: hut trials
Outcome: 4 Mosquito mortality (high resistance) hut/night
Study or subgroup PBO-LLINs LLINs Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
1 Unwashed
Bayili 2017 (1) 130/302 83/553 7.3 % 2.87 [ 2.26, 3.64 ]
Bayili 2017 (2) 92/425 72/482 6.9 % 1.45 [ 1.10, 1.92 ]
Corbel 2010 (3) 181/232 73/165 7.7 % 1.76 [ 1.47, 2.12 ]
Koudou 2011 (4) 117/214 78/224 7.4 % 1.57 [ 1.26, 1.95 ]
Pennetier 2013 (5) 53/66 39/95 7.0 % 1.96 [ 1.49, 2.56 ]
To 2018 (6) 146/272 97/310 7.6 % 1.72 [ 1.41, 2.09 ]
To 2018 (7) 62/221 57/293 6.5 % 1.44 [ 1.05, 1.97 ]
To 2018 (8) 116/249 52/269 6.9 % 2.41 [ 1.83, 3.18 ]
To 2018 (9) 125/199 116/325 7.8 % 1.76 [ 1.47, 2.11 ]
Subtotal (95% CI) 2180 2716 65.0 % 1.84 [ 1.60, 2.11 ]
Total events: 1022 (PBO-LLINs), 667 (LLINs)
Heterogeneity: Tau2 = 0.03; Chi2 = 25.39, df = 8 (P = 0.001); I2 =68%
Test for overall effect: Z = 8.65 (P < 0.00001)
2 Washed
Bayili 2017 (10) 65/420 92/550 6.7 % 0.93 [ 0.69, 1.24 ]
Bayili 2017 (11) 83/474 86/515 6.9 % 1.05 [ 0.80, 1.38 ]
Corbel 2010 (12) 119/241 79/263 7.4 % 1.64 [ 1.31, 2.06 ]
Koudou 2011 (13) 72/224 77/201 7.1 % 0.84 [ 0.65, 1.09 ]
Pennetier 2013 (14) 64/96 43/117 6.9 % 1.81 [ 1.38, 2.39 ]
Subtotal (95% CI) 1455 1646 35.0 % 1.20 [ 0.88, 1.63 ]
Total events: 403 (PBO-LLINs), 377 (LLINs)
Heterogeneity: Tau2 = 0.11; Chi2 = 27.69, df = 4 (P = 0.00001); I2 =86%
Test for overall effect: Z = 1.14 (P = 0.25)
Total (95% CI) 3635 4362 100.0 % 1.58 [ 1.34, 1.86 ]
Total events: 1425 (PBO-LLINs), 1044 (LLINs)
Heterogeneity: Tau2 = 0.08; Chi2 = 84.86, df = 13 (P<0.00001); I2 =85%
Test for overall effect: Z = 5.46 (P < 0.00001)
Test for subgroup differences: Chi2 = 6.11, df = 1 (P = 0.01), I2 =84%
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(1) Valle du Kou, DawaPlus 4.0, High resistance
(2) Valle du Kou, DawaPlus 3.0, High resistance
(3) Vall e du Kou, Permanet 3.0, High resistance
(4) Yaokoffikro, Permanet 3.0, High resistance
(5) Malanaville, Olyset Plus, High resistance
(6) Vallee du Kou 5, Olyset Plus, High resistance
(7) Tengrela, Olyset Plus, High resistance
(8) Tengrela, Permanet 3.0, High resistance
(9) Vallee du Kou 5, Permanet 3.0, High resistance
(10) Valle du Kou, DawaPlus 4.0, High resistance
(11) Valle du Kou, DawaPlus 3.0, High resistance
(12) Vall e du Kou, Permanet 3.0, High resistance
(13) Vall e du Kou, Permanet 3.0, High resistance
(14) Vall e du Kou, Permanet 3.0, High resistance
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Analysis 2.5. Comparison 2 Commercial pyrethroid-PBO nets versus commercial LLINs: hut trials,
Outcome 5 Mosquito blood-feeding success (high resistance) hut/night.
Review: Piperonyl butoxide (PBO) combined with pyrethroids in insecticide-treated nets to prevent malaria in Africa
Comparison: 2 Commercial pyrethroid-PBO nets versus commercial LLINs: hut trials
Outcome: 5 Mosquito blood-feeding success (high resistance) hut/night
Study or subgroup PBO-LLINs LLINs Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
1 Unwashed
Bayili 2017 (1) 102/302 333/553 10.8 % 0.56 [ 0.47, 0.67 ]
Bayili 2017 (2) 182/425 290/482 11.5 % 0.71 [ 0.62, 0.81 ]
Corbel 2010 (3) 48/232 58/165 7.6 % 0.59 [ 0.42, 0.82 ]
Pennetier 2013 (4) 7/66 11/95 2.1 % 0.92 [ 0.37, 2.24 ]
To 2018 (5) 28/199 119/325 6.8 % 0.38 [ 0.26, 0.56 ]
To 2018 (6) 31/272 83/310 6.7 % 0.43 [ 0.29, 0.62 ]
To 2018 (7) 63/249 113/269 9.0 % 0.60 [ 0.47, 0.78 ]
To 2018 (8) 62/221 94/293 8.8 % 0.87 [ 0.67, 1.14 ]
Subtotal (95% CI) 1966 2492 63.3 % 0.60 [ 0.50, 0.71 ]
Total events: 523 (PBO-LLINs), 1101 (LLINs)
Heterogeneity: Tau2 = 0.04; Chi2 = 23.11, df = 7 (P = 0.002); I2 =70%
Test for overall effect: Z = 5.76 (P < 0.00001)
2 Washed
Bayili 2017 (9) 170/420 277/550 11.3 % 0.80 [ 0.70, 0.93 ]
Bayili 2017 (10) 215/474 259/515 11.5 % 0.90 [ 0.79, 1.03 ]
Corbel 2010 (11) 88/241 127/263 10.0 % 0.76 [ 0.61, 0.93 ]
Pennetier 2013 (12) 12/96 29/117 3.7 % 0.50 [ 0.27, 0.93 ]
Subtotal (95% CI) 1231 1445 36.7 % 0.81 [ 0.72, 0.92 ]
Total events: 485 (PBO-LLINs), 692 (LLINs)
Heterogeneity: Tau2 = 0.01; Chi2 = 5.07, df = 3 (P = 0.17); I2 =41%
Test for overall effect: Z = 3.24 (P = 0.0012)
Total (95% CI) 3197 3937 100.0 % 0.66 [ 0.57, 0.76 ]
Total events: 1008 (PBO-LLINs), 1793 (LLINs)
Heterogeneity: Tau2 = 0.04; Chi2 = 48.33, df = 11 (P<0.00001); I2 =77%
Test for overall effect: Z = 5.72 (P < 0.00001)
Test for subgroup differences: Chi2 = 7.70, df = 1 (P = 0.01), I2 =87%
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(1) Vallee du Kou, DawaPlus 4.0, High resistance
(2) Vallee du Kou, DawaPlus 3.0, High resistance
(3) Vall e du Kou, Permanet 3.0, High resistance
(4) Malanville, Olyset Plus, High resistance
(5) Vallee du Kou 5, Permanet 3.0, High resistance
(6) Vallee du Kou 5, Olyset Plus, High resistance
(7) Tengrela, Permanet 3.0, High resistance
(8) Tengrela, Olyset Plus, High resistance
(9) Vallee du Kou, DawaPlus 4.0, High resistance
(10) Vallee du Kou, DawaPlus 3.0, High resistance
(11) Vall e du Kou, Permanet 3.0, High resistance
(12) Malanville, Olyset Plus, High resistance
Analysis 2.6. Comparison 2 Commercial pyrethroid-PBO nets versus commercial LLINs: hut trials,
Outcome 6 Mosquito mortality (moderate resistance) hut/night.
Review: Piperonyl butoxide (PBO) combined with pyrethroids in insecticide-treated nets to prevent malaria in Africa
Comparison: 2 Commercial pyrethroid-PBO nets versus commercial LLINs: hut trials
Outcome: 6 Mosquito mortality (moderate resistance) hut/night
Study or subgroup PBO-LLINs LLINs Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 Unwashed
N’Guessan 2010 (1) 59/115 45/102 54.7 % 1.16 [ 0.88, 1.54 ]
Subtotal (95% CI) 115 102 54.7 % 1.16 [ 0.88, 1.54 ]
Total events: 59 (PBO-LLINs), 45 (LLINs)
Heterogeneity: not applicable
Test for overall effect: Z = 1.05 (P = 0.29)
2 Washed
N’Guessan 2010 (2) 40/130 42/146 45.3 % 1.07 [ 0.74, 1.54 ]
Subtotal (95% CI) 130 146 45.3 % 1.07 [ 0.74, 1.54 ]
Total events: 40 (PBO-LLINs), 42 (LLINs)
Heterogeneity: not applicable
0.01 0.1 1 10 100
Favours LLINs Favours PBO-LLINs
(Continued . . . )
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(. . . Continued)
Study or subgroup PBO-LLINs LLINs Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Test for overall effect: Z = 0.36 (P = 0.72)
Total (95% CI) 245 248 100.0 % 1.12 [ 0.90, 1.40 ]
Total events: 99 (PBO-LLINs), 87 (LLINs)
Heterogeneity: Chi2 = 0.13, df = 1 (P = 0.72); I2 =0.0%
Test for overall effect: Z = 0.99 (P = 0.32)
Test for subgroup differences: Chi2 = 0.13, df = 1 (P = 0.72), I2 =0.0%
0.01 0.1 1 10 100
Favours LLINs Favours PBO-LLINs
(1) Akron, Permanet 3.0, Moderate resistance
(2) Akron, Permanet 3.0, Moderate resistance
Analysis 2.7. Comparison 2 Commercial pyrethroid-PBO nets versus commercial LLINs: hut trials,
Outcome 7 Mosquito blood-feeding success (moderate resistance) hut/night.
Review: Piperonyl butoxide (PBO) combined with pyrethroids in insecticide-treated nets to prevent malaria in Africa
Comparison: 2 Commercial pyrethroid-PBO nets versus commercial LLINs: hut trials
Outcome: 7 Mosquito blood-feeding success (moderate resistance) hut/night
Study or subgroup PBO-LLINs LLINs Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
1 Unwashed
N’Guessan 2010 (1) 55/115 56/102 39.3 % 0.87 [ 0.67, 1.13 ]
Subtotal (95% CI) 115 102 39.3 % 0.87 [ 0.67, 1.13 ]
Total events: 55 (PBO-LLINs), 56 (LLINs)
Heterogeneity: not applicable
Test for overall effect: Z = 1.04 (P = 0.30)
2 Washed
N’Guessan 2010 (2) 71/133 87/149 60.7 % 0.91 [ 0.74, 1.13 ]
Subtotal (95% CI) 133 149 60.7 % 0.91 [ 0.74, 1.13 ]
Total events: 71 (PBO-LLINs), 87 (LLINs)
Heterogeneity: not applicable
Test for overall effect: Z = 0.84 (P = 0.40)
0.01 0.1 1 10 100
Favours PBO-LLINs Favours LLINs
(Continued . . . )
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(. . . Continued)
Study or subgroup PBO-LLINs LLINs Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
Total (95% CI) 248 251 100.0 % 0.90 [ 0.76, 1.06 ]
Total events: 126 (PBO-LLINs), 143 (LLINs)
Heterogeneity: Tau2 = 0.0; Chi2 = 0.08, df = 1 (P = 0.78); I2 =0.0%
Test for overall effect: Z = 1.31 (P = 0.19)
Test for subgroup differences: Chi2 = 0.08, df = 1 (P = 0.78), I2 =0.0%
0.01 0.1 1 10 100
Favours PBO-LLINs Favours LLINs
(1) Akron, Permanet 3.0, Moderate resistance
(2) Akron, Permanet 3.0, Moderate resistance
Analysis 2.8. Comparison 2 Commercial pyrethroid-PBO nets versus commercial LLINs: hut trials,
Outcome 8 Mosquito mortality (low resistance) hut/night.
Review: Piperonyl butoxide (PBO) combined with pyrethroids in insecticide-treated nets to prevent malaria in Africa
Comparison: 2 Commercial pyrethroid-PBO nets versus commercial LLINs: hut trials
Outcome: 8 Mosquito mortality (low resistance) hut/night
Study or subgroup PBO-LLINs LLINs Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
1 Unwashed
Corbel 2010 (1) 170/176 177/200 32.3 % 1.09 [ 1.03, 1.16 ]
Corbel 2010 (2) 110/117 70/84 26.1 % 1.13 [ 1.01, 1.25 ]
Subtotal (95% CI) 293 284 58.4 % 1.10 [ 1.05, 1.16 ]
Total events: 280 (PBO-LLINs), 247 (LLINs)
Heterogeneity: Tau2 = 0.0; Chi2 = 0.31, df = 1 (P = 0.58); I2 =0.0%
Test for overall effect: Z = 3.70 (P = 0.00022)
2 Washed
Corbel 2010 (3) 82/105 112/199 19.6 % 1.39 [ 1.18, 1.63 ]
Corbel 2010 (4) 124/178 117/165 22.1 % 0.98 [ 0.86, 1.13 ]
Subtotal (95% CI) 283 364 41.6 % 1.16 [ 0.83, 1.63 ]
0.01 0.1 1 10 100
Favours LLINs Favours PBO-LLINs
(Continued . . . )
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(. . . Continued)
Study or subgroup PBO-LLINs LLINs Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
Total events: 206 (PBO-LLINs), 229 (LLINs)
Heterogeneity: Tau2 = 0.05; Chi2 = 10.36, df = 1 (P = 0.001); I2 =90%
Test for overall effect: Z = 0.88 (P = 0.38)
Total (95% CI) 576 648 100.0 % 1.13 [ 1.02, 1.25 ]
Total events: 486 (PBO-LLINs), 476 (LLINs)
Heterogeneity: Tau2 = 0.01; Chi2 = 11.26, df = 3 (P = 0.01); I2 =73%
Test for overall effect: Z = 2.25 (P = 0.025)
Test for subgroup differences: Chi2 = 0.11, df = 1 (P = 0.74), I2 =0.0%
0.01 0.1 1 10 100
Favours LLINs Favours PBO-LLINs
(1) Malanville, Permanet 3.0, Low resistance
(2) Pitoa, Permanet 3.0, Low resistance
(3) Pitoa, Permanet 3.0, Low resistance
(4) Malanville, Permanet 3.0, Low resistance
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Analysis 2.9. Comparison 2 Commercial pyrethroid-PBO nets versus commercial LLINs: hut trials,
Outcome 9 Mosquito blood-feeding success (low resistance) hut/night.
Review: Piperonyl butoxide (PBO) combined with pyrethroids in insecticide-treated nets to prevent malaria in Africa
Comparison: 2 Commercial pyrethroid-PBO nets versus commercial LLINs: hut trials
Outcome: 9 Mosquito blood-feeding success (low resistance) hut/night
Study or subgroup PBO-LLINs LLINs Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
1 Unwashed
Corbel 2010 (1) 33/117 13/84 31.1 % 1.82 [ 1.02, 3.25 ]
Corbel 2010 (2) 1/176 7/200 5.5 % 0.16 [ 0.02, 1.31 ]
Subtotal (95% CI) 293 284 36.7 % 0.67 [ 0.06, 7.37 ]
Total events: 34 (PBO-LLINs), 20 (LLINs)
Heterogeneity: Tau2 = 2.48; Chi2 = 5.08, df = 1 (P = 0.02); I2 =80%
Test for overall effect: Z = 0.33 (P = 0.74)
2 Washed
Corbel 2010 (3) 23/178 10/165 26.0 % 2.13 [ 1.05, 4.34 ]
Corbel 2010 (4) 26/105 40/199 37.4 % 1.23 [ 0.80, 1.90 ]
Subtotal (95% CI) 283 364 63.3 % 1.50 [ 0.89, 2.54 ]
Total events: 49 (PBO-LLINs), 50 (LLINs)
Heterogeneity: Tau2 = 0.06; Chi2 = 1.70, df = 1 (P = 0.19); I2 =41%
Test for overall effect: Z = 1.53 (P = 0.13)
Total (95% CI) 576 648 100.0 % 1.43 [ 0.85, 2.41 ]
Total events: 83 (PBO-LLINs), 70 (LLINs)
Heterogeneity: Tau2 = 0.14; Chi2 = 6.54, df = 3 (P = 0.09); I2 =54%
Test for overall effect: Z = 1.36 (P = 0.17)
Test for subgroup differences: Chi2 = 0.42, df = 1 (P = 0.52), I2 =0.0%
0.01 0.1 1 10 100
Favours PBO-LLINs Favours LLINs
(1) Pitoa, Permanet 3.0, Low resistance
(2) Malanville, Permanet 3.0, Low resistance
(3) Malanville, Permanet 3.0, Low resistance
(4) Pitoa, Permanet 3.0, Low resistance
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Analysis 2.10. Comparison 2 Commercial pyrethroid-PBO nets versus commercial LLINs: hut trials,
Outcome 10 Mosquito mortality (susceptible) hut/night.
Review: Piperonyl butoxide (PBO) combined with pyrethroids in insecticide-treated nets to prevent malaria in Africa
Comparison: 2 Commercial pyrethroid-PBO nets versus commercial LLINs: hut trials
Outcome: 10 Mosquito mortality (susceptible) hut/night
Study or subgroup PBO-LLINs LLINs Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
1 Unwashed
Moore 2016 (1) 23/161 22/239 2.7 % 1.55 [ 0.90, 2.69 ]
Tungu 2010 (2) 223/233 300/315 48.8 % 1.00 [ 0.97, 1.04 ]
Subtotal (95% CI) 394 554 51.5 % 1.20 [ 0.64, 2.26 ]
Total events: 246 (PBO-LLINs), 322 (LLINs)
Heterogeneity: Tau2 = 0.18; Chi2 = 5.47, df = 1 (P = 0.02); I2 =82%
Test for overall effect: Z = 0.57 (P = 0.57)
2 Washed
Moore 2016 (3) 23/186 28/198 3.0 % 0.87 [ 0.52, 1.46 ]
Tungu 2010 (4) 271/285 260/299 45.5 % 1.09 [ 1.04, 1.15 ]
Subtotal (95% CI) 471 497 48.5 % 1.07 [ 0.92, 1.25 ]
Total events: 294 (PBO-LLINs), 288 (LLINs)
Heterogeneity: Tau2 = 0.01; Chi2 = 1.16, df = 1 (P = 0.28); I2 =14%
Test for overall effect: Z = 0.93 (P = 0.35)
Total (95% CI) 865 1051 100.0 % 1.05 [ 0.96, 1.15 ]
Total events: 540 (PBO-LLINs), 610 (LLINs)
Heterogeneity: Tau2 = 0.00; Chi2 = 11.29, df = 3 (P = 0.01); I2 =73%
Test for overall effect: Z = 1.08 (P = 0.28)
Test for subgroup differences: Chi2 = 0.11, df = 1 (P = 0.74), I2 =0.0%
0.01 0.1 1 10 100
Favours LLINs Favours PBO-LLINs
(1) Ifakara, Veeralin, Susceptible, An. arabiensis. The population was resistant to deltamethrin and permethrin.
(2) Zeneti, Permanet 3.0, Susceptible
(3) Ifakara, Veeralin, Susceptible, An. arabiensis. The population was resistant to deltamethrin and permethrin.
(4) Zeneti, Permanet 3.0, Susceptible
74Piperonyl butoxide (PBO) combined with pyrethroids in insecticide-treated nets to prevent malaria in Africa (Review)
Copyright © 2018 The Authors. Cochrane Database of Systematic Reviews published by John Wiley & Sons, Ltd. on behalf of The
Cochrane Collaboration.
Analysis 2.11. Comparison 2 Commercial pyrethroid-PBO nets versus commercial LLINs: hut trials,
Outcome 11 Mosquito blood-feeding success (susceptible) hut/night.
Review: Piperonyl butoxide (PBO) combined with pyrethroids in insecticide-treated nets to prevent malaria in Africa
Comparison: 2 Commercial pyrethroid-PBO nets versus commercial LLINs: hut trials
Outcome: 11 Mosquito blood-feeding success (susceptible) hut/night
Study or subgroup PBO-LLINs LLINs Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
1 Unwashed
Moore 2016 (1) 6/161 8/239 21.3 % 1.11 [ 0.39, 3.15 ]
Tungu 2010 (2) 6/233 32/315 24.3 % 0.25 [ 0.11, 0.60 ]
Subtotal (95% CI) 394 554 45.6 % 0.52 [ 0.12, 2.22 ]
Total events: 12 (PBO-LLINs), 40 (LLINs)
Heterogeneity: Tau2 = 0.88; Chi2 = 4.73, df = 1 (P = 0.03); I2 =79%
Test for overall effect: Z = 0.89 (P = 0.37)
2 Washed
Moore 2016 (3) 13/186 8/198 24.2 % 1.73 [ 0.73, 4.08 ]
Tungu 2010 (4) 30/285 28/299 30.2 % 1.12 [ 0.69, 1.83 ]
Subtotal (95% CI) 471 497 54.4 % 1.25 [ 0.82, 1.91 ]
Total events: 43 (PBO-LLINs), 36 (LLINs)
Heterogeneity: Tau2 = 0.0; Chi2 = 0.73, df = 1 (P = 0.39); I2 =0.0%
Test for overall effect: Z = 1.03 (P = 0.30)
Total (95% CI) 865 1051 100.0 % 0.87 [ 0.40, 1.89 ]
Total events: 55 (PBO-LLINs), 76 (LLINs)
Heterogeneity: Tau2 = 0.46; Chi2 = 11.86, df = 3 (P = 0.01); I2 =75%
Test for overall effect: Z = 0.36 (P = 0.72)
Test for subgroup differences: Chi2 = 1.30, df = 1 (P = 0.25), I2 =23%
0.01 0.1 1 10 100
Favours PBO-LLINs Favours LLINs
(1) Ifakara, Veeralin, Susceptible, An. arabiensis. The population was resistant to deltamethrin and permethrin.
(2) Zeneti, Permanet 3.0, Susceptible
(3) Ifakara, Veeralin, Susceptible, An. arabiensis. The population was resistant to deltamethrin and permethrin.
(4) Zeneti, Permanet 3.0, Susceptible
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Analysis 2.12. Comparison 2 Commercial pyrethroid-PBO nets versus commercial LLINs: hut trials,
Outcome 12 Mosquito mortality (high resistance/Permanet) hut/night.
Review: Piperonyl butoxide (PBO) combined with pyrethroids in insecticide-treated nets to prevent malaria in Africa
Comparison: 2 Commercial pyrethroid-PBO nets versus commercial LLINs: hut trials
Outcome: 12 Mosquito mortality (high resistance/Permanet) hut/night
Study or subgroup PBO-LLINs LLINs Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
1 Not Washed
Corbel 2010 (1) 181/232 73/165 17.6 % 1.76 [ 1.47, 2.12 ]
Koudou 2011 (2) 117/214 78/224 16.9 % 1.57 [ 1.26, 1.95 ]
To 2018 (3) 116/249 52/269 15.4 % 2.41 [ 1.83, 3.18 ]
To 2018 (4) 125/199 116/325 17.6 % 1.76 [ 1.47, 2.11 ]
Subtotal (95% CI) 894 983 67.4 % 1.81 [ 1.56, 2.10 ]
Total events: 539 (PBO-LLINs), 319 (LLINs)
Heterogeneity: Tau2 = 0.01; Chi2 = 5.95, df = 3 (P = 0.11); I2 =50%
Test for overall effect: Z = 7.88 (P < 0.00001)
2 Washed
Corbel 2010 (5) 119/241 79/263 16.7 % 1.64 [ 1.31, 2.06 ]
Koudou 2011 (6) 72/224 77/201 15.9 % 0.84 [ 0.65, 1.09 ]
Subtotal (95% CI) 465 464 32.6 % 1.18 [ 0.61, 2.28 ]
Total events: 191 (PBO-LLINs), 156 (LLINs)
Heterogeneity: Tau2 = 0.21; Chi2 = 14.81, df = 1 (P = 0.00012); I2 =93%
Test for overall effect: Z = 0.49 (P = 0.63)
Total (95% CI) 1359 1447 100.0 % 1.59 [ 1.26, 2.01 ]
Total events: 730 (PBO-LLINs), 475 (LLINs)
Heterogeneity: Tau2 = 0.07; Chi2 = 34.38, df = 5 (P<0.00001); I2 =85%
Test for overall effect: Z = 3.90 (P = 0.000097)
Test for subgroup differences: Chi2 = 1.57, df = 1 (P = 0.21), I2 =36%
0.01 0.1 1 10 100
Favours LLINs Favours PBO-LLINs
(1) Vall e du Kou, Permanet 3.0, High resistance
(2) Yaokoffikro, Permanet 3.0, High resistance
(3) Tengrela, Permanet 3.0, High resistance
(4) Vallee du Kou 5, Permanet 3.0, High resistance
(5) Vall e du Kou, Permanet 3.0, High resistance
(6) Vall e du Kou, Permanet 3.0, High resistance
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Analysis 2.13. Comparison 2 Commercial pyrethroid-PBO nets versus commercial LLINs: hut trials,
Outcome 13 Mosquito blood-feeding success (high resistance/Permanet) hut/night.
Review: Piperonyl butoxide (PBO) combined with pyrethroids in insecticide-treated nets to prevent malaria in Africa
Comparison: 2 Commercial pyrethroid-PBO nets versus commercial LLINs: hut trials
Outcome: 13 Mosquito blood-feeding success (high resistance/Permanet) hut/night
Study or subgroup PBO-LLINs LLINs Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
1 Unwashed
Corbel 2010 (1) 48/232 58/165 23.1 % 0.59 [ 0.42, 0.82 ]
To 2018 (2) 28/199 119/325 20.8 % 0.38 [ 0.26, 0.56 ]
To 2018 (3) 63/249 113/269 26.8 % 0.60 [ 0.47, 0.78 ]
Subtotal (95% CI) 680 759 70.7 % 0.53 [ 0.40, 0.69 ]
Total events: 139 (PBO-LLINs), 290 (LLINs)
Heterogeneity: Tau2 = 0.03; Chi2 = 4.29, df = 2 (P = 0.12); I2 =53%
Test for overall effect: Z = 4.72 (P < 0.00001)
2 Washed
Corbel 2010 (4) 88/241 127/263 29.3 % 0.76 [ 0.61, 0.93 ]
Subtotal (95% CI) 241 263 29.3 % 0.76 [ 0.61, 0.93 ]
Total events: 88 (PBO-LLINs), 127 (LLINs)
Heterogeneity: not applicable
Test for overall effect: Z = 2.63 (P = 0.0085)
Total (95% CI) 921 1022 100.0 % 0.58 [ 0.45, 0.76 ]
Total events: 227 (PBO-LLINs), 417 (LLINs)
Heterogeneity: Tau2 = 0.05; Chi2 = 10.34, df = 3 (P = 0.02); I2 =71%
Test for overall effect: Z = 4.04 (P = 0.000054)
Test for subgroup differences: Chi2 = 4.40, df = 1 (P = 0.04), I2 =77%
0.01 0.1 1 10 100
Favours PBO-LLINs Favours LLINs
(1) Vall e du Kou, Permanet 3.0, High resistance
(2) Vallee du Kou 5, Permanet 3.0, High resistance
(3) Tengrela, Permanet 3.0, High resistance
(4) Vall e du Kou, Permanet 3.0, High resistance
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Analysis 2.14. Comparison 2 Commercial pyrethroid-PBO nets versus commercial LLINs: hut trials,
Outcome 14 Mosquito mortality (high resistance/Olyset) hut/night.
Review: Piperonyl butoxide (PBO) combined with pyrethroids in insecticide-treated nets to prevent malaria in Africa
Comparison: 2 Commercial pyrethroid-PBO nets versus commercial LLINs: hut trials
Outcome: 14 Mosquito mortality (high resistance/Olyset) hut/night
Study or subgroup PBO-LLINs LLINs Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
1 Unwashed
Pennetier 2013 (1) 53/66 39/95 24.4 % 1.96 [ 1.49, 2.56 ]
To 2018 (2) 146/272 97/310 44.8 % 1.72 [ 1.41, 2.09 ]
To 2018 (3) 62/221 57/293 17.8 % 1.44 [ 1.05, 1.97 ]
Subtotal (95% CI) 559 698 87.0 % 1.72 [ 1.48, 1.99 ]
Total events: 261 (PBO-LLINs), 193 (LLINs)
Heterogeneity: Tau2 = 0.00; Chi2 = 2.17, df = 2 (P = 0.34); I2 =8%
Test for overall effect: Z = 7.08 (P < 0.00001)
2 Washed
Pennetier 2013 64/96 21/57 13.0 % 1.81 [ 1.25, 2.61 ]
Subtotal (95% CI) 96 57 13.0 % 1.81 [ 1.25, 2.61 ]
Total events: 64 (PBO-LLINs), 21 (LLINs)
Heterogeneity: not applicable
Test for overall effect: Z = 3.16 (P = 0.0016)
Total (95% CI) 655 755 100.0 % 1.73 [ 1.51, 1.97 ]
Total events: 325 (PBO-LLINs), 214 (LLINs)
Heterogeneity: Tau2 = 0.0; Chi2 = 2.22, df = 3 (P = 0.53); I2 =0.0%
Test for overall effect: Z = 8.08 (P < 0.00001)
Test for subgroup differences: Chi2 = 0.07, df = 1 (P = 0.79), I2 =0.0%
0.01 0.1 1 10 100
Favours LLINs Favours PBO-LLINs
(1) Malanaville, Olyset Plus, High resistance
(2) Vallee du Kou 5, Olyset Plus, High resistance
(3) Tengrela, Olyset Plus, High resistance
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Analysis 2.15. Comparison 2 Commercial pyrethroid-PBO nets versus commercial LLINs: hut trials,
Outcome 15 Mosquito blood-feeding success (high resistance/Olyset) hut/night.
Review: Piperonyl butoxide (PBO) combined with pyrethroids in insecticide-treated nets to prevent malaria in Africa
Comparison: 2 Commercial pyrethroid-PBO nets versus commercial LLINs: hut trials
Outcome: 15 Mosquito blood-feeding success (high resistance/Olyset) hut/night
Study or subgroup PBO-LLINs LLINs Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
1 Unwashed
Pennetier 2013 (1) 7/66 11/95 15.0 % 0.92 [ 0.37, 2.24 ]
To 2018 (2) 31/272 83/310 29.7 % 0.43 [ 0.29, 0.62 ]
To 2018 (3) 62/221 94/293 33.2 % 0.87 [ 0.67, 1.14 ]
Subtotal (95% CI) 559 698 78.0 % 0.67 [ 0.38, 1.18 ]
Total events: 100 (PBO-LLINs), 188 (LLINs)
Heterogeneity: Tau2 = 0.18; Chi2 = 9.75, df = 2 (P = 0.01); I2 =79%
Test for overall effect: Z = 1.38 (P = 0.17)
2 Washed
Pennetier 2013 (4) 12/96 29/117 22.0 % 0.50 [ 0.27, 0.93 ]
Subtotal (95% CI) 96 117 22.0 % 0.50 [ 0.27, 0.93 ]
Total events: 12 (PBO-LLINs), 29 (LLINs)
Heterogeneity: not applicable
Test for overall effect: Z = 2.18 (P = 0.029)
Total (95% CI) 655 815 100.0 % 0.63 [ 0.40, 0.98 ]
Total events: 112 (PBO-LLINs), 217 (LLINs)
Heterogeneity: Tau2 = 0.14; Chi2 = 10.72, df = 3 (P = 0.01); I2 =72%
Test for overall effect: Z = 2.03 (P = 0.043)
Test for subgroup differences: Chi2 = 0.46, df = 1 (P = 0.50), I2 =0.0%
0.01 0.1 1 10 100
Favours PBO-LLINs Favours LLINs
(1) Malanville, Olyset Plus, High resistance
(2) Vallee du Kou 5, Olyset Plus, High resistance
(3) Tengrela, Olyset Plus, High resistance
(4) Malanville, Olyset Plus, High resistance
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Analysis 3.1. Comparison 3 Commercial pyrethroid-PBO nets versus commercial LLINs: village trials,
Outcome 1 Prevalence of malaria.
Review: Piperonyl butoxide (PBO) combined with pyrethroids in insecticide-treated nets to prevent malaria in Africa
Comparison: 3 Commercial pyrethroid-PBO nets versus commercial LLINs: village trials
Outcome: 1 Prevalence of malaria
Study or subgroup log [Odds Ratio] Odds Ratio Weight Odds Ratio
(SE) IV,Fixed,95% CI IV,Fixed,95% CI
Protopopoff 2018 (1) -0.9163 (0.3537) 100.0 % 0.40 [ 0.20, 0.80 ]
Total (95% CI) 100.0 % 0.40 [ 0.20, 0.80 ]
Heterogeneity: not applicable
Test for overall effect: Z = 2.59 (P = 0.0096)
Test for subgroup differences: Not applicable
0.01 0.1 1 10 100
Favours Pyrethoid-PBO net Favours LLINs
(1) 21 months after intervention
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Analysis 3.2. Comparison 3 Commercial pyrethroid-PBO nets versus commercial LLINs: village trials,
Outcome 2 Mosquito sporozoite-positive (adjusted ICC 0.1).
Review: Piperonyl butoxide (PBO) combined with pyrethroids in insecticide-treated nets to prevent malaria in Africa
Comparison: 3 Commercial pyrethroid-PBO nets versus commercial LLINs: village trials
Outcome: 2 Mosquito sporozoite-positive (adjusted ICC 0.1)
Study or subgroup Pyrethroid-PBO nets LLINs Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
Awolola 2014 (1) 0/4 0/16 Not estimable
Cisse 2017 (2) 1/43 1/35 19.7 % 0.81 [ 0.05, 12.55 ]
Cisse 2017 (3) 3/38 2/40 49.1 % 1.58 [ 0.28, 8.94 ]
Protopopoff 2018 (4) 1/106 4/122 31.2 % 0.29 [ 0.03, 2.53 ]
Stiles-Ocran 2013 (5) 0/9 0/11 Not estimable
Total (95% CI) 200 224 100.0 % 0.82 [ 0.24, 2.75 ]
Total events: 5 (Pyrethroid-PBO nets), 7 (LLINs)
Heterogeneity: Tau2 = 0.0; Chi2 = 1.46, df = 2 (P = 0.48); I2 =0.0%
Test for overall effect: Z = 0.33 (P = 0.74)
Test for subgroup differences: Not applicable
0.01 0.1 1 10 100
Favours Pyrethroid PBO Favours LLINs
(1) Permanet 3.0, Low resistance
(2) Permanet 3.0, Moderate resistance
(3) Olyset Plus, High resistance
(4) 2016
(5) Permanet 3.0, Moderate resistance
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Analysis 3.3. Comparison 3 Commercial pyrethroid-PBO nets versus commercial LLINs: village trials,
Outcome 3 Mosquito parous (adjusted ICC 0.1).
Review: Piperonyl butoxide (PBO) combined with pyrethroids in insecticide-treated nets to prevent malaria in Africa
Comparison: 3 Commercial pyrethroid-PBO nets versus commercial LLINs: village trials
Outcome: 3 Mosquito parous (adjusted ICC 0.1)
Study or subgroup Pyrethroid-PBO nets LLINs Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
Cisse 2017 (1) 30/40 29/37 42.3 % 0.96 [ 0.75, 1.22 ]
Cisse 2017 (2) 28/37 32/41 43.0 % 0.97 [ 0.76, 1.24 ]
Mzilahowa 2014 (3) 10/18 16/28 9.4 % 0.97 [ 0.58, 1.64 ]
Stiles-Ocran 2013 (4) 5/8 7/11 5.3 % 0.98 [ 0.49, 1.97 ]
Total (95% CI) 103 117 100.0 % 0.97 [ 0.82, 1.13 ]
Total events: 73 (Pyrethroid-PBO nets), 84 (LLINs)
Heterogeneity: Tau2 = 0.0; Chi2 = 0.01, df = 3 (P = 1.00); I2 =0.0%
Test for overall effect: Z = 0.43 (P = 0.66)
Test for subgroup differences: Not applicable
0.01 0.1 1 10 100
Favours Pyrethroid-PBO Favours LLIN
(1) Permanet 3.0, Moderate resistance
(2) Olyset Plus, HIgh resistance
(3) Permanet 3.0, funestus
(4) Permanet 3.0, Moderate resistance
A D D I T I O N A L T A B L E S
Table 1. World Health Organization Pesticide Evaluation Scheme (WHOPES) classification
WHOPES Phase Definition
WHOPES Phase I. Laboratory bioassays Cone bioassays: these are studies that are conducted in the laboratory setting and use
standardWHOprotocols (WHO2013, Section 2.2.1), where mosquitoes are exposed
to a suitable LLIN (treated intervention or untreated control), for three minutes using
a standard plastic WHO cone. Following net exposure, mosquitoes are transferred
to a holding container and maintained on a sugar solution diet while entomological
outcomes (mosquitoes knockeddownone hour post-exposure, andmosquitomortality
24 hours post-exposure), are measured
Tunnel tests: these are studies conducted in the laboratory setting that use standard
WHO protocols (WHO 2013, Section 2.2.2). Mosquitoes are released into a glass
tunnel covered at each end with untreated netting. The intervention or control LLIN
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Table 1. World Health Organization Pesticide Evaluation Scheme (WHOPES) classification (Continued)
net sample is placed one-third down the length of the tunnel and the net contains nine
holes that enable mosquitoes to pass through. A suitable bait is immobilized in the
shorter section of the tunnel where it is available for mosquito biting. Mosquitoes are
released into the opposite end of the tunnel and must make contact with the net and
locate holes before being able to feed on the bait. After 12 to 15 hours, mosquitoes are
removed from both sections of the tunnel and entomological outcomes (the number
of mosquitoes in each section, mortality, and blood-feeding inhibition at the end of
the assay and 24 hours post-exposure), are recorded
Wire-ball bioassays: these are studies conducted in the laboratory setting where
mosquitoes are introduced into a wire-ball frame that has been covered with either the
intervention or control LLIN. Mosquitoes are exposed for three minutes, after which
they are transferred to a holding container and entomological outcomes (mosquitoes
knocked down one hour post-exposure, and mosquito mortality 24 hours post-expo-
sure), are measured
WHOPES Phase II. Experimental hut trials WHOPES Phase II experimental hut trials are field trials conducted in Africa where
wild mosquito populations or local colonized populations are evaluated. Volunteers
or livestock sleep in experimental huts under a purposefully holed LLIN, with one
person or animal per hut. Huts are designed to resemble local housing based on aWest
or East African design (WHO 2013; Section 3.3.1-2). However they have identical
design features, such as eave gaps or entry slits to allow mosquitoes to enter, and exit
traps to capture exiting mosquitoes. LLINs and volunteers are randomly allocated to
huts and rotated in a Latin square to avoid bias, with huts cleaned between rotations
to avoid contamination. Several nets, including an untreated control net, can be tested
at the same time. Dead and live mosquitoes are collected each morning from inside
the net, inside the hut, and inside the exit traps. They are then scored as either blood-
fed or non-blood-fed, and either alive or dead, and live mosquitoes are maintained for
a further 24 hours to assess delayed mosquito mortality
WHOPES Phase III. Village trials WHOPES Phase III village trials are village trials conducted in Africa where wild
mosquito populations are evaluated. Villages chosen to be included in the study are
similar in terms of size, housing structure, location, and the data available on the
insecticide resistance status of the local malaria vectors. Households are assigned either
conventional LLINs or PBO-LLINs. Randomization can be at the household or village
level. Adult mosquitoes are collected from the study houses and mosquito density is
measured. An indication of malaria transmission is measured in the study sites either
by recording infections in mosquitoes, malaria prevalence, or malaria incidence
Abbreviations: LLIN: long-lasting insecticidal nets; PBO: pyrethroid-piperonyl butoxide; WHOPES: World Health Organization
Pesticide Evaluation Scheme
Table 2. World Health Organization (WHO)-recommended long-lasting insecticidal nets (LLINs)
Product name Product type Status of WHO recommendation
DawaPlus 2.0 Deltamethrin coated on polyester Interim
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Table 2. World Health Organization (WHO)-recommended long-lasting insecticidal nets (LLINs) (Continued)
DawaPlus 3.0 Combinationof deltamethrin coated onto polyester (side
panels), and deltamethrin and PBO incorporated into
polyester (roof )
Interim
DawaPlus 4.0 Deltamethrin and PBO incorporated into polyester Interim
Duranet Alpha-cypermethrin incorporated into polyethylene Full
Interceptor Alpha-cypermethrin coated on polyester Full
Interceptor G2 Alpha-cypermethrin and chlorfenapyr incorporated into
polyester
Interim
LifeNet Deltamethrin incorporated into polypropylene Interim
MAGNet Alpha-cypermethrin incorporated into polyethylene Full
MiraNet Alpha-cypermethrin incorporated into polyethylene Interim
Olyset Net Permethrin incorporated into polyethylene Full
Olyset Plus Permethrin (20g/kg) and PBO (10g/kg) incorporated
into polyethylene
Interim
Panda Net 2.0 Deltamethrin incorporated into polyethylene Interim
PermaNet 2.0 Deltamethrin coated on polyester Full
PermaNet 3.0 Combination of deltamethrin coated on polyester with
strengthened border (side panels), and deltamethrin and
PBO incorporated into polyethylene (roof )
Interim
Royal Sentry Alpha-cypermethrin incorporated into polyethylene Full
SafeNet Alpha-cypermethrin coated on polyester Full
Veeralin Alpha-cypermethrin and PBO incorporated into
polyethylene
Interim
Yahe Deltamethrin coated on polyester Interim
Yorkool Deltamethrin coated on polyester Full
Abbreviations: LLIN: long-lasting insecticidal nets; PBO: pyrethroid-piperonyl butoxide; WHO: World Health Organization.
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Table 3. World Health Organization (WHO)-recommended insecticide products for treatment of mosquito nets for malaria
vector control
Insecticide Formulation Dosagea
Alpha-cypermethrin SC 10% 20-40
Cyfluthrin EW 5% 50
Deltamethrin SC 1%
WT 25%
WT 25% + binderb
15-25
Etofenprox EW 10% 200
Lambda-cyhalothrin CS 2.5% 10-15
Permethrin EC 10% 200-500
Abbreviations: EC: emulsifiable concentrate; EW: emulsion, oil in water; CS: capsule suspension; SC: suspension concentrate; WT:
water dispersible tablet.
aActive ingredient/netting (mg/m2).
bK-O TAB 1-2-3.
Table 4. Definition of resistance level
Outcome Confirmed resistance Suspected resistance Susceptible Unclassified
WHOmosquitomortal-
itya
< 90% 90% to 97% 98% to 100% Unknown
CDC knock-downb < 90% 80% to 97% 98% to 100% Unknown
Abbreviations: CDC: Centers for Disease Control and Prevention; WHO: World Health Organization.
aDefinition of resistance level based on mosquito mortality (%) after exposure to insecticide in a WHO diagnostic dose assay.
bDefinition of resistance level based on mosquito mortality (%) after exposure to insecticide in a CDC bottle bioassay using the
methodology, diagnostic doses, and diagnostic times recommended by each test respectively.
Table 5. Stratification of resistance level
Outcome Low Moderate High Unclassified
Mosquito mortalitya 61% to 90% 31% to 60% < 30% Unknown
a24-hour post-exposure mortality (%).
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Table 6. Study inclusion screening form
Criteria Assessment Comments
Yes No Unclear
Mosquito population
Did the study test
Anopheles gambiae com-
plex orAnopheles funestus
group mosquitoes?
- State mosquito species
Were a minimum of
50 mosquitoes tested per
study arm?
-
Intervention
Did the study include
an long-lasting insectici-
dal net (LLIN) or insec-
ticide-treated net (ITN)
?
- State net LLIN or ITN
Was the intervention net
either of the following?
• A piperonyl
butoxide (PBO) LLIN
which received a
minimum of interim
World Health
Organization (WHO)
approval.
• An ITN
impregnated with
WHO-recommended
dose of pyrethroid +
PBO.
- State net type
Was the control net ei-
ther of the following?
• A pyrethroid LLIN
of the same fabric
impregnated with the
same insecticide and
dose as intervention net
(objective 1).
• A pyrethroid LLIN
impregnated with the
same insecticide at any
- State which objective study meets
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Table 6. Study inclusion screening form (Continued)
dose (objective 2 (a and
b)).
Study design
Was the study one of the
following?
• Laboratory
bioassay (cone, tunnel,
ball)
• Experimental hut
study
• Village trial
- State study type
For laboratory bioassay.
Did the study use stan-
dard-WHO protocol?
-
For experimental hut
study and village trial.
Was the study conducted
in Africa?
- State country
Outcome
Did the study include at
least one of the following
outcome measures?
• Mortality
• Blood feeding
• Sporozoite rate
• Not passed
through net
• Deterrence
• Exophily
• Mosquito density
• Parity rate
-
Decision
Is the study eligible for
inclusion?
- - State reason(s) for exclusion
Discuss with authors
Abbreviations: ITN: insecticide-treated net; LLIN: long-lasting insecticidal net; PBO: piperonyl butoxide; WHO: World Health
Organization.
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Table 7. Experimental hut trials: deterrence data
Study ID Locality Net type Net washed Total number
in ITN hut
Total number
in UTN hut
Deterrence
(%) reported
Deter-
rence (%) cal-
culated
Bayili 2017 Vallée du Kou DawaPlus 2.0 No 1548 1848 16.23 16.23
Bayili 2017 Vallée du Kou DawaPlus 2.0 Yes 2155 1848 0 -16.61
Bayili 2017 Vallée du Kou DawaPlus 3.0 No 1365 1848 26.13 26.14
Bayili 2017 Vallée du Kou DawaPlus 3.0 Yes 1981 1848 0 -7.20
Bayili 2017 Vallée du Kou DawaPlus 4.0 No 846 1848 54.22 54.22
Bayili 2017 Vallée du Kou DawaPlus 4.0 Yes 1646 1848 10.93 10.93
Corbel 2010 Malanville Permanet 2.0 Yes 195 285 31.58 31.58
Corbel 2010 Malanville Permanet 3.0 Yes 210 285 26.32 26.32
Corbel 2010 Malanville Permanet 2.0 No 243 285 14.74 14.74
Corbel 2010 Malanville Permanet 3.0 No 214 285 24.91 24.91
Corbel 2010 Pitoa Permanet 2.0 Yes 310 401 22.69 22.69
Corbel 2010 Pitoa Permanet 3.0 Yes 163 401 59.35 59.35
Corbel 2010 Pitoa Permanet 2.0 No 105 401 73.82 73.82
Corbel 2010 Pitoa Permanet 3.0 No 146 401 63.59 63.59
Corbel 2010 Vallée du Kou Permanet 2.0 Yes 788 908 13.22 13.22
Corbel 2010 Vallée du Kou Permanet 3.0 Yes 724 908 20.26 20.26
Corbel 2010 Vallée du Kou Permanet 2.0 No 329 908 63.77 63.77
Corbel 2010 Vallée du Kou Permanet 3.0 No 463 908 49.01 49.01
Koudou 2011 Yaokoffikro Permanet 3.0 No 303 796 62.1 61.93
Koudou 2011 Yaokoffikro Permanet 2.0 No 317 796 60.4 60.18
Koudou 2011 Yaokoffikro Permanet 3.0 Yes 313 796 60.1 60.68
Koudou 2011 Yaokoffikro Permanet 2.0 Yes 281 796 64.4 64.70
Moore 2016 Ifakara Veeralin LN No 722 810 11 10.86
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Table 7. Experimental hut trials: deterrence data (Continued)
Moore 2016 Ifakara Veeralin LN Yes 727 810 10 10.25
Moore 2016 Ifakara MAGNet LN No 1070 810 0 -32.10
Moore 2016 Ifakara MAGNet LN Yes 773 810 5 4.57
Moore 2016 Ifakara Veeralin LN No 89 170 48 47.65
Moore 2016 Ifakara Veeralin LN Yes 85 170 50 50.00
Moore 2016 Ifakara MAGNet LN No 114 170 33 32.94
Moore 2016 Ifakara MAGNet LN Yes 103 170 39 39.41
N’Guessan
2010
Akron Permanet 3.0 No 128 185 31 30.81
N’Guessan
2010
Akron Permanet 3.0 Yes 155 185 NR 16.22
N’Guessan
2010
Akron Permanet 2.0 No 114 185 38 38.38
N’Guessan
2010
Akron Permanet 2.0 Yes 174 185 NR 5.95
Pennetier
2013
Malanville Olyset Plus No 67 69 NR 2.90
Pennetier
2013
Malanville Olyset Plus Yes 101 69 NR -46.38
Pennetier
2013
Malanville Olyset Net No 96 69 NR -39.13
Pennetier
2013
Malanville Olyset Net Yes 124 69 NR -79.71
Toé 2018 Tengrela Olyset Net No 923 480 -92.29 -92.29
Toé 2018 Tengrela Olyset Plus No 695 480 -44.79 -44.79
Toé 2018 Tengrela Permanet 2.0 No 858 480 -78.75 -78.75
Toé 2018 Tengrela Permanet 3.0 No 794 480 -65.42 -65.42
Toé 2018 VK5 Olyset Net No 1458 1095 -33.15 -33.15
Toé 2018 VK5 Olyset Plus No 1278 1095 -16.71 -16.71
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Table 7. Experimental hut trials: deterrence data (Continued)
Toé 2018 VK5 Permanet 2.0 No 1075 1095 1.83 1.83
Toé 2018 VK5 Permanet 3.0 No 657 1095 40 40.00
Tungu 2010 Zeneti PermaNet 3.0 No 425 723 41 41.22
Tungu 2010 Zeneti PermaNet 2.0 No 574 723 21 20.61
Tungu 2010 Zeneti PermaNet 3.0 Yes 558 723 23 22.82
Tungu 2010 Zeneti PermaNet 2.0 Yes 586 723 19 18.95
Abbreviations: ITN: insecticide-treated net; LLIN: long-lasting insecticidal net; NR: not reported; PBO: piperonyl butoxide; UTN:
untreated net; WHO: World Health Organization.
Table 8. Village trials: mosquito density data
Study ID Net type Species Density mea-
surement
Collection
method
Baseline den-
sity
Post-inter-
vention den-
sity
Reduction
(%)
Awolola 2014 Untreated An gambiae s.l. Mean number
caught per
house
WT, IRC 16.2 17.1 -5.56
Awolola 2014 PermaNet 2.0 An gambiae s.l. Mean number
caught per
house
WT, IRC 21.3 7.2 66.20
Awolola 2014 PermaNet 3.0 An gambiae s.l. Mean number
caught per
house
WT, IRC 20.1 1.4 93.03
Cisse 2017 PermaNet 2.0 An gambiae s.l. Resting den-
sity per room
per day
IRC - 1.92 -
Cisse 2017 PermaNet 3.0 An gambiae s.l. Resting den-
sity per room
per day
IRC - 3.05 -
Cisse 2017 Olyset An gambiae s.l. Resting den-
sity per room
per day
IRC - 3.21 -
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Table 8. Village trials: mosquito density data (Continued)
Cisse 2017 Olyset Plus An gambiae s.l. Resting den-
sity per room
per day
IRC - 3.7 -
Mzilahowa
2014
Olyset An gambiae Mean number
caught per
catch
PSC - 0.10 -
Mzilahowa
2014
Olset Plus An gambiae Mean number
caught per
catch
PSC - 0.12 -
Mzilahowa
2014
PermaNet 2.0 An gambiae Mean number
caught per
catch
PSC - 0.13 -
Mzilahowa
2014
PermaNet 3.0 An gambiae Mean number
caught per
catch
PSC - 0.09 -
Mzilahowa
2014
Olyset An funestus Mean number
caught per
catch
PSC - 0.08 -
Mzilahowa
2014
Olyset Plus An funestus Mean number
caught per
catch
PSC - 0.16 -
Mzilahowa
2014
PermaNet 2.0 An funestus Mean number
caught per
catch
PSC - 0.27 -
Mzilahowa
2014
PermaNet 3.0 An funestus Mean number
caught per
catch
PSC - 0.13 -
Mzilahowa
2014
Olyset An gambiae Mean number
caught per
catch
LT - 1.23 -
Mzilahowa
2014
Olset Plus An gambiae Mean number
caught per
catch
LT - 0.27 -
Mzilahowa
2014
PermaNet 2.0 An gambiae Mean number
caught per
catch
LT - 0.96 -
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Table 8. Village trials: mosquito density data (Continued)
Mzilahowa
2014
PermaNet 3.0 An gambiae Mean number
caught per
catch
LT - 1.44 -
Mzilahowa
2014
Olyset An funestus Mean number
caught per
catch
LT - 2.02 -
Mzilahowa
2014
Olset Plus An funestus Mean number
caught per
catch
LT - 2.1 -
Mzilahowa
2014
PermaNet 2.0 An funestus Mean number
caught per
catch
LT - 5.76 -
Mzilahowa
2014
PermaNet 3.0 An funestus Mean number
caught per
catch
LT - 3.76 -
Protopopoff
2018
Olyset (2015) Anopheles
species
Mean number
caught
per house per
night
LT - 2.61 -
Protopopoff
2018
Olyset Plus
(2015)
Anopheles
species
Mean number
caught
per house per
night
LT - 1.85 -
Protopopoff
2018
Olyset (2016) Anopheles
species
Mean number
caught
per house per
night
LT - 3.60 -
Protopopoff
2018
Olyset Plus
(2016)
Anopheles
species
Mean number
caught
per house per
night
LT - 2.68 -
Stiles-Ocran
2013
No interven-
tion
An gambiae s.
s.
Mean number
caught per vil-
lage
IRC 230 79 65.65
Stiles-Ocran
2013
Permanet 2.0 An gambiae s.
s.
Mean number
caught per vil-
lage
IRC 39 36 7.69
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Table 8. Village trials: mosquito density data (Continued)
Stiles-Ocran
2013
Permanet 2.0 An gambiae s.
s.
Mean number
caught per vil-
lage
IRC 82 45 45.12
Stiles-Ocran
2013
Permanet 3.0 An gambiae s.
s.
Mean number
caught per vil-
lage
IRC 77 12 84.42
Stiles-Ocran
2013
Permanet 3.0 An gambiae s.
s.
Mean number
caught per vil-
lage
IRC 178 15 91.57
Stiles-Ocran
2013
No interven-
tion
An gambiae s.
s.
Mean number
caught
per person per
night per vil-
lage
Indoor & out-
door HLC
415 72 82.65
Stiles-Ocran
2013
Permanet 2.0 An gambiae s.
s.
Mean number
caught
per person per
night per vil-
lage
Indoor & out-
door HLC
33 31 6.06
Stiles-Ocran
2013
Permanet 2.0 An gambiae s.
s.
Mean number
caught
per person per
night per vil-
lage
Indoor & out-
door HLC
79 64 18.99
Stiles-Ocran
2013
Permanet 3.0 An gambiae s.
s.
Mean number
caught
per person per
night per vil-
lage
Indoor & out-
door HLC
98 19 80.61
Stiles-Ocran
2013
Permanet 3.0 An gambiae s.
s.
Mean number
caught
per person per
night per vil-
lage
Indoor & out-
door HLC
156 36 76.92
Abbreviations: An gambiae: Anopheles gambiae; An funestus: Anopheles funestus; HLC: human landing catch; IRC: indoor resting catch;
LT: light trap; PSC: pyrethrum spray catch; WT: window trap.
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A P P E N D I C E S
Appendix 1. Detailed search strategies
Cochrane Library
Description:
#1 “piperonyl butoxide” or PBO:ti,ab,kw (Word variations have been searched)
#2 MeSH descriptor: [Piperonyl Butoxide] explode all trees
#3 #1 or #2
#4 Net* or bednet* or hammock* or curtain* or ITN* or LLIN* or “Insecticide-Treated Bednet*” or “Insecticide-Treated net*”
#5 Olyset* or PermaNet* or Veeralin
#6 MeSH descriptor: [Insecticide-Treated Bednets] explode all trees
#7 #4 or #5 or #6
#8 #3 and #7
MEDLINE (PubMed)
Query
#1 Search “Piperonyl Butoxide”[Mesh]
#2 Search “piperonyl butoxide” or PBO Field: Title/Abstract
#3 Search Olyset* or PermaNet* or Veeralin Field: Title/Abstract
#4 Search “Insecticide-Treated Bednets”[Mesh] Field: Title/Abstract
#5 Search Nets OR bednet* OR hammock* OR curtain* OR ITN* OR LLIN* or “Insecticide-Treated Bednet*” or “Insecticide-
Treated net*” Field: Title/Abstract
#6 Search ((#5) OR #4) OR #3 Field: Title/Abstract
#7 Search (#2) OR #1
#8 Search (#7) AND #6
Embase (OVID)
1 “piperonyl butoxide”.mp.
2 piperonyl butoxide/
3 PBO.mp.
4 placebo/ or placebo.mp.
5 3 not 4
6 1 or 2 or 5
7 (Net* or bednet* or hammock* or curtain* or ITN* or LLIN* or “Insecticide-Treated Bednet*” or “Insecticide-Treated net*”).mp.
8 (Olyset* or PermaNet* or Veeralin).mp.
9 insecticide treated net/
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10 7 or 8 or 9
11 6 and 10
Web of ScienceT M Core Collection
Set
# 8 #7 AND #6
Indexes=SCI-EXPANDED, SSCI, CPCI-S, CPCI-SSH Timespan=All years
# 7 TOPIC: (malaria or mosquito* or pyrethroid* or insect* or huts or insecticide*)
Indexes=SCI-EXPANDED, SSCI, CPCI-S, CPCI-SSH Timespan=All years
# 6 #5 AND #4
Indexes=SCI-EXPANDED, SSCI, CPCI-S, CPCI-SSH Timespan=All years
# 5 TOPIC: (Net* OR bednet* OR insecticide treated net/ OR ITN* OR LLIN* or “Insecticide-Treated Bednet*” or “Insecticide-
Treated net*”) OR TOPIC: (Olyset* or PermaNet* or Veeralin)
Indexes=SCI-EXPANDED, SSCI, CPCI-S, CPCI-SSH Timespan=All years
# 4 #3 OR #1
Indexes=SCI-EXPANDED, SSCI, CPCI-S, CPCI-SSH Timespan=All years
# 3 TOPIC: (PBO) NOT TOPIC: (placebo)
Refined by: RESEARCH AREAS: ( CHEMISTRY )
Indexes=SCI-EXPANDED, SSCI, CPCI-S, CPCI-SSH Timespan=All years
# 2 TOPIC: (PBO) NOT TOPIC: (placebo)
Indexes=SCI-EXPANDED, SSCI, CPCI-S, CPCI-SSH Timespan=All years
# 1 TOPIC: (“Piperonyl Butoxide”)
Indexes=SCI-EXPANDED, SSCI, CPCI-S, CPCI-SSH Timespan=All years
CABI: CAB Abstracts®
Set
# 3 #2 AND #1
Indexes=CAB Abstracts Timespan=All years
# 2 TOPIC: (Net*OR bednet* ORhammock*OR curtain*OR ITN*ORLLIN* or “Insecticide-Treated Bednet*” or “Insecticide-
Treated net*”) OR TOPIC: (Olyset* or PermaNet* or Veeralin)
Indexes=CAB Abstracts Timespan=All years
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(Continued)
# 1 TOPIC: (PBO or “Piperonyl Butoxide”)
Indexes=CAB Abstracts Timespan=All years
ClinicalTrials.gov and WHO ICTRP
piperonyl butoxide and malaria
Appendix 2. Study characteristics extraction form
Table 2.1 Trial characteristics of the included cone bioassays
TrialID Trialname Mosquito
species
(strain/
origin)
Resistance
level
Resistance
status
Mosquito
age
Blood-fed
status
Interven-
tion
Washing Measured
outcome;
mosquito
mortality
Table 2.2 Trial characteristics of the included ball bioassays
TrialID Trialname Mosquito
species
(strain/
origin)
Resistance
level
Resistance
status
Mosquito
age
Blood-fed
status
Interven-
tion
Washing Measured
outcome;
mosquito
mortality
Table 2.3 Trial characteristics of the included tunnel tests
TrialID Trial-
name Mosquito
species
(strain/
origin)
Resis-
tance
level
Resis-
tance
status
Mosquito
age
Blood-
fed sta-
tus
Inter-
vention
Wash-
ing
Measured outcome
KD M BF NPTN
Abbreviations: KD: knock-down; M: mortality; BF; blood feeding; NPTN: not passed though net.
Table 2.4 Trial characteristics of the included experimental hut trials
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Tri-
alID
Trial-
name
Trial-
loca-
tion
Mosquito
species
(strain/
ori-
gin)
Resis-
tance
level
Resis-
tance
status
Trial-
start/
end
date
Inter-
ven-
tion
Net
washed
Net
holed
Measured outcome
M BF D E
Abbreviations: M: mortality; BF; blood feeding; D: deterrence; E: exophily.
Table 2.5 Trial characteristics of the included village trials
Tri-
alID
Tri-
al-
name
Tri-
allo-
ca-
tion
Mosquito
species
(strain/
ori-
gin)
Re-
sis-
tance
level
Re-
sis-
tance
sta-
tus
Tri-
al-
start/
end
date
In-
ter-
ven-
tion
Net
washed
Net
holed
Measured outcome
M BF SR MD PR PP CMC
Abbreviations: M: mortality; BF: blood feeding; SR: sporozoite rate; MD: mosquito density; PR: parity rate; PP: parasite presence;
CMC: clinical malaria confirmation.
Appendix 3. Data extraction form
Table 3.1 Data extracted from laboratory bioassays.
Tri-
alID
Trial-
name
Net
type
Net
washed Mosquito
species
Resis-
tance
level
Resis-
tance
status
Total
mosquito
Dead
Mosquito
mor-
tality
(%)
BF BF (%) NPTN NPTN
(%)
Abbreviations: BF: blood feeding; NPTN: not passed through net.
Table 3.2 Data extracted from experimental hut trials
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Tri-
alID
Tri-
al-
name
Net
type
Net
washed
Net
holed Mosquito
species
Re-
sis-
tance
level
Re-
sis-
tance
sta-
tus
To-
tal
mosquitoes
Dead Mosquito
mor-
tal-
ity
(%)
BF BF
(%)
BFI
Num-
ber
of
mosquitoes
de-
terred
De-
ter-
rence
(%)
Exit
trap
Ex-
ophily
(%)
To-
tal
num-
ber
of
peo-
ple
(N)
Abbreviations: BF: blood feeding; BFI: blood feeding inhibition; N: number of people.
Table 3.3 Data extracted from village trials
Tri-
alID
Tri-
al-
name
Net
type
Net
washed
Net
holed Mosquito
species
Re-
s s-
tance
level
Re-
sis-
tance
sta-
tus
To-
tal
mosquitoes
Dead Mosquito
mor-
tal-
ity
(%)
BF BF
(%)
BFI
Sporo-
zoite
(%)
Mosquito
den-
sity
(%)
Par-
ity
(%)
To-
tal
num-
ber
of
peo-
ple
(N)
PP
(%) CMC
(%)
Abbreviations: BF: blood feeding; PP: parasite prevalence; CMC: clinical malaria confirmation; N: number of people.
Appendix 4. ‘Risk of bias’ assessment form
Table 4.1 ‘Risk of bias’ assessment for laboratory bioassays
TrialID Trialname Comparabil-
ity of mosquitoes
in LLIN and LLIN
+ PBO groups
Observers blinded Incomplete
outcome data
Raw data reported
for
LLIN and LLIN +
PBO groups
Authors’ conflict-
ing interest
Abbreviations: LLIN: long-lasting insecticidal nets; PBO: piperonyl butoxide.
Table 4.2 ‘Risk of bias’ assessment for experimental hut trials
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TrialID Trial-
name
Com-
para-
bility
of
mosquitoes
in
LLIN
and
LLIN+PBO
groups
Col-
lectors
blinded
Sleep-
ers
blinded
Sleeper
bias
Treat-
ment
alloca-
tion
Treat-
ment
rota-
tion
Stan-
dard-
ized
hut de-
sign
Hut
clean-
ing be-
tween
treat-
ments
Incom-
plete
out-
come
data
Raw
data re-
ported
for
both
treat-
ment
groups
Au-
thors’
con-
flicting
interest
Table 4.3 ‘Risk of bias’ assessment for village trials
TrialID Trialname Com-
parability of
mosquitoes
in LLIN and
LLIN +
PBO house-
holds
Collectors
blinded
Household
blinded
Alloca-
tion of treat-
ments
Incomplete
outcome
data
Raw data re-
ported for
both groups
Authors’
conflicting
interest
Abbreviations: LLIN: long-lasting insecticidal nets; PBO: piperonyl butoxide.
Appendix 5. ‘Risk of bias’ assessment: laboratory bioassays
Risk of bias component Low Unclear High
Mosquito group comparability Same strain or population of
mosquitoes
No or unclear information re-
ported
Different strain or population
of mosquitoes
Observers blinded Outcomes assessed blinded No or unclear information re-
ported
If outcomes assessed were not
blinded, but this is unlikely to
influence the results, we will
judge this to be low risk
Outcomes assessed not blinded,
and this is likely to influence the
results
If outcomes assessed were not
blinded, but this is unlikely to
influence the results, we will
judge this to be low risk
Incomplete outcome data ad-
dressed
No or low missing data, reason
formissing data is unlikely to be
related to the true outcome
No or unclear information re-
ported
High missing data, reason for
missing data is likely to be re-
lated to the true outcome
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(Continued)
Raw data reported Raw data reported No or unclear information re-
ported
Raw data not reported
Conflicting interests No conflict of interest is stated No or unclear information re-
ported
Conflict of interest stated
Appendix 6. ‘Risk of bias’ assessment: experimental hut trials
Risk of bias component Low Unclear High
Mosquito group comparability Huts accessible to the same
mosquito population
No or unclear information re-
ported
Huts not accessible to the same
mosquito population
Collectors blinded Outcomes assessed blinded No or unclear information re-
ported
If outcomes assessed were not
blinded, but this is unlikely to
influence the results, we will
judge this to be low risk
Outcomes assessed not blinded,
and this is likely to influence the
results
If outcomes assessed were not
blinded, but this is unlikely to
influence the results, we will
judge this to be low risk
Sleepers blinded Outcomes assessed blinded No or unclear information re-
ported
If outcomes assessed were not
blinded, but this is unlikely to
influence the results, we will
judge this to be low risk
Outcomes assessed not blinded,
and this is likely to influence the
results
If outcomes assessed were not
blinded, but this is unlikely to
influence the results, we will
judge this to be low risk
Sleeper bias Sleepers were rotated between
huts using a Latin square design
No or unclear information re-
ported
Sleepers not rotated between
huts
Treatment allocation Treatments randomized
Treatments
not-randomized however equal
attractiveness demonstrated
No or unclear information re-
ported
Treatments not randomized,
and equal attractiveness not
demonstrated
Treatment rotation Treatments rotated through
huts using a Latin square design
No or unclear information re-
ported
Treatments not rotated
Standardized hut design Huts of West- or East-African
design
No or unclear information re-
ported
Huts of non-standardized de-
sign
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(Continued)
Cleaning Huts cleaned between treat-
ments
No or unclear information re-
ported
Huts not cleaned between treat-
ments
Incomplete outcome data ad-
dressed
No or low missing data, reason
formissing data is unlikely to be
related to the true outcome
No or unclear information re-
ported
High missing data, reason for
missing data is likely to be re-
lated to the true outcome
Raw data reported Raw data reported No or unclear information re-
ported
Raw data not reported
Conflicting interests No conflict of interest is stated No or unclear information re-
ported
Conflict of interest stated
Appendix 7. ‘Risk of bias’ assessment: village trials
Risk of bias component Low Unclear High
Recruitment bias No participants recruited after
clusters randomized
No or unclear information re-
ported
Recruitment bias not applicable
to trial design as it is related to
human participants
Paricipants recruited to trial af-
ter clusters randomized
Mosquito group comparability Mosquito populations compa-
rable
No or unclear information re-
ported
Mosquito populations compa-
rable
Collectors blinded Outcomes assessed blinded No or unclear information re-
ported
Outcomes assessed not blinded,
but this is unlikely to influence
the results
Outcomes assessed not blinded,
and this is likely to influence the
results
Household blinded Outcomes assessed blinded No or unclear information re-
ported
If outcomes assessed were not
blinded, but this is unlikely to
influence the results, we will
judge this to be low risk
Outcomes assessed not blinded,
and this is likely to influence the
results
If outcomes assessed were not
blinded, but this is unlikely to
influence the results, we will
judge this to be low risk
Treatment allocation Treatments randomized No or unclear information re-
ported
Treatments not randomized
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(Continued)
Allocation concealment Allocation concealment proce-
dures were adhered to.
No or unclear information re-
ported
Allocation concealment proce-
dures where not adhered to,
however this is unlikely to affect
the results
Allocation procedures were not
adhered to and this is likely to
have affected the results
Incomplete outcome data ad-
dressed
No or low missing data, reason
formissing data is unlikely to be
related to the true outcome
No or unclear information re-
ported
High missing data, reason for
missing data is likely to be re-
lated to the true outcome
Raw data reported Raw data reported No or unclear information re-
ported
Raw data not reported
Clusters lost to follow-up No complete clusters lost from
trial
No or unclear information as to
whether clusters were lost from
trial
At least one cluster lost from
trial
Selective reporting No selective reporting, all mea-
sured outcomes reported in re-
sults
No or unclear information on
whether all measured outcomes
were reported in results
Selective reporting; not all mea-
sured outcomes were reported
in results
Correct statistical methods; ad-
justed for clustering
Clustering was taken into ac-
count and statistical methods
adjusted for clustering
No or unclear information
as to whether clustering was
taken into account for statisti-
cal methods
Trial did not take clustering into
account for statistical methods
Conflicting interests No conflict of interest is stated No or unclear information re-
ported
Conflict of interest stated
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D I F F E R E N C E S B E TW E E N P R O T O C O L A N D R E V I E W
Previously PBO-nets were classified as PBO-LLINs, however as the durability of PBO on nets has not been classified as long lasting,
these were subsequently referred to as pyrethroid-PBO nets. As a result of this our review title changed from ‘Piperonyl butoxide
(PBO) combined with pyrethroids in long-lasting insecticidal nets (LLINs) to prevent malaria in Africa’ to ‘Piperonyl butoxide (PBO)
combined with pyrethroids in insecticide-treated nets (ITNs) to prevent malaria in Africa’.
We added Leslie Choi as a review author.
Additional criteria for assessing the risk of bias of village trials were added. These are in line with the Cochrane ‘Risk of bias’ tool
(Higgins 2017), and the five additional criteria listed in Section 16.3.2 of the Cochrane Handbook for Systematic Reviews of Interventions
that relate specifically to cluster-randomized trials (Higgins 2011).
The published protocol stated all stratified analysis factors under subgroup analysis (Gleave 2017). We have corrected this to state that
subgroup analysis was only performed on whether nets were unwashed or washed.
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